Mechanistic approach to predicting the sorption characteristics of pharmaceuticals by Berthod, Laurence Mireille Calire
 
 
 
 
 
 
 
 
 
Mechanistic Approach to Predicting the 
Sorption Characteristics of Pharmaceuticals 
 
 
 
 
 
 
 
 
 
Laurence Mireille Claire Berthod 
 
 
 
 
 
 
 
 
 
 
 
 
 
The thesis is submitted in partial fulfilment of the requirements 
for the award of the degree of Doctor of Philosophy of the 
University of Portsmouth 
 
January 2015 
1 
 
Abstract 
Over the past forty years concerns over the presence of pharmaceuticals in the 
environment have grown considerably. Some pharmaceuticals can be effectively 
biodegraded in wastewater treatment plants but others can be sorbed onto sludges that are 
often subsequently used as fertilisers or disposed of to landfill.  
 
This work aimed to understand how a given pharmaceutical will be distributed 
between the aqueous and solid phases (characterised by the sorbed:dissolved partition 
coefficient, 𝐾𝑑) within a treatment plant, which is important to be able to make accurate risk 
assessments. An official guideline test to measure the partitioning of a pharmaceutical in 
sewage sludge is available, but it is time consuming and fastidious. As activated sewage 
sludge is a complex matrix, commercially available solid-phase extraction (SPE) cartridges 
with different chemistries were used to characterise the pharmaceutical-sludge binding 
processes. As part of this work a new solid-phase extraction screening method has been 
developed to provide rapid measurements of 𝐾𝑑 and its performance was evaluated against 
partition coefficients obtained with the official guideline method with a correlation coefficient 
of 0.93 and a 𝑟2 of 0.94. In addition, this rapid method allowed the measurement of partition 
coefficients for pharmaceuticals for which values were not available in the literature and 
these have been used to further validate new predictive models. 
 
Predictive models based on the octanol-water partition coefficient have been 
developed to calculate partitioning properties of compounds in soil, and these have been 
extended for application to sewage sludge. These models are optimised mainly for neutral 
organic chemicals, and only a few consider ionic substances. The work described in this 
thesis compared the performance of these soil-based models for a range of 
pharmaceuticals, including ionisable compounds, and assessed their application for the 
binding of ionic and non-ionic pharmaceuticals in sewage sludge. It also explored other 
predictive models based on molecular descriptors obtained from chemical structure. These 
models provided improved predictions over previous models based solely on the octanol-
water partition coefficient. In this thesis, partial least squares (PLS) and Bayesian artificial 
neural network (ANN) models were evaluated for their accuracy in predicting the partition 
coefficient for neutral, basic, acidic and zwitterionic pharmaceuticals. Literature values were 
used to develop the models based on a range of molecular descriptors, and their predictive 
ability was assessed on an external test set of compounds excluded from the model-building 
process. The performance of the linear PLS and non-linear ANN models were discussed, 
and their predictive performance and interpretability were compared.  
 
Attempts to apply the method for rapid measurement of the sorption of pharmaceuticals to 
soils were also made to investigate potential read-across from one environmental matrix to 
another but the two matrices were too dissimilar to achieve this. 
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Chapter 1: Introduction 
 
1.1 Pharmaceuticals  
Pharmaceuticals are natural or synthesised products used to prevent or treat 
diseases, to restore, correct or modify physiological functions by exerting a 
pharmacological, immunological or metabolic action, and to facilitate medical 
diagnoses in humans and animals (EEC, 2004). They are also referred to as active 
pharmaceutical ingredients (APIs) due to their biological activity on target 
organisms. Pharmaceuticals are typically large and complex chemical structures, 
with molecular weights ranging from 130 to 1,000, and are often ionisable, with a 
tendency to form polymorphic solid state for neutral compounds and associated 
salts (Cunningham, 2008). Their physico-chemical properties, functionality and 
mode of action vary considerably, which makes them a challenging group to 
categorise. Pharmaceuticals are used worldwide, with over 3,000 authorised in 
Europe, including many consumed in hundreds of tonnes per year (Fent, Weston, & 
Caminada, 2006; Jones, Voulvoulis, & Lester, 2002)(967 tonnes of antidiabetic 
metformin were consumed in 2011 (Intercontinental Medical Statistics data obtained 
by AstraZeneca).   
 
The use of oral drug products is increasing every year due to progress in medical 
treatments (Jones et al., 2002) and the ageing of the population (Brown, Kulis, 
Thomson, Chapman, & Mawhinney, 2006; Heberer, 2002). Depending on their 
bioavailability, pharmaceuticals are fully or partially metabolised and excreted with 
urine and faeces, and the main environmental exposure route for human 
pharmaceuticals (as opposed to veterinary products consumed by animals) is 
normally via a wastewater treatment plant (WWTP). 
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1.2 Pharmaceuticals in the Environment 
Human pharmaceuticals were first reported as a potential issue in the environment 
by Stumm-Zollinger and Fair in 1965 (cited by Snyder et al., 2003). Since then, 
progress in analytical chemistry has allowed many more pharmaceuticals to be 
detected and quantified in the environment (Jones-Lepp & Stevens, 2007; Löffler & 
Ternes, 2003; Martín et al., 2012; Richardson, 2004, 2011; Richardson & Ternes, 
2011; Ternes et al., 2005). The routes of entry of pharmaceuticals into the 
environment are divided mainly into two categories: human (medicinal use) and 
animal (veterinary or agricultural use) as shown in Figure 1.1 (Kümmerer, 2001). 
Pharmaceuticals can partition in the aquatic environment between water and solid 
matrices such as sediment or sewage sludge. As a consequence of their ubiquity, 
pharmaceuticals have the potential to be found, and have been shown to be present 
in drinking water. Hence various regulatory requirements have been put in place to 
control the level of chemicals in drinking water (WHO, 2011). In addition, 
wastewater treatment has been introduced in an attempt to reduce the potential 
impact of pharmaceuticals and other pollutants on the environment (EEC, 1991).  
 
 
Figure 1.1 Anticipated exposure routes of pharmaceuticals in the environment (Kummerer, 
2001). 
16 
 
The human (Figure 1.2a) and veterinary (Figure 1.2b) routes of exposure are shown 
in more detail in Figure 1.2, which indicates the links between these pathways and 
the fate and effects of pharmaceuticals in the environment (Jørgensen & Halling-
Sørensen, 2000). 
 
 Figure 1.2 Anticipated environmental exposure routes of pharmaceuticals for human (a) 
and veterinary (b) treatment (from Jørgensen & Halling-Sørensen, 2000). 
 
The fate of pharmaceuticals that are not biodegraded in WWTPs depends on the 
ability of the compound to sorb to sewage sludge. Pharmaceuticals that sorb 
strongly to sewage sludge will remain in the sludge phase, which will be burnt or 
used as fertiliser or disposed of in landfill. Depending on the use of the sludge, the 
pharmaceuticals could then be transferred to soil and potentially to plants and crops 
(Carter et al., 2014). Pharmaceuticals that do not sorb to sludge will remain in the 
aqueous phase and be released in the environment though effluent water (Hignite & 
17 
 
Azarnoff, 1977). In this case, they have a the potential for a negative impact on 
aquatic ecosystems and organisms such as fish (Owen et al., 2009; Schultz et al., 
2011; Snyder et al., 2003; Zhao, Li, Zhang, Zeng, & Zhou, 2008), algae (Bent 
Halling-Sørensen et al., 1998; Wilson, Smith, deNoyelles, & Larive, 2003) and 
aquatic invertebrates (Meredith-Williams et al., 2012). The effects of 
bioconcentration (where the concentration of a chemical in an aquatic organism 
exceeds that in water as a result of exposure to a waterborne chemical) and 
bioaccumulation (the process through which pollutants enter a food chain) cannot 
be neglected as they put at risk many fish species and associated ecosystems 
(Gobas, Zhang, & Wells, 1993; Mackay & Fraser, 2000). Earthworms and soil 
bacteria are among the organisms potentially affected by the presence of 
pharmaceuticals in soil (Kinney et al., 2008). It is important to identify the first 
organisms to be exposed as their entire ecosystem can be affected via the food 
chain but this is an arduous task due to the vast soil biodiversity.  
 
Various papers have reported the presence of pharmaceuticals in the environment, 
especially endocrine modulators (EMs) and antibiotics (Suárez, Carballa, Omil, & 
Lema, 2008; Tolls, 2001; Whitacre, Monteiro, & Boxall, 2010) indicating that 
pharmaceuticals have transited through WWTPs. Sorption to sludge is a good 
indicator of how much of each pharmaceutical will be removed during treatment and 
how much will be released to the aquatic environment. Data for many sorption 
measurements are available (Barron et al., 2009, 2010; Göbel, Thomsen, McArdell, 
Alder, et al., 2005; Joss, Andersen, Ternes, Richle, & Siegrist, 2004; Joss et al., 
2005; Lajeunesse, Smyth, Barclay, Sauvé, & Gagnon, 2012; Radjenović, Petrović, 
& Barceló, 2009; Stevens-Garmon, Drewes, Khan, McDonald, & Dickenson, 2011; 
Stuer-Lauridsen, Birkved, Hansen, Holten Lützhøft, & Halling-Sørensen, 2000; 
Ternes, Bonerz, & Schmidt, 2001; Ternes et al., 2004, 2005; Thiele-Bruhn, 2003; 
Urase & Kikuta, 2005) highlighting the fact that numerous pharmaceuticals from 
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various therapeutic areas such as anti-inflammatories, antibiotics, EMs and 
antipsychotics, are already present in the aquatic environment. These data show 
the importance of understanding the behaviour of pharmaceuticals in a WWTP to 
avoid potentially detrimental effects on the environment. For example, it was found 
that diclofenac had a negative effect on a population of vultures, causing kidney 
failure to the animal leading to death (Oaks et al., 2004; Shultz et al., 2004). Studies 
have also suggested that hormones released from birth-control tablets could lead to 
feminisation in some fish populations (Filby, Thorpe, Maack, & Tyler, 2007; Piferrer, 
2001; Snyder et al., 2003; Tyler & Jobling, 2008). 
 
A number of standard tests are performed to determine the effects of 
pharmaceuticals and other chemicals on the aquatic environment. Several 
guidelines have been published covering the measurement of the ecotoxicity of 
chemicals on different types of aquatic organisms such as algae (OECD, 2011), fish 
(OECD, 2012b, 2013a, 2013b) or crustaceans (OECD, 2012a). Some studies have 
also been performed on terrestrial organisms such as plants (Carter et al., 2014), 
earthworms (Kinney et al., 2008) and snails (Iguchi & Katsu, 2008).  
 
1.3 Legislation 
Since 2006, all pharmaceuticals for human use in Europe require an environmental 
risk assessment (ERA) to be performed following the European Agency for the 
Evaluation of Medicinal Products (EMEA), now European Medicines Agency (EMA), 
guideline (EMEA, 2006). This ERA scheme is based on a two-phased, two-tiered 
approach (Table 1.1). 
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Table 1.1 The phased approach in the EMA environmental risk assessment. 
Stage in 
regulatory 
evaluation 
Stage in risk 
assessment 
Objective Method Test/Data 
Requirement 
Phase I  Pre-
screening  
Estimation of exposure  Action limit  Consumption data, 
log 𝐾𝑂𝑊 
Phase II 
Tier A  
Screening  Initial prediction of risk  Risk 
Assessment  
Base set aquatic 
toxicology and fate  
Phase II 
Tier B  
Extended  Substance and 
compartment-specific 
refinement and risk 
assessment 
Risk 
Assessment  
Extended data set on 
emission, fate and 
effects  
 
Phase I is a pre-screening stage in which the predicted environmental concentration 
in the aquatic environment (PECsurfacewater) is calculated based on the maximum daily 
dose of the pharmaceutical (Kümmerer & Cunningham, 2008; Straub, 2002) (Eq. 
1.1). 
 
𝑃𝐸𝐶𝑠𝑢𝑓𝑎𝑐𝑒𝑤𝑎𝑡𝑒𝑟 =
𝐷𝑂𝑆𝐸𝑎𝑖 × 𝐹𝑝𝑒𝑛
𝑊𝐴𝑆𝑇𝐸𝑊𝑖𝑛ℎ𝑎𝑏 × 𝐷𝐼𝐿𝑈𝑇𝐼𝑂𝑁
   Eq. 1.1 
Here:  
DOSEai = maximum daily dose consumed per inhabitant (mg/inh/d)  
Fpen = percentage of market penetration  
WASTEWinhab = amount of wastewater per inhabitant per day (L/inh/d)  
DILUTION = dilution factor  
PECSURFACEWATER = local surface water concentration (mg/L)  
 
Phase I takes into account the bioaccumulation potential, assessing the lipophilicity 
of the pharmaceutical by calculating the octanol/water partition coefficient, 𝐾𝑂𝑊. If 
the substance is lipophilic (log 𝐾𝑂𝑊 > 4.5), this is an indication that the substance 
may accumulate in the fat tissue of fish, the exposed organisms, and further tests 
for persistence, bioaccumulation potential and toxicity (PBT) will be required. If the 
PECsurfacewater is below the threshold of 10 ng/L and log 𝐾𝑂𝑊 is below 4.5, it is 
assumed that the pharmaceutical is unlikely to present a risk to the environment, 
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and the assessment ends (Kümmerer & Cunningham, 2008; Ternes & Joss, 2006). 
If the PECsurfacewater is above the 10 ng/L threshold, the assessment carries on to 
Phase II.  
 
Phase II consists of a quantitative risk assessment, by refining PECsurfacewater, 
providing an estimation of the PEC in groundwater (PECgroundwater) with extended 
fate data through STP modelling, using metabolite data, and refined sales 
figures (EMEA, 2006) and performing studies on the fate and effects of the 
compound in the environment. Phase II is divided in two tiers, A and B, where Tier A 
allows a rapid prediction of the environmental risk associated with the use of the 
substance by calculating a risk quotient based on data obtained from a standard set 
of studies, while Tier B is more substance-specific in the case where one or more of 
the values obtained in Tier A exceed the trigger value set in the guideline. Tier A 
generally follows the OECD guidelines for sorption (OECD 106), transformation in 
aquatic sediments (OECD 308), ready biodegradation test (OECD 301), algal 
growth inhibition test (OECD 201) and a fish early life stage test (OECD 210) (Table 
1.2) (EMEA, 2006). In Phase II Tier A, the partitioning behaviour of pharmaceuticals 
must be characterised (EMEA, 2006).   
 
 
Table 1.2 Physico-chemical, fate and effects studies recommended in Phase II Tier A of the 
EMA environmental risk assessment. 
Study Type  Recommended Protocol  
Adsorption - Desorption Using a Batch Equilibrium Method  OECD 106/  
OECD 121/ 
OPPTS 835.1110*  
Ready Biodegradability Test  OECD 301  
Aerobic and Anaerobic Transformation in Aquatic Sediment Systems  OECD 308  
Algae, Growth Inhibition Test  OECD 201  
Daphnia sp. Reproduction Test  OECD 211  
Fish, Early Life Stage Toxicity Test  OECD 210  
Activated Sludge, Respiration Inhibition Test  OECD 209  
*One study is generally sufficient. 
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If the ratio between PEC and the predicted no effect concentration (PNEC) is below 
1, the ERA can stop with no further assessment. Tier B is performed when one or 
more physico-chemical or fate data exceed the threshold defined in the guideline. 
Tier B consists of refining PEC and PNEC by taking into account other substance 
specific factors such as human excretion rate, biodegradation and elimination rate in 
a WWTP in a more environmentally realistic context (Table 1.3). 
 
Table 1.3 Terrestrial fate and effects studies recommended in Phase II Tier B of the EMA 
environmental risk assessment. 
Study Type  Recommended Protocol  
Aerobic and Anaerobic Transformation in Soil  OECD 307  
Soil Micro-organisms: Nitrogen Transformation Test  OECD 216  
Terrestrial Plants, Growth Test  OECD 208  
Earthworm, Acute Toxicity Tests  OECD 207  
Collembola, Reproduction Test  ISO 11267  
 
 
If PEC/PNEC is above or equal to 1, the risk is deemed unacceptable and further 
refinement may be required. If, after refinement, the PEC/PNEC ratio remains 
above 1 then risk management measures are required (EMEA, 2006; Kümmerer & 
Cunningham, 2008; Straub, 2002; Ternes & Joss, 2006). This could lead to 
restriction of clinical use or close environmental monitoring after introduction of the 
compound to the environment. These precautions may include appropriate labelling 
which aims to minimise the quantity of drug discharged into the environment. In this 
instance, the EMA guideline (2006) recommends that the package leaflet should 
include a special statement stipulating not to dispose of this particular medicine via 
wastewater or household waste and to return it to a pharmacist for disposal. Further 
risk mitigation can be undertaken by manufacturers to introduce other product 
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forms, such as sprays or patches, which may be a lesser risk to the environment 
(Ternes & Joss, 2006). Figure 1.3 summarises the whole ERA process. 
 
 
Figure 1.3 Schematic ERA scheme according to the assessment procedure proposed by 
the EMEA (2006) (Ternes & Joss, 2006).  
 
 
In addition to the ERA, the European regulation (EC) No 1907/2006, known as the 
Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) 
regulation, was adopted by the EU in 2006 (ECHA, 2006). This requires that any 
business that manufactures or imports more than 1.0 t of a chemical per year must 
register it before it can be marketed. Human and veterinary pharmaceuticals are 
exempt as they are covered under the EMA guidelines; however, REACH guidelines 
are still applicable for intermediate products, manufacturing raw materials and 
production materials even if they are not contained in the finished pharmaceutical 
product (Covington & Burling, 2007).  
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Finally, the Water Framework Directive (WFD) must be taken into consideration. 
The WFD aims for ‘good status’ for all ground, surface and coastal waters in order 
to address pollution from urban wastewater and from agriculture. The WFD was 
enacted in 2000 (2000/60/EC) and implemented in 2003 (European Commission, 
2000). The first step was to establish by way of Decision 2455/2001/EC a list of 
priority substances (Annex X of the WFD). This was replaced by Annex II of the 
Directive on Environmental Quality Standards (Directive 2008/105/EC) (EQSD), 
also known as the Priority Substances Directive, which set environmental quality 
standards (EQS) for these substances in surface waters (river, lake, transitional and 
coastal zone) and confirmed their designation as a priority since they pose a 
significant risk to or via the aquatic environment (EC, 2014). This list of priority 
substances is reviewed every four years along with their EQS for surface water, 
sediment or biota. To meet good chemical status, water bodies must meet EQS set 
for the priority pollutants. During the latest revision, it was agreed to include a watch 
list of substances for which more robust evidence is needed to assess their 
suitability for future addition to the priority substances list. Three pharmaceuticals 
(diclofenac, 17α-ethinylestradiol (EE2) and 17β-estradiol (E2)) are currently on this 
watch list, which involves monitoring and collecting information from a network of 
monitoring sites across Europe (Water UK, 2013). 
 
1.4 Waste-water Treatment Plants 
Since 2006, most pharmaceuticals for human use in Europe require an 
environmental risk assessment (ERA) to be performed. In Phase II Tier A, the 
partitioning behaviour of pharmaceuticals needs to be characterised (EMEA, 2006). 
As most pharmaceuticals are consumed and subsequently excreted by the patient 
the main environmental exposure route is normally via a WWTP. Therefore, the 
partitioning of pharmaceuticals between the aqueous phase and the bio-solids 
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(sludge) present in a WWTP is important in describing the fate of the 
pharmaceutical during this process. The main types of WWTP are conventional 
activated sludge plants and trickling filter plants but for the purpose of this research, 
the focus is only on the former type. Many authors have studied the sorption of 
several commonly used pharmaceuticals in sewage sludge. Some studies 
compared the sorption of pharmaceuticals on different types of sludge within the 
same WWTP (Carballa, Fink, Omil, Lema, & Ternes, 2008; Carballa et al., 2004; 
Carballa, Omil, Ternes, & Lema, 2007; Hörsing et al., 2011). The different types of 
sludge within a WWTP include primary, activated, secondary and digested sludge 
(Figure 1.4). 
 
 
Figure 1.4 Processes in a typical conventional activated sludge wastewater treatment plant.  
 
Most of the sorption processes occur in primary and activated sludge, as they are 
the first two sludge receiving the influent waters, with lower levels of sorption in 
secondary sludge. For digested sludge, sorption is not the main path of removal; 
biodegradation is more important (Tchonanoglous, Burton, & Stensel, 2002). All 
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sewage influent is collected in the primary clarifier, where the bio-solids are left to 
settle to form the primary sludge. Primary sludge is stored and then used further 
down the line in the anaerobic digester. All influent waters then go through the 
activation tank, where they are mixed with the activated sludge via an aeration 
process. Activated sludge has an aerobic microbial population which biodegrades 
molecules using oxygen. The effluent waters are collected in the second clarifier, 
where the bio-solids are allowed to settle to become the secondary sludge. The 
effluent waters from the second clarifier then sometimes go through a sand filter 
before being released into the aquatic environment. A portion of primary and 
secondary sludge is then mixed and left in the digester, an anaerobic unit where the 
remaining chemicals are biodegraded by an anaerobic microbial population, 
ultimately forming methane and carbon dioxide. The digested sludge is then 
incinerated, or stored and disposed of in landfill or used as fertiliser by the 
agriculture industry. Although biodegradation is an important means of removal for 
pharmaceuticals (Rosal et al., 2010; Carballa, Omil, & Lema, 2005), it will not be 
studied in this research, where interest will be focused only on sorption mechanisms 
to sludge phases. 
 
Sorption has been proven to be an important removal mechanism in WWTP and is 
likely to be an adsorption process (where a substance binds to a solid surface) as 
opposed to an absorption process (where the substance penetrates the organic 
medium) (Byrns, 2001; Carballa et al., 2004). The affinity of each compound to 
sludge and its removal from the aqueous phase of a WWTP depends on its physico-
chemical properties. Sorption onto activated sludge is a key factor in the removal of 
organic micropollutuants in conventional WWTPs (Bolong et al., 2009). Therefore, 
information on sludge-water partitioning is vital to predict the influence of sorption on 
the fate of pharmaceuticals in WWTPs. 
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The most commonly used sludge for sorption studies is activated sludge, which is 
recommended in the guideline of the Office of Prevention, Pesticides and Toxic 
Substances (OPPTS) sorption studies (EPA, 1998). This sludge is consistent across 
different WWTPs and within a WWTP and is fairly easy to sample (Tchonanoglous 
et al., 2002). It can be used directly in biodegradation studies or sorption studies 
when sterilised. Sludge is a complex matrix containing faeces, soap residues, hair, 
and other waste which is difficult to characterise (Artola-Garicano, Borkent, Damen, 
Jager, & Vaes, 2003; Ternes, Janex-Habibi, Knacker, Kreuzinger, & Siegrist, 2006). 
Attempts have been made using nuclear magnetic resonance (NMR) and Fourier 
transform infra-red spectroscopy (FTIR), to obtain more insight into the exact nature 
of sewage sludge but direct measurements of quantities such as the combination of 
volatile suspended solids (VSS), total suspended solids (TSS), organic carbon 
(OC), iron (Fe), nitrogen (N) and potassium (K) content have proven to be  more 
useful and interpretable (Amir et al., 2004; Chen, Jeyaseelan, & Graham, 2002; 
Chiou et al., 2006; Chu, Wang, & Wang, 2011; Menéndez, Inguanzo, & Pis, 2002; 
Smernik, Oliver, & Merrington, 2003). Many authors characterise it solely by the 
organic carbon content. 
 
Municipal and hospital effluents are the most important sources of pharmaceuticals 
entering the aquatic environment (Nikolaou, Meric, & Fatta, 2007; Whitacre et al., 
2010). Although some pharmaceuticals are removed by WWTPs, many substances 
are not fully biodegraded during treatment processes (Ternes & Joss, 2006). In this 
case, the partitioning behaviour of the pharmaceutical between sludge and aqueous 
phases, expressed as a partition coefficient 𝐾𝑑, is the key indicator of their 
environmental fate (Kummerer, 2001).  
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1.5 Measurement of Partition Coefficients 
It is recognised that 𝐾𝑑 is the most suitable value to determine affinity or sorption to 
the solid phase (Carballa et al., 2005; Schwarzenbach et al., 2002; Ternes et al., 
2004), the higher the 𝐾𝑑  value the more the pharmaceutical will sorb to the sludge.  
𝐾𝑑 is defined as the ratio of the equilibrium concentrations of the substance in the 
sludge and aqueous phases: 
 
𝐾𝑑  =  [𝑝ℎ𝑎𝑟𝑚𝑎𝑐𝑒𝑢𝑡𝑖𝑐𝑎𝑙]𝑠𝑙𝑢𝑑𝑔𝑒/[𝑝ℎ𝑎𝑟𝑚𝑎𝑐𝑒𝑢𝑡𝑖𝑐𝑎𝑙]𝑎𝑞𝑢𝑒𝑜𝑢𝑠 Eq. 1.2 
 
The Freundlich sorption isotherm (empirical relation between the concentration of a 
solute on the surface of an adsorbent to the concentration of the solute in the liquid 
with which it is in contact).can often be used to describe the equilibrium between 
concentrations of a chemical in the aqueous phase and the solid phase. If Cs is the 
concentration in the solids (ng/kg) and Cw is the concentration in the water (mg/L) 
then 𝐾𝑓 the Freundlich sorption coefficient, and n, the Freundlich affinity constant, 
are the Freundlich parameters that characterise the sorption isotherm (Andersen et 
al., 2005): 
 
 Cs =  𝐾𝑓  × Cw
n      Eq. 1.3 
 
If the sorption isotherm is linear (n = 1) then sorption is independent of 
concentration and therefore it is more appropriate to describe the sorption as the 
sludge-water distribution coefficient (kg/L) (Wick et al., 2011):  
 𝐾𝑑 =  
𝐶𝑠
𝐶𝑤
 Eq. 1.4 
 
Going back to the legislation aspects discussed in section 1.3, Rogers (1996) 
estimated the sorption potential of hydrophobic contaminants according to 
their 𝐾𝑂𝑊. The octanol-water partition coefficient is a measure of how hydrophilic or 
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hydrophobic a chemical substance is. The measurements are often restricted to the 
use of two immiscible solvents, one aqueous and the other hydrophobic such as 
octanol. Contaminants with log 𝐾𝑂𝑊 < 2.5 would have a low sorption potential, those 
with 2.5 <  log 𝐾𝑂𝑊 < 4.0 would have a medium sorption potential and those with 
log 𝐾𝑂𝑊 > 4.0 would have a high sorption potential. These log 𝐾𝑂𝑊 values may be 
transposed to sludge-water partition coefficients using empirical equations (Dobbs, 
Wang, & Govind, 1989) such as:  
 
log 𝐾𝑑  =  1.14 +  0.58 ×  log 𝐾𝑂𝑊  (n = 10) Eq. 1.5.  
 
Chemicals with a low 𝐾𝑑 value (around log 𝐾𝑑  < 2.6), will remain mainly in the 
aqueous effluent, and those with a high 𝐾𝑑 value (around log 𝐾𝑑  > 3.6) will be 
predominantly adsorbed by the bio-solids (sludge) phase.  
 
In the latter case, precautions may be required for the disposal of sludge to 
agricultural land, as there are potential risks associated with leaching of desorbed 
chemicals and the movement of these chemicals into crops destined for livestock or 
human consumption. Often, organic carbon to water 𝐾𝑑 expressed the term of 
partition coefficient, 𝐾𝑂𝐶, i.e: 
 
 𝐾𝑑  =  𝐾𝑂𝐶  ×  𝑓𝑂𝐶    Eq. 1.6 
  
where 𝑓𝑂𝐶 is the mass fraction of organic carbon in the sludge or soil 
(Schwarzenbach et al., 2002). Pharmaceuticals with log 𝐾𝑂𝐶 > 4 require the 
performance of terrestrial risk assessment (EMEA, 2006). 
 
Values of 𝐾𝑑 can be measured experimentally or estimated by mathematical 
models. Usually, experimental measurements use specific guidelines, e.g. 
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Organisation for Economic Co-operation and Development (OECD) 106 (OECD, 
2000), OECD 121 (OECD, 2001), or the Environmental Protection Agency’s Office 
of Prevention, Pesticides and Toxic Substances (OPPTS) guideline 835.1110 (EPA, 
1998). The OPPTS 835.1110 guideline is currently the only international protocol 
applicable to partitioning behaviour in sewage sludge. In this guideline, a series of 
experiments is performed using different aqueous concentrations of sludge and the 
linear portion of the slope of the resultant isotherm is used to calculate 𝐾𝑑. The 
guideline recommends the use of activated sewage sludge, even though this matrix 
may not exhibit all of the different types of partitioning mechanism that can 
potentially occur in a WWTP. The test does not specify what kind of buffer to use, 
whereas guidelines e.g. OECD 106 stipulates to use 0.01 M calcium chloride. The 
method is complex, especially for chemicals that are poorly water soluble, adsorb to 
the test vessels or degrade rapidly in the test. The test can take several days to 
complete, due to long equilibration times, phase separation and long analytical run 
times. The method described in the guideline is laborious and requires experience 
and time, and often does not allow measurement for all manufactured 
pharmaceuticals potentially present in the environment. Moreover, with the 
increased usage of chemicals and REACH requiring intermediate pharmaceuticals 
to have environmental data (Tammler, 2008), measurement for all of them is 
impractical.  
 
Recent progress in extraction and instrumental techniques has allowed alternative 
methods to be used to experimentally measure Kd by analysing both the biosolid 
sludge sample and its associated aqueous supernatant (Göbel et al., 2005; Joss et 
al., 2005; Lajeunesse et al., 2012; Radjenović et al., 2009). Systems include stirred 
bottles (Hörsing et al., 2011; Wick et al., 2009) and batch type experiments in 
laboratory scale reactors (Ternes et al., 2004; Urase & Kikuta, 2005). All these 
different methods involve a certain degree of complexity, up to 14 h equilibration 
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time and specific expensive equipment, making them not easily adaptable from 
laboratory to laboratory.  
 
The range of pharmaceuticals that have been tested for sludge affinity is wide, 
covering different families of pharmaceuticals such as analgesics, antibiotics, anti-
inflammatories and antidepressants with different modes of action. 
Chromatographic methods such as silica-based chromatographic stationary phases 
(Ternes et al., 2001) have been used to model the behaviour of such a large mixture 
of compounds on known phases. Attempts have been made to relate 𝐾𝑑 and 𝐾𝑂𝐶 to 
molecular properties. Molecular properties are under the form of molecular 
descriptors unique for a specific molecule. For example two molecules can have the 
same 𝐾𝑂𝑊, but their molecular weight and number of double bond would be 
different. Other more complex sets of descriptors have been developed and used in 
the prediction of 𝐾𝑂𝑊. For example, the Abraham descriptors, consisting of five 
explanatory variables (excess molar refraction, solute dipolarity or polarisability, 
McGowan’s characteristic volume, solute hydrogen-bond acidity and basicity) 
(Abraham, 1993a, 1993b;  Abraham et al., 1994; Abraham, Chadha, & Leo, 1994; 
Abraham & McGowan, 1987; Abraham et al., 1990a, 1990b, 1991) have been 
widely used to predict water solubility, octanol-water partition coefficient (𝐾𝑂𝑊) and 
blood brain barrier exchange (Abraham et al., 1999; Abraham & Le, 1999; Kamlet et 
al., 1988). The Abraham descriptors have been applied to explain sorption 
mechanisms through chromatographic retention measurement (Zissimos et al., 
2002; Zissimos, Abraham, Du, et al., 2002). Recent research investigated the 
possibility of using sediment phases as known chromatographic phases, enabling 
experiments to be performed that directly measure sorption affinity with more control 
and this would help to elucidate the mechanisms occurring during the partitioning 
(Bäuerlein et al., 2011). 
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Quite often, the value of 𝐾𝑑 is predicted from other parameters, such as the octanol-
water partition coefficient, 𝐾𝑂𝑊. However, the poorly understood nature of the 
sludge makes it hard to build robust models to predict how pharmaceuticals behave 
in this matrix. With this in mind, estimated values obtained from mathematical 
models developed on similar compounds can be used, considerably reducing the 
number of experiments. The use of validated predictive models is therefore 
authorised and, in order to limit animal testing, encouraged (Eriksson et al., 2003). 
Most models of this type were developed initially for neutral hydrophobic 
compounds and applied later to pharmaceuticals. 
 
1.6 Predictive Modelling of Partition Coefficients 
Prediction of the partition coefficient, 𝐾𝑑, by statistical models has been an area of 
interest over the past few decades (Katritzky, Karelsonb, & Lobanova, 1997). 
Initially, models were applied to pesticides in a soil matrix, but since the presence of 
pharmaceuticals in the environment has grown, models have also been developed 
for this class of compounds (Cronin et al., 2003). The most commonly used model 
to predict a compound’s affinity for a solid phase is based on the organic carbon 
partition coefficient of the compound, 𝐾𝑂𝐶, which is a normalised variable to allow 
comparison between different solid phases, related to 𝐾𝑑 by Eq. 1.5. Values of 𝐾𝑂𝐶  
are obtained from measured or estimated values of the octanol-water partition 
coefficient, 𝐾𝑂𝑊, using models of the form (Karickhoff et al., 1979, Karickhoff, 1981):  
 
log 𝐾𝑂𝐶 =  a log 𝐾𝑂𝑊 +  b    Eq. 1.7 
 
Using Eq. 1.5 to convert 𝐾𝑂𝐶 into 𝐾𝑑, models of this type for 𝐾𝑑  depend on the 
quality of the 𝐾𝑂𝑊 values used and are acceptable, though not perfect, for non-ionic 
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pharmaceuticals but do not predict accurate values of 𝐾𝑑 for ionisable or ionic 
pharmaceuticals (Tolls, 2001).  
 
A series of models of this type was developed by Sabljic (1989) for different classes 
of chemicals, with a strong focus on pesticides in soil. Later, similar models were 
developed for other classes of chemicals such as ‘predominantly hydrophobic’ and 
‘non-hydrophobic’ compounds, including specific models for phenols, amides, 
alcohols, organic acids and many other different groups (Sabljic et al., 1995). The 
Sabljic 𝐾𝑂𝑊 models form part of the technical guidance document (EC, 2003) used 
for European regulatory requirements and are included in the EpiSuite™ estimation 
software (US EPA, 2013).  
 
Models have been proposed for the prediction of 𝐾𝑑  values in soil for small, non-
polar molecules and fragments (Andrić et al., 2010; Poole & Poole, 1999; Sabljic et 
al., 1995; Schüürmann, Ebert, & Kühne, 2006) but these are not acceptable for 
complex and charged molecules. Models derived for the prediction of sorption in soil 
and sewage sludge are based mainly on molecular connectivity indices (Baker, 
Mihelcic, & Sabljic, 2001; Sabljic et al., 1995) or on 𝐾𝑂𝑊. All these models are 
limited to the prediction of partitioning in organic matter only, which does not 
represent accurately the complexity of the sewage sludge matrix. Sludge is a 
combination of organic and inorganic materials, and models describing sorption to 
this matrix should require additional variables to ensure accuracy.  
 
The 𝐾𝑂𝑊 approach also assumes that hydrophobicity is the only mechanism of 
sorption between pharmaceuticals and sludge, which might not be appropriate as 
the models fail to predict accurate values of 𝐾𝑑 for ionisable compounds such as 
many pharmaceuticals. For example, the multiple charged compound 
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oxytetracycline is often predicted to have a low sorption coefficient due to its low 
𝐾𝑂𝑊 while in fact it is reported to have a high 𝐾𝑑 and 𝐾𝑂𝐶 in sludge and soil (Stuer-
Lauridsen et al., 2000). Typically the pH in the sewage sludge is 6-8. Here, basic 
compounds are predominantly in their uncharged form, and behave as neutrals. 
Acidic and zwitterionic substances are mainly ionised in this pH range and hence 
hydrophobicity is no longer the main mechanism of sorption. Most of the existing 
models are based on hydrophobicity, with only a few taking into consideration other 
interactions such as ion-exchange and electronegativity mechanisms. Guidelines 
exist for the measurement of log 𝐾𝑂𝑊 (Berthod & Carda-Broch, 2004; OECD, 2004) 
but for some measured data, it is not clear if the measurement was log 𝐾𝑂𝑊 or 
log 𝐷𝑂𝑊 (distribution coefficient at a given pH) as the experimental conditions are 
often omitted. For these models, 𝐾𝑑  is correlated with 𝐾𝑂𝑊 through 𝐾𝑂𝐶 but the 
predictions are not accurate enough to justify a model based only on this parameter 
(ECETOC, 2013). Poole et al. (1999) developed fragment-approach predictive 
models for 𝐾𝑂𝐶 and 𝐾𝑂𝑊 using the Abraham descriptors, but these descriptors kept 
being refined over time and it was not clear as to which ones to use for new 
molecules (Abraham, Chadha, & Leo, 1994; Abraham, Ibrahim, & Zissimos, 2004; 
Abraham & Le, 1999; Abraham et al., 1991). The 𝐾𝑂𝐶 prediction was refined by 
Andrić et al. (2010) for bigger molecules rather than fragments.   
 
The chemical space to which these models apply does not include a wide range of 
complex and ionisable molecules such as pharmaceuticals. A model for neutral 
organic compounds was developed by Schüürmann et al. (2006) involving the 
compound’s molecular weight, bond connectivity and molecular ε-state (intensity of 
vibronic transitions are the simultaneous changes in electronic and vibrational 
energy levels of a molecule due to the absorption or emission of a photon of the 
appropriate energy), as well as fragment correction factors and structural indicator 
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variables. The Weighed Holistic Invariant Molecular (WHIM) descriptors have also 
been used to obtain models for the prediction of 𝐾𝑂𝑊 (Todeschini & Gramatica, 
1997; Todeschini & Gramatica 2002) as this set of descriptors is linked to the 
geometrical structure of a compound. A similar set of descriptors linked to the 
geometrical structure with different leverage, the GETAWAY descriptors are also 
considered (Consonni & Todeschini, 2002).  
 
Other authors have derived models applicable to specific groups of chemicals such 
as alcohols and organophosphates (Tao et al., 1999). Struijs et al. (1991) developed 
a model to predict 𝐾𝑂𝐶 from 𝐾𝑂𝑊 which is implemented in the Simple Treat™ 
software. The European Union System for the Evaluation of Substances (EUSES) 
uses this model for the calculation of predicted environmental concentrations (PEC). 
The Simple Treat™ model takes into account the sorption of a chemical to sewage 
sludge as well as the biodegradation rate of the chemical. It has been refined 
several times since its creation, first in 1996 to be adapted to EUSES, second in 
2004 to incorporate the class-specific Sabljic 𝐾𝑂𝑊 equations and most recently to 
include predictions for specific ion classes (Franco et al., 2013; Franco & Trapp, 
2008). Improved mathematical models for sorption and biodegradation, with a focus 
on ionisable compounds, specifically acids, bases and amphoteres (compounds that 
can act either as a base or an acid) have also been developed (Franco, Fu, & 
Trapp, 2009). These were refined later for bases (Franco et al., 2013), but do not 
cover zwitterions, a subgroup of amphoteres that have the ability to bear a positive 
and a negative charge at the same time (Franco & Trapp, 2008). This refinement for 
ionisable compounds was needed since a survey of the distribution of compounds in 
different ion classes in the REACH chemical space (Franco et al., 2010) showed 
that only half of the compounds pre-registered for REACH were neutral (Figure 1.5). 
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Figure 1.5 Distribution of 1,510 pre-registered REACH chemicals between ion classes, 
including acids (with pKa < 12), bases (with pKa > 2) and zwitterionics together with other 
amphoteres (Franco et al., 2010). 
 
1.7 Aims and Objectives 
The legislation for chemical registration consists of a set of rules for both 
experimentation and modelling. These rules are in the form of official guidelines, 
such as those of the OECD and OPPTS, or computational programs, such as 
SimpleTreat™. Experimental guidelines are based on soil experimentation and are 
not specifically focused on sewage sludge or pharmaceutical risk assessment. The 
guidelines are not clear on the choice of buffer or sludge type chosen. The 
computer programs have been developed based on the assumption that 
hydrophobicity is the major factor determining sorption, with very little consideration 
for other parameters. This research explores, in depth, the experimentation as well 
as the mathematical modelling of pharmaceuticals in sewage sludge by gathering 
more information on the mechanistic interaction of pharmaceuticals in sewage 
sludge.  
 
The aim of this research was to understand sorption mechanisms between 
pharmaceuticals and sewage sludge in order to develop new models to predict their 
fate in the environment. Prior to this work one of the major barriers to accurate 
sorption modelling was that hydrophobicity was assumed to be the only binding 
acids 
27% 
bases 
14% zwitter- 
ionics 
8% 
neutrals 
51% 
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mechanism in sludge and the majority of current models take only this parameter 
into account. A better understanding of the mechanism of interaction is critically 
needed to refine and improve the predictive models currently used in environmental 
risk assessment of pharmaceuticals. Specifically, new models are needed to 
address specific ion classes such as zwitterions, which are currently not 
appropriately covered by existing models. 
 
The first objective was to obtain a better chemical and physico-chemical 
characterisation of the sludge. Even though numerous papers mention NMR, FTIR 
and elemental analysis characterisation (section 1.4), it was not clear how this 
information would help identify the important factors affecting partitioning of 
pharmaceuticals in sewage sludge. Physico-chemical information on the sludge 
itself, such as specific surface area, porosity, particle size, poly-dispersity, 
aggregation state, viscosity or rigidity and water content of the sludge is often 
missing from reported studies. This research investigated a new approach for the 
assessment of sorption by measuring 𝐾𝑑 in a quicker way, using an amended solid-
phase extraction (SPE) technique as the OPPTS guideline method is extremely time 
consuming. For this purpose, more physico-chemical properties of the sludge are 
needed  
 
The second objective was to build and validate an accurate model for the sorption of 
pharmaceuticals in sewage sludge, to select appropriate existing data, and to 
generate new data in the given time of this project. Limitations of the 𝐾𝑂𝑊-based 
predictive models necessitated the exploration of descriptors other than the octanol-
water partition coefficient. The use of two sets of Dragon® descriptors (Maur et al., 
2006), WHIM and Getaway (GEometry, Topology and Atom-Weights AssemblY) 
descriptors (Consonni & Todeschini, 2002) have been investigated in this research 
as well as the Molecular Operating Environment© (MOE) (Chemical Computing 
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Group Inc., 2014) and the Parasurf® descriptors (Clark, 2010) in order to build 
robust models. A less complex set of descriptors based on physico-chemical 
properties have been used as well from AstraZeneca’s in-house software CLab®. 
Partial least squares (PLS) and artificial neural network (ANN) techniques were 
used to improve the existing models and develop new ones.  
 
The specific objectives of this thesis were: 
• To characterise physico-chemical properties of different sewage 
sludge matrices and to understand sorption and partitioning mechanisms occurring 
between the sewage sludge matrix and human pharmaceuticals (Chapter 3). 
• To develop and validate a new SPE method for fast experimental 
measurements of 𝐾𝑑   values as an alternative to the OPPTS 835.1110 test (Chapter 
4). 
• To assess the existing models for the prediction of 𝐾𝑑 from 𝐾𝑂𝑊, 𝐾𝑂𝐶 
and 𝑓𝑂𝐶; specifically to address the gap regarding partitioning of ionisable 
compounds by developing new  𝐾𝑂𝑊-based model using the latest measured 𝐾𝑑 
values available in the literature (Chapter 5).  
• To investigate the use of different types of molecular descriptors to 
build PLS and ANN models for the prediction of 𝐾𝑑, and to compare the 
performance of these models with that of  models currently in use (Chapter 6). 
• To attempt to link the knowledge gathered for the sewage sludge 
matrix with the soil matrix by extending the newly developed SPE method to soils 
(Chapter 7). 
• To incorporate the findings of this study into recommendations that 
would yield a better awareness of the fate of products in the environment and help 
further development of current environmental risk assessment guidelines (Chapter 
8).   
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Chapter 2: Study Compounds 
 
2.1 Introduction 
The study compounds selected are all APIs more generally referred to as 
pharmaceuticals. Medicinal products are classified in various different ways. One of 
the key divisions is between traditional small molecule drugs, usually chemically 
synthesised, and biologic medicinal products such as recombinant proteins and 
vaccines. This thesis focused on the first type, the chemically synthesised APIs. The 
main therapeutic areas consist of: 
o Oncology: cancer therapy. 
o Infectious diseases:  caused by pathogenic microorganisms. 
o Central nervous system/Neurology: includes epilepsy, headaches, 
Parkinson’s and Alzheimer’s diseases, cerebro-vascular disease and 
infections. 
o Cardiovascular: caused by disorders of the heart and blood vessels, 
including coronary heart disease (heart attacks), cerebro-vascular disease 
(stroke), raised blood pressure (hypertension). 
o Pain/inflammation and arthritis: includes anti-inflammatories and analgesics.  
o Metabolic disorders: such as diabetes. 
o Respiratory: ranging from mild and self-limiting infections, such as the 
common cold, chronic lung disease, most commonly chronic obstructive 
pulmonary disease, to life-threatening entities like bacterial pneumonia, 
pulmonary embolism and lung cancer. 
o Gastroenterology: focused on the digestive system and its disorders. 
o Ophthalmology: any disease related to the eye. 
o Haematology: any disease related to the blood. 
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o Autoimmune diseases: a condition that occurs when the immune system 
mistakenly attacks and destroys healthy body tissue. There are more than 
80 different types of autoimmune disorders including Addison’s disease 
(kidneys), celiac disease (gluten reaction) or multiple sclerosis (MS). 
o Dermatology: any disease related to the skin. 
o Renal Disease: any disease related to the kidneys.  
o Hormone and endocrine therapies: use of hormones or hormone antagonists 
in medical treatment or endocrine system regulation. 
In some cases, a pharmaceutical can belong to more than one therapeutic class. 
 
The study compounds for this work were chosen to represent a maximum number 
of therapeutic areas, but were also chosen according other criteria, such as their 
presence in the environment, their consumption and the risk they might pose to 
aquatic organisms (Appendix A). The compounds for this study were used for: 
method development, method validation and model validation. 
 
2.2 Method Development Compounds 
 
Initial development of experiments for measuring the distribution coefficient 𝐾𝑑 was 
based on three ionisable pharmaceuticals: clofibric acid, diclofenac and oxytetra-
cycline. These compounds covered the range of low (Barron et al., 2009; Urase & 
Kikuta, 2005), medium (Ternes et al., 2004) and high (Stuer-Lauridsen et al., 2000) 
𝐾𝑑 values, respectively, and were chosen for their acidic or zwitterionic character 
and their widespread and long-term use explaining their frequent presence in the 
environment. Clofibric acid (98.6%), diclofenac (99%) and oxytetracyline (97%) 
were purchased from Sigma Aldrich (Gillingham, Dorset, UK). Their physico-
chemical properties are listed in Table 2.1. 
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Table 2.1 Physico-chemical properties of the three compounds for method development. 
 
Compound Structure 
Therapeutic 
class 
MW 𝐥𝐨𝐠 𝑲𝑶𝑾
a
 𝒑𝑲𝒂
a 𝐥𝐨𝐠 𝑲𝒅
* 
Clofibric acid 
 
Lipid regulator 
(cardiovascular) 
215 2.7 3.0 1.5
b 
Diclofenac 
 
Analgesic, anti- 
inflammatory 
296 4.1 4.15 
1.5 - 
2.7
b,c 
Oxytetracycline 
 
Antibacterial, 
antibiotic 
460 1.6 
3.3, 
7.3, 
9.1 
3.5
d 
a
Predicted by ACDLabs (www.acdlabs.com) 
c
Ternes et al., 2004
 
b
Urase & Kikuta, 2005   
d
Stuer-Lauridsen et al., 2000 
*in sewage sludge 
 
2.2.1 Clofibric acid 
Clofibric acid was one of the first APIs to be detected in the environment by Stumm-
Zollinger and Fair in 1965 (cited by Snyder et al., 2003). Since this early 
observation, it has often been detected in the aquatic environment (Barron et al., 
2009; Fent et al., 2006, Ternes et al., 2004). This compound has a low reported 𝐾𝑑 
value in sewage sludge (Urase & Kikuta, 2005).  
 
2.2.2 Diclofenac 
The presence of diclofenac in the environment has had a drastic effect on wildlife 
especially in Pakistan, where studies have shown a link between diclofenac 
exposure and acute kidney failure in vultures, when they fed on treated cattle 
carcasses (Oaks et al., 2004; Shultz et al., 2004). Oaks et al. (2004) reported a 
sharp decline in vulture population in the Indian subcontinent (95% decline in 2003) 
due to the use of veterinary diclofenac on livestock. As a consequence, diclofenac 
has recently been added to the WFD watch list (Water UK, 2013). Diclofenac has a 
𝐾𝑑 value in the middle range of those observed (Ternes et al., 2004; Urase & 
Kikuta, 2005). 
Cl O
COOH
H3C
CH3
NH
Cl
Cl
HOOC
OH OH
OH
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CONH2
HO CH3 OH
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2.2.3 Oxytetracycline 
Oxytetracycline is an antibiotic used in human and veterinary medicine. It is only 
partially metabolised in mammals and a significant fraction of that ingested can be 
excreted in manure. It is, therefore, found in manure and soil, with the potential to 
reach crops and ground water. This phenomenon can contribute to antimicrobial 
resistance. This compound was chosen due to its high 𝐾𝑑 value in sludge (Stuer-
Lauridsen et al., 2000). Oxytetracycline is also a zwitterion, a compound that can 
bear simultaneously negative and positive charges depending on the pH of the 
aqueous solution it is in. 
 
 
2.3 Method Validation Compounds 
In order to validate the SPE method developed in Chapter 4, ten additional APIs 
with a range of physico-chemical properties were selected. These are listed in Table 
2.2. They cover a wide range of therapeutic areas, and are widely used and hence 
likely to be found in WWTPs. In addition, AstraZeneca had previously measured the 
𝐾𝑑 values of these substances, using the method described in the OPPTS 835.1110 
guideline.  
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Table 2.2 Physico-chemical properties
a
 of the ten compounds used for the validation of the 
SPE method. 
Compound Structure 
Therapeutic 
area 
MW 𝐥𝐨𝐠 𝑲𝑶𝑾 𝒑𝑲𝒂 𝐥𝐨𝐠 𝑲𝒅 
Bicalutamide 
 
Non-steroidal 
anti-androgen 
Hormone therapy 
430.4 2.4 11.9 2.2 
Candesartan 
 
Hypertension 440.5 1.6 
2.1, 
4.6 
1.2 
Esomeprazole 
 
Gastrointestinal 345.4 1.7 
4.0, 
8.8 
1.7 
Felodipine 
 
Cardiovascular 
and diabetes 
384.3 5.0 5.4 3.5 
Gefitinib 
 
Oncology 446.9 4.2 - 3.3 
Ibuprofen 
 
Anti-inflammatory 
Pain 
206.3 3.7 4.8 0.9
b
 
Propranolol 
 
Beta-blockers, 
hypertension 
259.3 3.5 9.5 2.6 
Quetiapine 
 
CNS 383.5 1.4-2.7 
3.3, 
6.8 
2.5 
Ticagrelor 
 
Cardiovascular 
and diabetes 
522.6 > 4.0 - 3.2 
Vandetanib 
 
Oncology 475.4 
-0.7-
3.9 
9.3 3.9 
a
http://www.astrazeneca.com/Responsibility/The-environment/Pharmaceuticals-in-the-
environment/era-data-2012 
b
Data not reported on the AstraZeneca portal. 
 
2.4 Literature Compounds 
Nine former compounds where measured 𝐾𝑑 values were available in the literature 
were selected. These compounds were tested by a number of different researchers, 
and for some there was a large variation between the published values. Where 𝐾𝑑  
43 
 
values were not in agreement across different authors, or were noticeably different 
from expected values from 𝐾𝑂𝐶-based predictions, the compounds were re-tested 
under the same laboratory conditions (SPE method in Chapter 4) and the SPE 𝐾𝑑   
value determined. 
 
Table 2.3 Compounds re-tested due to inconsistencies between 𝐾𝑑  values found in the 
literature and/or  𝐾𝑂𝑊 values.  
Compound Structure 
Therapeutic 
area 
MW 𝐥𝐨𝐠 𝑲𝑶𝑾
* 𝒑𝑲𝒂
* 𝐥𝐨𝐠 𝑲𝒅** 
Carbamazepine 
 
Neurology 236.3 1.9 - 1.73
1,3,2,4,5
 
Clomipramine 
 
Neurology 314.9 4.94 
pKb 
9.67 
4.23
6
 
Clotrimazole 
 
Infection 344.8 4.92 
pKb 
6.05 
4.51
6
 
Flutamide 
 
Hormone 
therapy, 
Oncology 
276.2 3.52 - 3.18
6
 
Hydrochlorothiazide 
 
Cardiovascular 297.7 -0.02 - 1.31
3
 
Mecillinam 
 
Infection 325.4 2.33 
pKb 
9.04 
1.74
7 
Paracetamol 
 
Pain 151.2 0.48 - 2.77
3,4
 
Roxithromycin 
 
Infection 837.1 2.84 
pKb 
8.30 
2.45
2
 
TCEP 
tris(2-carboxyethyl) 
phosphine  
N/A 250.2 -0.22 
pKa 
4.04 
1.81
4
 
*
Predicted by ACDLabs (www.acdlabs.com)  **Mean of reported values in sludge 
1
Stevens-Garmon et al., 2011 
2
Radjenović et al., 2009 
3
Lajeunesse et al., 2012  
4
Urase & Kikuta, 2005 
5
Andersen et al., 2005 
 6
Wick et al., 2009 
7
Halling-Sørensen et al., 2000  
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One of the notable pharmaceuticals in this list is carbamazepine, which is on the 
WHO’s list of essential medicines (WHO, 2013), and it has been shown to persist and 
accumulate in the organic components of soil and sludge (Stamatelatou et al., 2003). 
The pseudo-persistence (chemicals continually infused to the aquatic environment 
essentially become “persistent” pollutants even if their half-lives are short) and the low 
biodegradability of carbamazepine make it an ideal anthropogenic marker in water 
bodies (Clara et al., 2005; Zhang, Geißen, & Gal, 2008). 
 
 
2.5 Model Validation Compounds 
After testing and validating the new SPE method, as described in Chapter 4, the 
procedure was applied to measure the 𝐾𝑑 values of additional compounds for later 
use in assessing the statistical models developed in Chapter 6. These compounds 
are distributed in two categories: the first includes six compounds supplied by 
AstraZeneca (2.5.1) and the second includes twelve compounds from the top twenty 
prescribed drugs in England for which 𝐾𝑑 values were not available in the literature 
(2.5.2). The 𝐾𝑑 values for these compounds measured with the SPE method were 
compared with the values predicted by the new statistical models in order to assess 
their performance. 
 
2.5.1 AstraZeneca Compounds 
The six compounds listed in Table 2.3 were supplied by AstraZeneca. The 𝐾𝑑 
values of some of these had never been measured in sludge before, making them 
ideal candidates for the assessment of the models in Chapter 6.  
 
 
 
 
 
 
 
45 
 
Table 2.4 AstraZeneca compounds for model validation. 
Compound Structure 
Therapeutic 
area 
MW 𝐥𝐨𝐠 𝑲𝑶𝑾
* 𝒑𝑲𝒂
* 
Allopurinol 
 
Metabolism, 
Inflammatory 
136.1 -0.55 - 
Ceftazidime 
 
Infection 547.6 -2.50 
pKa:2.43, 
2.89 
pKb:1.34 
Fulvestrant 
 
Oncology 606.8 8.07 - 
Lesinurad 
 
Metabolism, 
Inflammatory 
404.3 6.10 2.91 
Selumetinib 
 
Oncology 457.7 2.59 - 
Zibotentan 
 
Oncology 424.4 1.15 5.62 
*
Predicted by ACDLabs (www.acdlabs.com) 
 
 
 
2.4.2 Top Twenty Prescription Compounds 
The top twenty pharmaceutical products prescribed in England in 2010 are listed in 
Table 2.5. Only a few of these had partition coefficients for activated sewage sludge 
reported in the literature. The SPE method was applied to the remaining twelve 
compounds, listed in Table 2.6, to measure their 𝐾𝑑 values. 
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Table 2.5 Top twenty pharmaceuticals in England, by prescription volume, 2010.  
Chemical name Therapeutic area Prescriptions 
(thousands) 
𝑲𝒅 in sludge 
Simvastatin Cardiovascular  39,551 N/A 
Aspirin Cardiovascular  32,315 N/A 
Levothyroxine Sodium Endocrine  23,446 N/A 
Ramipril Cardiovascular 20,988 N/A 
Omeprazole Gastro-Intestinal  20,674 119.0 
Paracetamol Central Nervous  19,890 307.0 
Salbutamol Respiratory  19,092 N/A 
Bendroflumethiazide Cardiovascular  18,724 N/A 
Amlodipine Cardiovascular  18,086 N/A 
Lansoprazole Gastro-Intestinal  15,952  N/A 
Co-Codamol (Codeine 
Phos/Paracetamol) 
Central Nervous  14,892  14.0/307.0 
Metformin Hydrochloride Endocrine  14,277 N/A 
Amoxicillin Infections 13,500 N/A 
Atenolol Cardiovascular  12,882 122.0 
Furosemide Cardiovascular  11,999  158.0 
Citalopram 
Hydrobromide 
Central Nervous  11,823 540.0 
Ergocalciferol Nutrition and blood 11,701 N/A 
Atorvastatin Cardiovascular  11,055 207.0 
Bisoprolol Fumarate Cardiovascular  10,215 40.0 
Lisinopril Cardiovascular  9,797 N/A 
Source: The Information Centre, NHS, 'Prescription Cost Analysis: England', 2010. 
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Table 2.6 Compounds from the top twenty prescription drugs with no reported measured 
partition coefficients.   
Compound Structure MW 𝐥𝐨𝐠 𝑲𝑶𝑾
*
 𝒑𝑲𝒂
*
 𝐥𝐨𝐠 𝑲𝑶𝑪
** 
Amlodipine 
 
408.9 3.01 pKb:9.36 1.00 
Amoxicillin 
 
365.4 0.88 
pKa:2.44, 
9.76 
pKb:7.14 
3.98 
Aspirin 
 
180.2 1.40 pKa 3.48 1.50 
Bendroflumethiazide 
 
421.4 1.29 - 4.38 
Ergocalciferol 
 
396.7 9.15 - 3.52 
Lansoprazole 
 
369.4 2.58 - 4.41 
Levothyroxine 
Sodium 
 
776.9 4.72 
pKa:2.12, 
6.91 
pKb: 8.27 
6.40 
Lisinopril 
 
405.5 3.47 
pKa:2.18, 
3.16 
pKb: 10.5, 
7.4 
2.94 
Metformin 
Hydrochloride 
 
129.2 -1.02 pKb:13.1 2.15 
Ramipril 
 
416.5 4.37 
pKa:3.15  
pKb: 5.44 
4.85 
Salbutamol 
 
239.3 0.69 pKb:9.62 3.22 
Simvastatin 
 
418.6 4.72 - 1.64 
*
Predicted by ACDLabs (www.acdlabs.com) 
**Predicted by EpiSuite (http://www.epa.gov/opptintr/exposure/pubs/episuite.htm) using the Sabljic 
molecular connectivity method with improved correction factors 
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2.6 Detection of Compounds 
All the compounds in this chapter were quantified using high performance liquid 
chromatography (HPLC) with ultraviolet (UV) detection. The method was developed 
and validated for the three method development compounds and then applied to the 
others. Some deviations from the HPLC method were made for compounds that 
could not be detected properly due to poor retention, low sensitivity, or poor 
resolution. The HPLC method has previously been validated according to the 
International Conference on Harmonisation Guidelines (ICH, 1996). Two Agilent 
1100 and 1200 HPLC systems, in combination with a Gemini C18 column (150 x 4 
mm, 3 µm particle size) (Phenomenex, Macclesfield, UK), were used to detect and 
quantify all the pharmaceuticals used in this research.      
 
2.6.1 Method Validation 
2.6.1.1 Linearity 
Linearity is established over a selected range if the Pearson correlation coefficient 
between the concentration of standards and the UV response was greater than 
0.999. This was the case for clofibric acid and oxytetracycline with a linearity range 
of 0.30-500 mg/L and for diclofenac with a linearity range of 0.10-500 mg/L. 
 
2.6.1.2 Stability  
For all three compounds stability was demonstrated when a heat stressed sample 
had no major degradation products that interfered with any peak of interest. The 
solution stability was established when 100% ± 5% recovery of spiked standard in 
buffer solution was achieved. Aqueous solutions for clofibric acid and diclofenac 
were stable up to 4 days when stored in refrigerated and dark conditions. Aqueous 
solutions of oxytetracycline were stable up to 1 d when stored in refrigerated and 
dark conditions. 
49 
 
2.6.1.3 Limit of Quantification 
Limit of Quantification (LOQ) was determined by a signal/noise ratio greater than 10 
(ICH, 1996). Limit of Detection (LOD) was typically set at a third of the LOQ. A LOQ 
of 0.30 mg/L with a LOD of 0.10 mg/L was achieved for clofibric acid and 
oxytetracycline. Diclofenac produced a LOQ of 0.10 mg/L with a LOD of 0.03 mg/L. 
 
2.6.2 Final HPLC Conditions 
The final chromatographic conditions using a Gemini C18 3 µm; 150 × 3.0 mm 
stationary phase were: 
Flow Rate: 0.7 mL/min  Injection Volume: 20 μL 
Column Temperature: 30 °C Detection Wavelength: 220 nm 
 
Table 2.7 Gradient conditions for the HPLC method. 
Time (mins) %A: 0.01 M phosphate buffer pH 
3 
%B: acetonitrile 
0.0 90 10 
1.0 90 10 
11.0 30 70 
13.0 30 70 
14.0 90 10 
15.0 90 10 
 
 
2.6.3 Study compounds LOD and LOQ 
LOQ were measured for all the tested compounds and the LOD was set at a third of 
the LOQ. The results are shown Table 2.8 
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Table 2.8 LOD and LOQ for pharmaceuticals tested using the HPLC-UV method. 
Compound Limit of Detection 
(mg/L) 
Limit of Quantification 
(mg/L) 
Allopurinol 0.0103 0.0309 
Amlodipine* 0.1896 0.5688 
Amoxicillin* 0.1120 0.3359 
Aspirine 0.0850 0.2550 
Bendroflumethiazide* 0.3200 0.9600 
Bicatulamide 0.0300 0.0900 
Candesartan 0.0100 0.0300 
Carbamazepine 0.0313 0.0939 
Ceftazidime* 0.0608 0.1824 
Clomipramine 0.0530 0.1590 
Clotrimazole 0.0495 0.1485 
Ergocalciferol* 0.1996 0.5988 
Esomeprazole 0.0192 0.0576 
Felodipine* 0.0100 0.0300 
Flutamide 0.1280 0.3840 
Fulvestrant* 0.2760 0.8280 
Gefitinib 0.0290 0.0870 
Hydrochlorothiazide* 0.0511 0.1533 
Ibuprofen 0.0152 0.0456 
Lansoprazole* 0.2026 0.6078 
Lesinurad 0.0051 0.0152 
Levothyroxine 0.0533 0.1600 
Lisinopril* 0.2003 0.6009 
Mecillinam 0.1580 0.4740 
Metformin* 0.2501 0.7503 
Paracetamol* 0.0784 0.2352 
Propranolol 0.0042 0.0125 
Quetiapine fumarate 0.0111 0.0333 
Ramipril 0.2400 0.7200 
Roxithromycin* 0.2081 0.6217 
Salbutamol* 0.4950 1.4900 
Selumetanib 0.0094 0.0282 
Simvastatin 0.1100 0.3300 
TCEP* 0.0948 0.2844 
Ticagrelor 0.0199 0.0597 
Vanderanib 0.0102 0.0306 
Zibotentan 0.0151 0.0453 
*compounds tested with a deviation from the method. 
 
2.6.4 Deviations from the Standard HPLC Method 
Some modifications were made to the analytical method in order to improve the 
detection of certain compounds. The fifteen compounds in Table 2.8 marked with an 
asterix needed an amendment of the method to be detected and tested 
appropriately. The amendments are as follows: 
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Amlodipine  
The gradient was changed to an isocratic elution 30/70% 0.01 M phosphate buffer 
at pH = 3/acetonitrile to allow the compound to be sufficiently retained on the 
column. 
 
Amoxicillin 
The gradient was extended to 30 s with a change in both mobile phase A and B for 
phosphate buffer to reverse osmosis (RO) water and acetonitrile to a mixture 50/50 
v/v% methanol/acetonitrile as shown in Table 2.9. 
 
Table 2.9 HPLC gradient elution conditions for amoxicillin. 
Time (mins) %A: 1 mL H3PO4 in 500 mL RO 
water 
%B: 50/50 v/v 
acetonitrile/methanol 
0.0 90 10 
1.0 90 10 
11.0 30 70 
11.5 30 70 
13.5 90 10 
15.0 90 10 
 
 
Bendroflumethiazide 
The gradient elution was amended to slow down the elution as shown in Table 2.10, 
and mobile phase A was changed from 0.01 M phosphate buffer at pH = 3 to RO 
water. 
 
Table 2.10 HPLC gradient conditions for bendroflumethiazide. 
Time (mins) %A: RO Water %B: acetonitrile 
0.0 95 5 
2.5 95 5 
8.0 50 50 
10.0 50 50 
12.0 95 5 
15.0 95 5 
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Ceftazidime 
For ceftazidime the elution gradient was slowed down and the overall runtime was 
shortened as shown in Table 2.11. 
Table 2.11. HPLC gradient conditions for ceftazidime. 
Time (mins) %A: 0.01 M phosphate buffer pH 
3 
%B: acetonitrile 
0.0 100 0 
9.0 90 10 
10.0 90 10 
11.0 100 0 
12.0 100 0 
 
Ergocalciferol 
Ergocalciferol gradient time was amended in order to slow the elution of the 
compound, the overall runtime was shortened to 8 min and mobile phase A was 
changed for RO water (Table 2.12). 
 
Table 2.12 HPLC gradient conditions for ergocalciferol. 
Time (mins) %A: RO water %B: acetonitrile 
0.0 100 0 
2.0 100 0 
5.5 89 11 
6.5 89 11 
7.0 100 0 
8.0 100 0 
 
Felodipine 
Felodipine gradient was amended to speed the gradient up to 9 min instead of 11 
min to reach 70% acetonitrile as the compound initially eluted too close to the end of 
the run (Table 2.13). 
 
Table 2.13 HPLC gradient conditions for felodipine. 
Time (mins) %A: 0.01 M phosphate buffer pH 
3 
%B: acetonitrile 
0.0 90 10 
1.0 90 10 
9.0 30 70 
13.0 30 70 
14.0 90 10 
15.0 90 10 
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Fulvestrant 
For fulvestrant the elution regime was changed to an isocratic elution with 70/30% 
acetonitrile/0.01 M phosphate buffer (pH = 3). The detection wavelength was also 
changed from 220 nm to 285 nm. Injection volume was set at 40 µL instead of 20 
µL. 
 
Hydrochlorothiazide 
For hydrochlorothiazide, the elution gradient was amended to start at 100% 
phosphate buffer instead of 90% as shown in Table 2.14. The detection wavelength 
was amended to 272 nm. 
 
Table 2.14 HPLC gradient conditions for hydrochlorothiazide. 
Time (mins) %A: 0.01 M phosphate buffer pH 
3 
%B: acetonitrile 
0.0 100 0 
1.0 100 0 
11.0 30 70 
13.0 30 70 
14.0 100 0 
15.0 100 0 
 
Lansoprazole 
Lansoprazole gradient was amended by delaying the start of the increase in 
acetonitrile and by shortening the overall runtime from 15 min to 8 min as shown in 
Table 2.15 to improve the retention time. 
 
Table 2.15 HPLC gradient conditions for lansoprazole. 
Time (mins) %A: RO water %B: acetonitrile 
0.0 100 0 
5.0 100 0 
6.5 50 50 
7.0 50 50 
7.5 100 0 
8.0 100 0 
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Lisinopril  
Lisinopril elution was changed to an isocratic run of 80/10/10 0.5% H3PO4 in RO 
water/acetonitrile/methanol. 
 
Metformin 
Metformin method was also changed to an isocratic elution 79/21 0.01 M phosphate 
buffer (pH = 3) with 0.5 mM sodium dodecyl sulphate/acetonitrile. 
 
Paracetamol 
The gradient for paracetamol was amended and was the same as that for 
hydrochlorothiazide (Table 2.14). This was due to elution of paracetamol being too 
close to the solvent front. The wavelength was also changed from 220 nm to 245 
nm. 
 
Roxithromycin 
For roxithromycin the wavelength was changed from 220 nm to 200 nm to improve 
sensitivity. 
 
Salbutamol 
Salbutamol gradient was changed as shown in Table 2.16 the mobile phase A was 
also changed to RO water. 
 
Table 2.16 HPLC gradient conditions for salbutamol. 
Time (mins) %A: RO Water %B: Acetonitrile 
0.0 100 0 
2.0 100 0 
9.0 40 60 
9.5 40 60 
10.0 100 0 
11.0 100 0 
 
 
55 
 
TCEP 
TCEP elution was amended to an isocratic condition 90/10 % 0.01 M phosphate 
buffer pH = 3/acetonitrile. 
 
 
2.7 Closing Remarks 
The development of the analytical method was not the focus of this study; therefore, 
it will not be discussed further in this thesis. In the next chapter, any experimental 
description of the work includes solely sorption-related experimental details. The 
method development compounds are mainly used in the work described Chapter 3. 
The method validation compounds are predominantly used in the work described in 
Chapter 4. The model validation compounds are used in both Chapters 4 and 6. 
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Chapter 3: Sewage Sludge as an Environmental 
Matrix  
 
The general term ‘sewage sludge’ can describe at least four types of sludge: 
primary, activated, secondary and digested, and in some cases it is not clear which 
type of sludge is most appropriate for environmental testing. Sewage sludge is a 
complex matrix and its sorption mechanisms are not fully understood. To identify 
these mechanisms, information about the physico-chemical properties of sewage 
sludge is needed. Once this information is available, a comparison with reference 
materials with known mechanisms of interaction would be possible. This chapter is 
divided into three sections: (1) a discussion around which type of sludge to use in 
environmental testing, (2) information on the chosen sludge physico-chemical 
characterisation and, (3) the main types of interaction between organic compounds 
and sewage sludge.  
 
3.1 Comparison of Partitioning in Different Sludges for 
Environmental Testing 
This section focuses on the possible effects that the type of sludge used in sorption 
experiments may have on measured 𝐾𝑑 values. The underlying hypothesis is that 
sludge may change in composition as it progresses through a WWTP. Hence, the 
different physico-chemical processes involved across a plant give insights into the 
sludge type and possible consequences for partitioning. If such sorption differences 
are significant, it may help to explain the significantly different 𝐾𝑑 values reported in 
the literature. If the different sludges have different sorption properties, assessment 
of the fate of pharmaceuticals in the environment could be improved by using a 
range of sludge types that are appropriate for a particular WWTP.  
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Within the literature, all four types of sludge (primary, activated, secondary and 
digested) found in a WWTP have been used in laboratory-based sorption 
experiments. The matrix used has been shown to have an effect on the 
experimental values obtained. For example, comparisons have been made between 
primary and secondary (Hörsing et al., 2011; Ternes et al., 2004), activated versus 
primary (Joss et al., 2005; Radjenović et al., 2009; Stevens-Garmon et al., 2011) 
and activated versus digested (Suárez et al., 2008). Activated sludge was found to 
be comparable to primary sludge (Radjenović et al., 2009; Stevens-Garmon et al., 
2011). Primary sludge behaved differently to secondary sludge. This was attributed 
to differences in pH (Ternes et al., 2004), and surface properties of the material 
(Hörsing et al., 2011). The relationship between activated sludge and digested 
sludge was less clear (Suárez et al., 2008).   
   
The location of the sampling point for the sludge within the WWTP is important but 
there is often inconsistency in different studies. For example, primary sludge can be 
sampled before the first clarifier (Stevens-Garmon et al., 2011; Ternes et al., 2004) 
or after it (Radjenović et al., 2009). In one study primary sludge was sampled from a 
primary clarifier that had no secondary sludge recirculation (Hörsing et al., 2011). 
Comparison of sludge samples obtained from two different types of digesters, 
mesophilic and thermophilic, showed that sorption was not influenced by the 
operational conditions of the digester as long as the pH remained between 5.4 and 
6.9 (Carballa et al., 2008). The effect of sludge retention time on sorption has also 
been studied by Horsing et al. (2011). They compared the sorption behaviour of 
APIs with secondary sludge of different ages and found that sorption was lower with 
short retention times (2-3 days), than with longer retention times (10 days).  
 
The physico-chemical properties of the sludge vary from plant to plant as well as 
between different locations within a WWTP. This contributes to the variability of the 
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𝐾𝑑 values reported in the literature for APIs and related compounds. These 
inconsistencies could lead to incorrect environmental risk assessments (ERA) being 
made for some APIs. For example, 𝐾𝑑 values are frequently measured using 
activated sludge as the solid phase. However, if assessing the potential for leaching 
of an API to soil when waste material is subsequently applied to land, it may be 
more appropriate to use digested sludge as the solid matrix in laboratory 
measurements. 
 
This section undertakes a meta-analysis of the 𝐾𝑑 values of APIs published in the 
literature. It aims to identify the possible effects that the type of sewage sludge used 
in sorption experiments may have on the measured 𝐾𝑑 values, and to investigate 
possible associations between the sorption behaviour of these matrices. This 
information may be useful in guiding the disposal of sewage sludge, aiding ERA and 
generating larger datasets for use in developing predictive models that describe the 
partitioning behaviour of APIs. 
 
3.1.1 Data Collection and Analysis Methods 
Partition coefficient values covering a wide range of APIs (antibiotics, anticancers, 
anti-inflammatories, cardiovasculars, central nervous system drugs and hormones) 
were taken from fourteen papers (Barron et al., 2009; Carballa et al., 2008; Göbel, 
Thomsen, McArdell, Joss, et al., 2005; Hörsing et al., 2011; Joss et al., 2005; Kim et 
al., 2010; Lajeunesse et al., 2012; Radjenović et al., 2009; Stevens-Garmon et al., 
2011; Stuer-Lauridsen et al., 2000; Suárez et al., 2008; Ternes et al., 2004; Urase & 
Kikuta, 2005; Wick et al., 2009). The type of sewage sludge (primary, activated, 
secondary or digested) used in these measurements was recorded. 
 
Primary sludge was collected just after the grit removal stage and before the first 
clarifier in some experiments, or just after the primary clarifier in others (Figure 1.3). 
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In some experiments the primary clarifier had no secondary sludge recirculation; 
while in others it did (Hörsing et al., 2011; Radjenović et al., 2009; Stevens-Garmon 
et al., 2011; Ternes et al., 2004). Activated sludge was always sampled in the 
activation tank in the nitrification zone (Radjenović et al., 2009; Stevens-Garmon et 
al., 2011; Suárez et al., 2008). Secondary sludge was collected in the secondary 
clarifier. However, there were differences in sludge age and secondary clarifier 
volume (Hörsing et al., 2011; Ternes et al., 2004). Anaerobically digested sludge 
was sampled from the digester. Some papers reported the type of digester 
(mesophilic or thermophilic) and sludge age (Carballa et al., 2008).  
 
The key physico-chemical properties (pH, total suspended solids (TSS), total 
organic carbon (TOC), volatile suspended solids (VSS) and chemical oxygen 
demand (COD)) of the four sludge types, where available, are listed in Table 3.1. 
 
Table 3.1 Typical physico-chemical properties of sewage sludge types found within a 
wastewater treatment plant reported in the literature. 
 
Sludge 
type 
Primary Activated Secondary Digested 
pH 5.0-8.0
1 
6.8
2 
6.8
3 
7.7-8.6
1 
TSS
a 
50-125 g/L
4 
10-35 g/L
4
 9 g/L
3 
27-42 g/L
1 
TOC
b 
35%
5 
29
2
-49% 25
3
-34
5
% 25% 
VSS
c 25-70 g/L
4
  
(50-80%
1
) 
10-30 g/L
4
  
(87
6
-100%) 
60%
5
 
12-20 g/L
4
  
(44-48%) 
COD
d 
45-120 g/L
4
 10-50 g/L
4
 - 15-32 g/L
4
 
COD/TSS 90-96%, 146%
5
 100-143% 110%
5
 56-76% 
P/TSS
e 
0.8
1
-3.0%
5 
2.8-11.0%
1 
3.0%
5
 1.5-4.0%
1 
Fe(III)/TSS
f 
< 1.0%
5 
- 4.0%
5
 3.0-8.0%
1 
N/TSS
g 
1.5-4.0%
1 
2.4-5.0%
1
 5.8%
5
 1.6-3.0%
1
 
1Tchobanoglous, Burton, & David, 2002  4Carballa et al., 2007  
2Wick, Marincas, Moldovan, & Ternes, 2011  5Ternes et al., 2004 
3Wick et al., 2009   6Radjenović et al., 2009 
 
a
TSS: Total suspended solids    eP/TSS: Phosphorus per TSS  
bTOC: Total organic carbon    fFe(III)/TSS: Iron (III) per TSS 
cVSS: Volatile suspended solids   gN/TSS: Nitrogen per TSS 
dCOD: Chemical oxygen demand 
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All the data were obtained experimentally and the 𝐾𝑑 values were calculated using a 
linear isotherm. These data were grouped by sludge type regardless of any 
sampling differences. When a compound had more than one 𝐾𝑑 value for the same 
type of sludge, the values were averaged and the mean was used. Compounds 
were included only if 𝐾𝑑 values were available for more than one type of sludge. 
This resulted in a set of 82 compounds associated with a set of 202 𝐾𝑑  values 
(Table 3.2). Only some of these compounds had 𝐾𝑑  values available in the literature 
for all sludge types. 
 
Table 3.2 Partition coefficients (𝐾𝑑) of the selected active pharmaceutical ingredients in 
different sludge types.  
 
Pharmaceutical  𝑲𝒅 Activated 𝑲𝒅Primary 𝑲𝒅Secondary 𝑲𝒅 Digested 
Acetaminophen 595.0
1,2
 18.0
1,2
 - - 
Alfuzosin - 180.0
3
 1,200.0
3
 - 
Amitriptyline 4,555.0
1
 4,897.0
1,3
 5,020.0
3,4
 1,049.0
5
 
Androstenedione 156.0
1 
174.0
1
 - - 
Androsterone 579.0
1
 534.0
1
 - - 
Atenolol 44.0
1,2,6
 200.3
1,2,3
 2,800.0
3
 11.0
5
 
Atorvastatin 198.0
1 
216.0
1
 - - 
Atracurium - 350.0
3
 1,600.0
3
 - 
Atrazine 60.0
1
 122.0
1
 - - 
Azelastine - 6,400.0
3
 470.0
3
 - 
Biperiden - 820.0
3
 750.0
3
 - 
Bisoprolol 40.0
6
 - 110.0
3
 - 
Bisphenol A 338.0
1,7
 314.0
1
 - - 
Bupropion - 85.0
3
 140.0
3
 - 
Caffeine 30.0
1
 30.0
1
 - 14.0
5
 
Carbamazapine 53.8
1,2,6,7,8
 102.3
1,2,8,9
 80.2
4,9,10
 39.5
5,8,10
 
Chlorprothixene - 38,000.0
3
 20,000.0
3
 - 
Citalopram - 540.0
3
 2,105.0
3,4
 282.0
5
 
Clofibric Acid 25.5
7
 - 4.8
10
 5.0
5
 
Clomipramine - 17,000.0
3
 6,700.0
3
 - 
Clotrimazol - 32,000.0
3
 34,000.0
3
 8,128.0
5
 
Clozapine 1,642.0
1,6
 1,730.0
1
 - - 
Cyclophosphamide - 55.0
10
 2.4
10
 - 
Cyproheptadine - 11,000.0
3
 3,600.0
3
 - 
DEET
a 
42.0
1
 100.0
1
 - - 
Desloratadine - 3,700.0
3
 2,900.0
3
 - 
Diazapam 91.8
1,6,8
 125.0
1,8
 21.0
9
 - 
Diclofenac 73.5
2,7,8
 403.5
2,8,9,10
 16.0
9,10
 77.5
5,8
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Dicycloverine - 1,400.0
3
 1,700.0
3
 - 
Dilantin 81.0
1
 45.0
1
 - - 
Donepezil - 3,600.0
3
 970.0
3
 - 
Duloxetine - 13,000.0
3
 2,900.0
3
 - 
Erythromycin 116.0
2,8
 309.0
2
 - 190.0
5
 
Estradiol (E2) 787.8
1,7,8,11
 560.0
1
 - 375.5
12,8
 
Estriol 63.0
1
 58.0
1
 - - 
Estrone (E1) 424.2
1,7,8,11
 636.0
1
 - 352.1
12,8
 
Ethinylestradiol (EE2) 763.0
1,7,8,11
 515.3
1,8,10
 349.0
10
 414.1
12
 
Ezetimibe - 2,300.0
3
 3,000.0
3
 - 
Fexofenadine - 2,700.0
3
 360.0
3
 - 
Fluoxetine - 10,000.0
3
 8,800.0
3,4
 - 
Flutamide - 1,500.0
3
 750.0
3
 - 
Gemfibrozil 54.8
1,7
 34.0
1,2
 - - 
Glibenclamide 239.0
2
 1,941.0
2,3,
 1300.0
3
 - 
Glimepiride - 2,100.0
3
 960.0
3
 - 
Haloperidol - 10,000.0
3
 2,900.0
3
 - 
Hydroclorothiazide 20.2
2
 25.8
2
 - - 
Hydroxyzine 819.0
1
 989.0
1,3
 720.0
3
 - 
Ibuprofen 32.4
7,8,13
 13.2
2,8,9
 124.7
3,9,1
 31.4
8,10
 
Ifosfamide - 22.0
10
 1.4
10
 - 
Indomethacin 39.0
7
 - - 214.0
5
 
Iopromide 10.0
8
 5.0
9
 11.0
9,10
 10.0
8,10
 
Irbesartan - 700.0
3
 940.0
3
 - 
Ketoconazole - 9,700.0
3
 8,500.0
3
 - 
Ketoprofen 22.5
2,7
 226.0
2
 - - 
Loperamide - 14,000.0
3
 5,500.0
3
 - 
Loratidine 3321.0
2
 2,336.0
2
 - - 
Maprotiline - 6,700.0
3
 4,500.0
3
 - 
Mefenamic acid 434.0
2
 294.0
2
 - - 
Meprobamate 30.0
1
 42.0
1
 - - 
Metoprolol 65.0
6
 - - 18.0
5
 
Mianserin - 3,000.0
3
 910.0
3
 - 
Naproxen 24.0
7
 217.0
9 
217.0
9 
29.0
5,8
 
Nefazodone - 14,000.0
3
 8,300.0
3
 - 
Nortriptyline - - 6,200.0
11
 600.0
5
 
Omeprazole 107.0
1
 130.0
1
 - - 
Oxazepam 13.0
6
 790.0
3
 1,100.0
3
 - 
Paroxetine - 14,000.0
3
 11,650.0
3,4
 - 
Phenylphenol 347.0
1
 652.0
1
 - - 
Pizotifen - 4,700.0
3
 3,100.0
3
 - 
Primidone 18.5
1,3
 45.0
1
 - - 
Progesterone - 750.0
3
 1,100.0
3
 - 
Propanolol 376.3
2,6
 641.0
2
 - 331.0
5
 
Repaglinide - 170.0
3
 210.0
3
 - 
Risperidone 861.0
1
 1,432.0
3
 650.0
3
 - 
Roxithromycin 282.0
8
 400.0
9
 170.0
9 
49.0
8,12
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Sertraline - 35,000.0
3
 24,000.0
3,4
 1,883.0
5
 
Sotalol 18.0
6
 - 360.0
3
 - 
Sulfamethoxazole 205.0
2,8,14
 241.1
2,3,9
 315.0
3,9
 24.7
5,8,10
 
TCEP
b
 65.0
1
 162.0
1
 - - 
Testosterone 157.0
1
 178.0
1
 - - 
Tramadol 447.0
6
 110.0
3
 190.0
3
 - 
Trimethoprim 195.0
1,2,8,14
 356.0
1,2,3
 420.0
3
 68.0
5
 
Verapamil 1,501.0
1
 1,722.0
1,3
 400.0
3
 - 
1
Stevens-Garmon et al., 2011 
6
Wick et al., 2009 
11
Andersen et al., 2005  
2
Radjenović et al., 2009 
7
Urase & Kikuta, 2005 
12
Carballa et al., 2008 
3
Hörsing et al., 2011 
8
Suárez et al., 2008 
13
Stuer-Lauridsen et al., 2000 
4
Lajeunesse et al., 2012  
9
Joss et al., 2005 
14
Göbel, et al., 2005 
5
Barron et al., 2009 
10
Ternes et al., 2004  
 
aDEET: N,N-Diethyl-meta-toluamide 
bTCEP: tris(2-carboxyethyl)phosphine 
 
3.1.2 Statistical Analysis 
To assess any differences in sorption behaviour between sludge types a number of 
statistical tests were performed. These tests require the data to have a normal 
distribution, and a Box-Cox plot revealed that a log transformation was required to 
normalise the data and stabilise the variation. The effectiveness of the 
transformation was confirmed for the transformed data using normal probability 
plots (Appendix B, Figure B2). Three standard procedures were then carried out, as 
follows. (i) The correlations between the measured log 𝐾𝑑 values of the 
pharmaceuticals on different pairs of the four sludge types available in the literature 
were calculated. Pearson correlation coefficients were considered significant if their 
associated p-value was below 0.05. (ii) Multiple pairwise comparisons of the log 𝐾𝑑 
values for different sludge types may be made using analysis of variance (ANOVA) 
followed by a Tukey test. However, when this approach was followed, it became 
apparent that the results were affected by the sparseness of the data matrix. The 
mean log 𝐾𝑑 value for primary sludge, for example, is increased by a number of high 
values for compounds where no measurements are available in the other sludge 
types. Therefore, a paired sample t-test was performed for each pair of sludge types 
to assess their similarity, using compounds with measured values for both cases, 
and a Bonferroni correction (Bland & Altman, 1995) was applied to reduce the 
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chance of a Type I error through the use of repeated t-tests. (iii) Linear regression 
was used to quantify the relationships between the log 𝐾𝑑 values obtained on the 
four different sludge types. The results of these three statistical tests were used in 
combination to assess the feasibility of inferring the log 𝐾𝑑   value of an API on one 
sludge type from its measured value on another sludge type. 
 
 
3.1.3 Comparison of Sludge Types 
As mentioned at the start of this section, the OPPTS guideline on sludge partitioning 
(EPA, 1998) recommends the use of activated sludge for 𝐾𝑑 measurements. Also, 
activated sludge was sampled consistently in the nitrification zone of the activation 
tank across all the selected literature articles. Hence, particular interest was given to 
activated sludge. The statistical analysis of the different sludge pairs is summarized 
in Table 3.3; the full results of the statistical tests are provided in Appendix B. This 
includes suggested criteria for the pooling of 𝐾𝑑 values based on the three statistical 
tests. 
 
Table 3.3 Summary of the results of statistical tests performed on log 𝐾𝑑values from pairs of 
different sludge types. 
 Correlation matrix Paired t-test Linear regression 
analysis 
Pooled 
 
Pooling 
Criteria 
Pearson 
Coefficient 
p-
value 
p-
value/6 
tests 
Confidence 
interval 
Regression 
coefficient 
(slope) 
Intercept 
Close to 1 < 0.05 > 0.008 To 
include 0 
Close to 1 
± 0.1 
Close to 0 
± 1.0 
Pairs        
Activated/ 
Primary 
(n=43) 
0.72 < 0.01 0.051 Yes 0.69 Yes Yes 
Activated/ 
Secondary 
(n=21) 
0.48 0.03 0.157 Yes 0.50 No No 
Activated/ 
Digested 
(n=19) 
0.82 < 0.01 0.014 No 0.81 Yes No 
Primary/ 
Secondary 
(n=51) 
0.85 < 0.01 0.013 No 0.89 Yes No 
Primary/ 
Digested 
(n=19) 
0.88 < 0.01 < 0.001 No 0.77 Yes No 
Secondary/
Digested 
(n=16) 
0.80 < 0.01 0.001 No 0.64 Yes No 
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3.1.3.1 Activated and Primary Sludge 
The correlation coefficient between the log 𝐾𝑑 values of activated and primary 
sludge was 0.72 with a p-value < 0.01 (Table 3.3). This indicated that the sorption 
behaviour of the APIs in the dataset for these sludge types was similar as they were 
significantly highly correlated. The paired sample t-test for the log 𝐾𝑑 activated-
log 𝐾𝑑 primary sludge pair gave a p-value of 0.051 (Table 3.3). This was above the 
threshold value of p/number of tests = 0.05/6 = 0.008, indicating that these two 
sludge types behaved similarly. The confidence interval associated with the t-test 
included zero, also showing that there was no significant difference between the 
sorption behaviour of these two sludges. 
  
The linear regression of log 𝐾𝑑 activated against log 𝐾𝑑 primary gave a regression 
coefficient of 0.69 and a coefficient of determination 𝑟2 = 0.52 (Figure 3.1). These 
results showed that activated and primary sludge have similar sorption properties 
for a diverse set of compounds (n = 43). These findings are consistent with the 
observation that primary and activated sludge have similar physico-chemical 
properties; both have a relatively neutral pH, high TOC and comparable COD (Table 
3.1). 
 
In a WWTP the first partitioning of an API occurs in the primary clarifier 
(Tchobanoglous et al., 2002) so primary sludge might be considered to be 
representative of the partitioning occurring with all types of sludge found prior to and 
including the activated sludge tank (Figure 1.3).  
 
It should be noted that, although the average reported 𝐾𝑑 values for activated and 
primary sludge were found to be similar, a higher variability in 𝐾𝑑 values was 
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observed for some APIs with primary sludge than for activated sludge. A measure of 
the relative variability in 𝐾𝑑 values is given by the coefficient of variation, CV = 
standard deviation/mean. For example, in primary sludge, 𝐾𝑑 values ranging from 
194 to 501 (CV = 0.86) were reported for the anti-inflammatory diclofenac, from 20 
to 314 (CV = 1.55) for the anti-convulsant carbamazepine, from 46 to 460 (CV = 
1.13) for the cardiovascular drug atenolol, from 32 to 320 (CV = 0.87) for the 
antibiotic sulfamethoxazole and from 251 to 427 (CV = 0.27) for the antibiotic 
trimethoprim. This may have been due to differences in the sludge sampling 
locations (e.g. before or after the first clarifier) used to collect primary sludge. By 
comparison, in activated sludge the variability in 𝐾𝑑 values was lower, ranging from 
16 to 128 (CV = 0.76) for diclofenac, 17 to 135 (CV = 0.97) for carbamazepine, 30 
to 64 (CV =0.40) for atenolol, 77 to 282 (CV = 0.54) for sulfamethoxazole and 119 to 
253 (CV = 0.26) for trimethoprim (Table 3.2). This was attributed to the activated 
sludge being a more homogeneous material due to the aeration process used in the 
activation tank. These differences aside, analysis of the available data suggests that 
using either activated or primary sludge would lead to similar measured values of 
𝐾𝑑. 
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Figure 3.1 Plot for 𝐥𝐨𝐠 𝐊𝐝 values reported for primary sludge (𝐥𝐨𝐠 𝐊𝐝 primary) against the 
𝐥𝐨𝐠 𝐊𝐝 values of the same compound obtained with activated sludge (𝐥𝐨𝐠 𝐊𝐝 activated). The 
regression equation is 𝐥𝐨𝐠 𝐊𝐝 𝐩𝐫𝐢𝐦𝐚𝐫𝐲 =  𝟎. 𝟔𝟗 𝐥𝐨𝐠 𝐊𝐝 𝐚𝐜𝐭𝐢𝐯𝐚𝐭𝐞𝐝 +  𝟎. 𝟖𝟑 (solid line) with 𝐫
𝟐 
= 0.52 (n = 43 compounds).  The dashed line is the diagonal (𝐲 = 𝐱  ). 
 
  
 
 3.1.3.2 Activated and Secondary Sludge 
The correlation coefficient between the log 𝐾𝑑 values of activated and secondary 
sludge was 0.48 with a p-value = 0.03 (Table 3.3). This was a weaker association 
than that found between activated and primary sludge. The paired sample t-test 
indicated that there was no significant difference between the log𝐾𝑑 values for 
activated and secondary sludge.  
 
The regression analysis of these two sludge types for the available dataset (n = 21) 
produced an 𝑟2 of 0.23 (Figure 3.2), which indicated a weak relationship. However, 
this result was heavily biased by the reported values for amitriptyline (𝐾𝑑 ~ 5,000). 
These were considerably greater than for the other compounds, which typically had 
𝐾𝑑 values below 1,500. 
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Figure 3.2 Plot for 𝐾𝑑 values reported for secondary sludge (𝐾𝑑 secondary) against the 𝐾𝑑 
values of the same compound obtained with activated sludge (𝐾𝑑 activated). The regression 
line is 𝑙𝑜𝑔𝐾𝑑  𝑠𝑒𝑐𝑜𝑛𝑑𝑎𝑟𝑦 =  0.50 𝑙𝑜𝑔𝐾𝑑  𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑒𝑑 +  1.30 (solid line) with an 𝑟
2 of 0.23 (n = 
21 compounds).  The dashed line is the diagonal (𝑦 = 𝑥).  
 
 
In a WWTP, secondary sludge is formed mainly from activated sludge which has 
been allowed to settle, and their physico-chemical properties, with the exception of 
TSS, are broadly similar (Table 3.1). This would suggest that the sorption properties 
of these two sludges would be similar, but this was not supported by the analysis of 
the data reported in the literature. Sorption of pharmaceuticals to sewage sludge is 
a complex process. Unlike some other environmental media, such as soils, the 
mechanisms involved are not well understood. The bulk properties commonly used 
to characterise sewage sludge may not be adequate to describe fully these 
interactions and the inclusion of other properties of the matrix may be required. 
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3.1.3.3 Activated and Anaerobically Digested Sludge  
A higher correlation coefficient (0.82, p < 0.001) was found between the 𝐾𝑑 values 
of activated and digested sludge (Table 3.3). The paired sample t-test (p = 0.014) 
showed difference between activated and digested sludges because zero was not 
included in the confidence interval (Table 3.3). 
The linear regression of the 𝐾𝑑 values (n = 19) gave a regression coefficient of 0.81 
with an 𝑟2 of 0.67 (Figure 3.3).  
 
 
Figure 3.3 Plot for 𝐾𝑑 values reported in digested sludge (𝐾𝑑 digested) against the 𝐾𝑑 values 
of the same compound obtained with activated sludge (𝐾𝑑  activated). The regression line is 
𝑙𝑜𝑔𝐾𝑑  𝑑𝑖𝑔𝑒𝑠𝑡𝑒𝑑 =  0.81 𝑙𝑜𝑔𝐾𝑑   𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑒𝑑 +  0.14 (full line) with an r
2
 of 0.67 (n = 19 
compounds). The dashed line is the diagonal (x = y).  
 
 
These observed differences between the sorptive properties of activated and 
digested sludges may be influenced by their physico-chemical properties and the 
availability of oxygen. Generally, digested sludge is more basic than activated 
sludge (Table 3.1). The pH of the sludge affects the sorption of ionic compounds 
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and will be more influential for APIs with pKa values in the range 6-9. There are 
differences in other physico-chemical properties, such as TOC, TSS and VSS, 
between these sludge types but their effect on sorption is more difficult to predict. 
Sorption may also be affected by local variations of the bacterial population in the 
digester. 
 
3.1.3.4 Primary and Secondary Sludge 
In a WWTP a portion of primary and secondary sludge is mixed to form the sludge 
which is fed in to the anaerobic digester (Figure 1.3). Secondary sludge is formed 
after the activation treatment in which microorganisms biodegrade some 
compounds and generate new biomass material. Therefore, the primary and 
secondary sludges may be expected to have different sorption characteristics for 
compounds.  
The correlation coefficient between the log 𝐾𝑑 values of primary and secondary 
sludge was 0.85 with a p-value < 0.001 (Table 3.3). The paired sample t-test 
indicated that the 𝑙𝑜𝑔 𝐾𝑑 values obtained from primary and secondary sludge were 
different in terms of their partitioning properties, with a confidence interval not 
including zero.  
 
The linear regression of the 𝑙𝑜𝑔𝐾𝑑 values (n = 51) gave a slope of 0.89 and an 𝑟
2 of 
0.72 (Figure 3.4). This indicated that the sorption properties of APIs between 
primary and secondary sludge are correlated, with APIs sorbed more strongly to 
primary sludge than to secondary sludge. 
 
Some differences in the physico-chemical properties of primary and secondary 
sludge are apparent (Table 3.1). Most notably, TSS is markedly lower for secondary 
sludge compared with primary sludge. A smaller difference between TOC values 
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suggests that the higher TSS value in primary sludge is mainly due to inorganic 
material.  
 
Figure 3.4 Plot for 𝒍𝒐𝒈𝑲𝒅 values reported in secondary sludge (𝒍𝒐𝒈𝑲𝒅 secondary) against 
the 𝒍𝒐𝒈𝑲𝒅 values of the same compound obtained with primary sludge (𝒍𝒐𝒈𝑲𝒅 primary). The 
regression line is 𝒍𝒐𝒈𝑲𝒅 𝒔𝒆𝒄𝒐𝒏𝒅𝒂𝒓𝒚 =  𝟎. 𝟖𝟗 𝒍𝒐𝒈𝑲𝒅 𝒑𝒓𝒊𝒎𝒂𝒓𝒚 + 𝟎. 𝟏𝟕 (full line) with an 𝒓
𝟐 of 
0.72 (n = 51 compounds). The dashed line is the diagonal (𝒚 = 𝒙). 
 
3.1.3.5 Primary/secondary and Anaerobically Digested Sludge 
Anaerobic digestion leads to changes in the physico-chemical properties of the 
sludge (Table 3.1). Therefore the partitioning behaviour for both primary and 
secondary sludge was expected to differ from the behaviour for anaerobically 
digested sludge. However, both primary and secondary sludges are used as 
feedstocks to form the digested sludge within a WWTP (Figure 1.3), so their 
relationships with digested sludge were investigated together at the same time. This 
section contains both results for primary/digested and secondary/digested pairs of 
sludge. 
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The correlation coefficients of the 𝑙𝑜𝑔𝐾𝑑 values for primary and secondary sludge 
with digested sludge were 0.88 and 0.80, respectively (both with p-values < 0.001) 
(Table 3.3). The paired sample t-tests did highlight differences in 𝑙𝑜𝑔𝐾𝑑, with the 
confidence intervals for both pairs (primary/digested and secondary/digested) not 
including zero and the p-value being below the Bonferroni correction threshold of 
0.008 (Table 3.3). The linear regressions of the 𝑙𝑜𝑔𝐾𝑑 values between primary and 
digested sludge (n = 19), and between secondary and digested sludge (n = 16) 
gave 𝑟2 values of 0.78 and 0.64, respectively. Their corresponding regression 
coefficients were 0.77 and 0.64 (p-value < 0.001 for both which is low but 
significantly different to zero).   
 
3.1.4 Choice of Sludge for Environmental Testing 
The sludges formed in a WWTP are complex matrices, with variable properties 
depending in part on design and hydraulic retention times within the plant. It is 
possible to identify the broad physico-chemical characteristics of the different sludge 
types. However, there is often a wide variation in properties (Table 3.1), making it 
hard to identify the specific interactions contributing to the sorption of APIs 
throughout the treatment process. This is in contrast to soils, where the matrices are 
more clearly defined, for example as clays, loams, sands and silts, which are 
available commercially as standard materials for testing the sorption behaviour of 
compounds. Activated sewage sludge is recommended for use in regulatory 
sorption tests (EPA, 1998). However, it is important to understand the partitioning of 
chemicals with other sludge types. For example, if digested sludge is disposed of to 
land, there is a subsequent potential for the leaching of pharmaceuticals into ground 
and surface waters. Pharmaceuticals form a diverse set of chemicals, but tend to 
occupy specific regions in physico-chemical property space, for example satisfying 
the Lipinski rules (Lipinski, Lombardo, Dominy, & Feeney, 2001) (No more than 5 
hydrogen bond donors; Not more than 10 hydrogen bond acceptors; a molecular 
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mass less than 500 Daltons; an octanol-water partition coefficient log P not greater 
than 5). Unlike many pollutants, the majority of pharmaceuticals exhibit ionic 
behaviour which must be considered when their environmental fate is assessed. 
The sorption behaviour of pharmaceuticals reported in the literature covers a large 
range of 𝐾𝑑 values (up to ~ 40,000), but these are not distributed uniformly, with 
large regions containing few values. Other sorption measurements may have been 
made during in-house studies for ERA of drug candidates, but this data is not 
readily available in the public domain. To strengthen the statistical analysis of the 
reported 𝐾𝑑 values with all the different sludge types, further measurements are 
needed to obtain a more comprehensive dataset with more even coverage of the 
range of the observed partitioning behaviour of these compounds. In particular, 
there is a paucity of data for digested sludge. 
 
Despite the limited availability of the reported dataset and the variability of 𝐾𝑑 
measurements between different studies, there are sufficient data to undertake an 
initial meta-analysis. The statistical analysis showed that the sorption behaviour of 
the pharmaceuticals in the dataset with activated and primary sludges was similar. 
More data points were available for the comparison of these sludge types (n = 43) 
and this dataset included compounds with a range of 𝐾𝑑 values. Either matrix could 
be used in laboratory tests to assess sorption of pharmaceuticals in a WWTP. 
However, it may be advantageous to use activated sludge to avoid the higher 
variability observed in 𝐾𝑑 measurements with primary sludges. For mathematical 
modelling, where it is beneficial to have large datasets for the development of 
predictive models, 𝐾𝑑 values for these sludge types may be pooled. Comparisons of 
the sorption behaviour of other sludge pairs did not show such similarities. 
Therefore, it is not recommended that the experimental 𝐾𝑑 values for these matrices 
are combined directly.  
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3.2 Characterisation of Sewage Sludge  
Having identified activated sludge as the recommended type of sludge for 
environmental testing, more information on the physico-chemical properties of 
activated sludge was needed. To be able to reproduce sorption experiment in 
smaller scale, activated sludge needed to be assessed as suitable packing material 
for small device such as solid phase extraction cartridges. It was then characterised 
using physico-chemical analyses to assess if it could be used as a potential packing 
material in environmental devices. To be able to vary the ratio of activated sludge in 
the device, a suitable packing material that would be chemically inert was required. 
Activated sludge was tested alongside other reference materials such as silica 
(SiO2), silicon carbide (SiC), polytetrafluoroethylene (PTFE) (also known as Teflon
®) 
and poly-ether-ether-ketone (PEEK). Silica (100 µm average particle diameter) was 
chosen for its well-known packing properties in HPLC (Hennion, 1999), silicon 
carbide (200 µm) was evaluated as it is used in many different environmental 
applications (Bäuerlein et al., 2011; Droge & Goss, 2012), PTFE (200 µm) was 
selected for its very low polarity and non-adsorptive properties, and PEEK (chunks 
of solids) was chosen for its chemical stability, being commonly used as plastic 
connecting tubing in liquid chromatography. All were purchased from Sigma Aldrich 
(Gillingham, Dorset, UK). The PEEK material was ground with a pestle and mortar 
before being sieved through a 500 µm grid. 
 
The four reference materials and freeze-dried sludge were analysed to obtain their 
physico-chemical properties (Table 3.4) which are further described in Appendix C. 
They were observed by a scanning electron microscope (SEM) NeoScope JCM 
5000 SEM (Jeol, France) (Figure 3.5). The specific surface areas were obtained 
using the Brunauer, Emmett and Teller method with a Sorptomatic 1990 (Thermo 
Scientific, France). Thermogravimetric analysis (TGA) was performed using a TGA 
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92-12 (Setaram, France) and particle size distribution was assessed on a 
Mastersizer 2000 laser diffractometer (Malvern, UK).   
 
 
Figure 3.5 SEM photographs of freeze-dried activated sludge, compared to reference 
materials. From left to right: Top: spherical silica, coarse silicon carbide, PTFE; bottom: 
PEEK, two different magnifications of the freeze dried sludge.  White bars are 20 µm. 
 
 
Table 3.4 Physico-chemical data of the SPE stationary phase powders and sludge. 
Sample Aspect Thermogravimetry
1 
Particle 
size
2 
µm 
Surface 
area 
m
2
/g 
Porosity
3
 
 
Silica 
White hard 
powder 
Stable 
2-100 
35 
420 
0.8 cm
3
/g 
7.5 nm 
Silicon carbide 
Green 
powder 
Stable 
3-110 
62 
2.9 
Non 
porous 
Polytetrafluoro
ethylene 
White soft 
powder 
Decompose around 
500
o
C 
80-700 
250 
2.6 
Non 
porous 
Polyether 
ether ketone 
Beige 
powder 
Decompose around 
500
o
C 
4-1,000 
330 
80 
0.19 
cm
3
/g 
9.5 nm 
Activated 
sludge 
Black powder 
5% weight loss at 
100
o
C, 76% weight 
loss between 100 
and 300
o
C 
1-2,000 
480 
2.5 
0.03 
cm
3
/g 
53 nm 
1- Sample weight loss upon heating under nitrogen circulation. 
2- Minimum and maximum particle size and mean value (see Figure 3.5 for particle shape). 
3- Mesoporosity, pore thinner than 2 nm were not assessed.  Pore volume (cm
3
/g) and mean 
diameter (nm) are listed. 
 
 
3.2.1 Thermal Stability 
Silica and silicon carbide were stable across the 10-800oC thermogravimetric 
temperature range while the PTFE and PEEK degraded above 500°C. The freeze 
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dried activated sludge lost about 5% weight at 100°C due to its residual water 
content and subsequently 76% weight loss occurred at temperatures between 110 
and 300oC, which was attributed to the loss of volatile organic matter. All the 
reference materials were found to be thermally stable.  
 
3.2.2 Particle Shape and Size Distribution 
Scanning electron microscopy gave a good view of the particle shapes, surface 
topography and particle size distribution (Figure 3.5). The silica sample was made 
of very spherical particles but with a significant polydispersity. The average silica 
particle diameter was 35 µm with particles as small as 2 µm and others as big as 
100 µm (Table 3.4). The second inorganic material was the silicon carbide sample. 
The SEM pictures show coarse irregular particles with a wide polydispersity (mean 
particle diameter 62 µm). The PTFE and PEEK organic materials had the same 
polymeric microstructure but larger aggregates were observed for PEEK. The 
freeze-dried activated sludge sample was heterogeneous and non-spherical with 
aggregated particles (Figure 3.5).  
 
3.2.3 Surface Area and Porosity 
The surface area was determined by nitrogen monolayer adsorption at 77 K  
(-196 oC) using the BET equation (Brunauer, Emmett, & Teller, 1938) and could 
assess only mesopores (2-50 nm). Silica had the largest surface area with 420 
m2/g. Such a large surface area was due to the internal surface of pores, not to the 
external particle surface. Silica also had the larger pore volume (0.8 cm3/g) (Table 
3.4). The other inorganic material, silicon carbide (SiC), was non-porous with a 
surface area of 2.9 m2/g, more than two orders of magnitude lower than that of 
silica.  Similarly, with the two organic materials: PEEK was porous with a large (80 
m2/g) surface area and PTFE was not porous with a 2.6 m2/g surface area, similar 
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to SiC. The freeze-dried activated sludge was also tested, giving a surface area of 
2.5 m2/g corresponding to a very low porosity (Table 3.4). The freeze-dried activated 
sludge was the most heterogeneous sample with particle size ranging from 1-2,000 
µm (mean 480 µm). Due to the low surface area and the large particle size it would 
not be recommended to compress freeze-dried activated sludge. The knowledge of 
the surface area gives information about the likelihood of interactions happening; 
the larger the surface area, the better chance of interaction between a solute and 
the material. PTFE, silicon carbide and freeze-dried activated sludge were in the 
same surface area range as one another but lower than for silica and PEEK.  
 
These data gave useful information on the potential packing ability of the freeze-
dried activated sludge in an environmental sorption testing device. It also helped 
understanding which reference material could be used as a support phase to help 
the packing of the freeze-dried activated sludge. All the reference materials tested, 
as well as freeze-dried activated sludge, seemed suitable for packing under ambient 
conditions. 
 
3.3 Interactions of Pharmaceuticals with Sewage 
Sludge 
Sewage sludge is mainly made of organic matter and nutrients from residual solids 
produced during wastewater treatment (Smernik et al., 2003). Little is known about 
sorption mechanisms of pharmaceuticals occurring in sewage sludge.  
 
SPE is a commercially available technique that uses a number of stationary phase 
chemistries to extract analytes from a wide variety of different liquid matrices 
(Thurman & Mills, 1998). The main advantage of SPE is its ease of use. SPE is not 
time consuming and generally requires only small volumes of extraction solvents. All 
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interaction mechanisms can be used and combined offering possible mixed modes 
of interaction to favour the extraction of one class of compounds or another (Żwir-
Ferenc & Biziuk, 2006). The selection of the stationary phase is associated with the 
desired class of compounds; hence the mechanism of interaction must be known 
(Hennion, 1999). 
 
The work described in this section used the SPE technique to gain insights into the 
mechanism of interaction between pharmaceuticals and sewage sludge. The three 
ionisable method development pharmaceuticals (clofibric acid, diclofenac and 
oxytetracycline) were selected for the study (Chapter 2). The behaviour of these 
three pharmaceuticals was tested on commercially available SPE cartridges to 
order to obtain insights into the possible interaction mechanisms in the sludge. 
Sewage sludge could not be used directly as an SPE stationary phase as the 
aqueous eluent phase could not percolate through any wet sludge sample. To 
overcome this issue, various sludge-SPE packing mixtures were used as the 
stationary phase. The four reference materials used in the sludge characterisation 
work were tested as SPE packing material candidates.    
 
3.3.1 Materials and Methods 
Salts for buffer preparation such as potassium dihydrogen orthophosphate, 
dipotassium hydrogen phosphate and sodium phosphate were all purchased from 
Fisher Scientific Ltd. (Loughborough, Leicestershire, UK). Acetonitrile and methanol 
were obtained from Sigma Aldrich UK. Water was purified by reversed osmosis on 
an Elga Purelab Option-Q system (Elga LabWater, Marlow, UK). 
 
The commercially available SPE cartridges were purchased from Sigma Aldrich as 
part of a method development pack including Supelco C18, C8, CN, Phenyl, Diol, 
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NH2, SAX, SCX, WCX and Si cartridges. The main types of interaction for each 
phase are shown in Table 3.5. 
 
Table 3.5  Types of interactions for the SPE stationary phases. 
 
Type of 
interaction 
van der Waals 
(Hydrophobic) 
π-π H-Bonding Coulomb forces
1 
SPE phases 
 
C
18
 &  C
8
 
Phenyl 
CN 
CN 
NH2 
Phenyl 
Si 
Diol 
NH2 
NH2 
SCX & WCX 
SAX 
1
- NH2 is a weak anion exchanger at low pH levels in its –NH3
+
 form.  SCX and WCX are strong 
and weak cation exchangers, respectively, and SAX is a strong anion exchanger. 
 
 
All SPE phases were tested but the results of only five cartridges corresponding to 
the four types of interaction defined in Table 3.5 are presented in this thesis. They 
included C8, Phenyl, SAX, SCX and Si cartridges (results for NH2 are given in 
Appendix E). All adsorption measurements were performed in triplicate with 
buffered spiked mobile phases.  
 
The activated sewage sludge was collected from the activation tank in the 
nitrification zone at Totnes Sewage Treatment Works (Devon, UK) which treats 
domestic wastewaters (Appendix D). It was freeze-dried and ground before being 
passed through the 500 µm sieve. Empty SPE cartridges and frits were purchased 
from Sigma Aldrich.   
 
A 500 mg aliquot of packing material was weighed and packed into empty SPE 
cartridges to determine their sorption properties. The sludge/packing material 
experiments were performed with three different ratios: 20.0% 50.0% and 80.0% 
activated sludge in packing material w/w. After careful mixing of the sludge and 
packing materials, 500 mg of the mixture was packed into a SPE cartridge for 
sorption experiments. Attempts to use 100% sludge (no added packing material) 
were unsuccessful (results of these experiments are presented in Appendix E). All 
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adsorption measurements were performed in triplicate resulting in a total of 48 
cartridges per elution, 12 per packing material. 
 
Eight different elution conditions were tested to assess the impact of solvent ratio, 
organic modifier and pH level on the sorption of the three pharmaceuticals (Table 
3.6). Five elutions were run with 0, 20, 50, 80 and 100% v/v methanol in water. 
Methanol was replaced by acetonitrile at 20% ratio for a sixth elution. Another two 
elutions were added to study the effect of pH, with an acidic and a basic elution. In a 
typical experiment the SPE cartridges were prepared as described in the previous 
paragraph and the SPE cartridges were hand packed. Then the cartridge was 
wetted by 2 mL of methanol or conditioning solvent by allowing the solvent to 
percolate freely through the cartridge by gravity. A 100 µL aliquot of a 50 mg/L 
solution of the three pharmaceuticals was loaded onto each SPE cartridge via 
displacement pipette and the appropriate solvent was passed through the SPE 
cartridge. Next the pharmaceuticals were desorbed from the cartridge using the two 
eluents listed in Table 3.6. A 2 mL aliquot of the first eluent, with opposite polarity to 
that of conditioning solvent, were first passed freely through the cartridge and the 
eluent collected. This elution 1 step was followed by a second elution step with the 
same solvent as the conditioning solvent. A 2 mL aliquot of eluent 2 was used to 
ensure maximum desorption from the sorbent phase. The eluting solvent phases 
were collected by gravity principles into HPLC vials and loaded onto the HPLC 
system for analysis without further treatment. The elution process for the pH study 
was slightly modified (Table 3.6, experiments 7 and 8). 
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Table 3.6 Composition of the mobile phases used for experimental conditions tested for 
each SPE material and sludge/PTFE mixture. 
Experiment 
Conditioning, 
% (v/v) 
Elution 1,  
% (v/v) 
Elution 2,  
% (v/v) 
1 Pure Methanol Pure water Pure methanol 
2 Methanol 80 Methanol 20 Methanol 80 
3 Methanol 50 Methanol 50 Methanol 50 
4 Methanol 20 Methanol 80 Methanol 20 
5 Pure water Pure methanol Pure water 
6 Acetonitrile 80 Acetonitrile 20 Acetonitrile 80 
7 Pure methanol 
Phosphate 
buffer (pH 7.2) 
Phosphate buffer (pH 2) 20/ 
methanol 80 
8 Pure methanol 
Phosphate 
buffer (pH 2) 
Phosphate buffer (pH10) 50/ 
methanol 50  
 
 
An Agilent 1100 HPLC system was used to determine the desorbed amount of 
pharmaceutical collected after SPE experiments as described in Section 2.5. The 
detection limit for clofibric acid, diclofenac and oxytetracycline were respectively 0.1, 
0.03 and 0.1 mg/L. Quantification was performed using an external standard 
containing the three pharmaceuticals at known concentrations. As the two 
successive SPE elutions were performed using different solvents, it was not 
possible to determine an overall 𝐾𝑑, as each 𝐾𝑑 was solvent dependent. However, 
the percentage sorbed onto the solid phase was calculated according to equation 
3.1: 
 
%sorbed = 100 - %recovered 1 - %recovered 2   Eq. 3.1 
 
 in which  %sorbed is the percentage of pharmaceutical remaining sorbed after the 
whole desorption procedure, 
%recovered1 is the pharmaceutical recovered percentage after the first 
solvent desorption, 
%recovered2 is the pharmaceutical recovered percentage after the second 
solvent desorption. 
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The amount sorbed with hand-packed sludge cartridges was compared with those 
obtained using the commercial SPE phases. Trends in sorption behaviour between 
hand-packed and commercial SPEs were studied and, depending on the different 
mechanisms of interaction of the commercial SPE, the mechanism of interaction 
attributed to the hand-packed SPE. 
 
3.3.2 Results and Discussion 
The best results were obtained with using PTFE as the packing material (data for 
other packing materials are shown in Appendix E). Diclofenac and oxytetracycline 
sorbed moderately to strongly to the other packing materials (silica, silicon carbide 
and PEEK), which made the results harder to interpret as the sorption could not be 
clearly attributed to the sludge or the packing material. In the case of PTFE, very 
low sorption was observed for only one compound (clofibric acid) under only one 
condition (high methanol ratio), therefore, this packing material seemed more 
suitable to assess the sorption on sewage sludge. 
 
Wet sludge was not compatible with SPE elution as very little aqueous phase could 
go through a SPE cartridge filled with sludge. With 80% sludge content (20% 
PTFE), elution was possible but very slow and the adsorption results showed an 
unacceptably large variability and a lack of reproducibility (a relative standard 
deviation of 170% was obtained in the worst case). It was possible to elute the 
aqueous phase through SPE cartridges containing an equal weight of PTFE and 
sludge.  
 
Sorption under the eight experimentally tested elution conditions are presented in 
Figure 3.6a for the cartridges containing 20% sludge in PTFE. The oxytetracycline 
adsorption was higher with 20% sludge in PTFE (Figure 3.6a) than with 50% sludge 
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in PTFE (Figure 3.6b). Also, the oxytetracycline overall sorption was much less 
dependent on the elution conditions being between 70% and 90% for the eight 
tested elution conditions of Table 3.6 (Figure 3.6a). Sorption for oxytetracycline was 
expected to be high on hydrophobic, phenyl and cation exchange phases since this 
compound had aromatic rings and amine functional groups. Similarly, diclofenac 
showed an acceptable variability with the 20% sludge in PTFE mixture. It adsorbed 
between 5% and 20%, except for experiment 8 which enhanced the sorption. 
Clofibric acid sorption was consistently low under all conditions, as expected for this 
low sorptive relatively small molecule. Figure 3.6b shows the results obtained for the 
50% sludge in PTFE mixture. Better precision was achieved for this ratio of sludge 
with RSD values lower than 20% (the highest RSD was 15.1% for oxytetracycline 
with elution condition 2 and the mass recovered for the triplicate measurements 
were 0.834, 1.119 and 1.070 µg). The higher sludge in PTFE ratios was correlated 
with 𝐾𝑑 values listed in Table 2.1 when methanol/water mobile phases (conditions 2, 
3 and 4) were used for adsorption (Figure 3.6b). 
 
 
 
Figure 3.6 Bar charts comparing the adsorbed percentage of the three test pharmaceuticals 
under eight experimental adsorption conditions (Table 3.6) using 20%(a) and 50%(b) sludge 
in PTFE mixtures. 
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Figure 3.7 summarises the sorption results for the hydrophobic C8 and phenyl SPE 
sorbents (Figures 3.7a and 3.7b, respectively) and for the SCX cation and SAX 
anion exchanger SPE sorbents (Figures 3.7c and 3.7d, respectively) under the eight 
adsorption conditions (Table 3.6) for the three pharmaceuticals selected. Apart from 
conditions 1, 7 and 8, similarities can be observed between the sorption results 
obtained with 20% sludge in PTFE, Figure 3.6a) and the C8 and phenyl SPE sorbent 
(Figures 3.7a and 3.7b).   
 
 
Figure 3.7 Bar charts comparing the adsorbed percentage of the three test pharmaceuticals 
under the eight experimental adsorption conditions for four different SPE materials (without 
the addition of sludge). 
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Since the C8 SPE sorbent mainly interacts with solutes through hydrophobic van der 
Waals interactions and the phenyl SPE sorbent through hydrophobic and π-π 
interactions (Hennion, 1999; Żwir-Ferenc & Biziuk, 2006), these results suggest that 
hydrophobic interactions play an important role in solute sorption mechanisms for 
the three pharmaceuticals.   
 
However, the hydrophobic interaction mechanism is not the sole mechanism 
responsible for the sorption of these pharmaceuticals to sewage sludge. At 50% 
sludge in PTFE (Figure 3.6b), it was clear that the increased adsorption of clofibric 
acid and diclofenac was due to non-hydrophobic mechanisms. Observing the 
phenyl SPE adsorption (Figure 3.7b), it seems that π-π interactions were significant 
since the SPE phase and all the selected pharmaceuticals had at least one aromatic 
ring. However, the percentage sorption obtained with the SCX cation exchanger 
SPE phase (Figure 3.7c) was comparable to the phenyl SPE results (Figure 3.7b). 
This suggests that charge-charge Coulomb interactions induced by the SCX cation 
exchanger SPE phase may have been as effective as hydrophobic and π-π 
interactions.   
 
The strong clofibric acid and diclofenac sorption obtained with SAX anion exchanger 
(Figure 3.7d) was not observed with sludge containing PTFE (Figure 3.6). This 
suggests that anion exchange was not part of the pharmaceutical-sludge sorption 
mechanism, at least at low and neutral pH values. The sorption behaviour of the 
three pharmaceuticals on the silica SPE (Figure 3.8) was similar to their behaviour 
on the phenyl and SCX SPE phases (apart from condition 7). The silanol groups of 
the silica surface can ionise at pH values higher than 7 giving negatively charged 
sites able to exchange cations (Petruczynik et al., 2005) which may explain the 
similarity with the SCX SPE phase at higher pH. For lower pH values, the main 
interaction with the silica surface is likely to be hydrogen bonding with molecular 
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silanols, which excludes hydrophobic interaction. The pharmaceutical sorption 
results with silica (Figure 3.8) suggested that the pharmaceuticals could also sorb 
via hydrogen bonding. All three tested pharmaceuticals have hydroxyl or carboxyl 
function groups as well as accessible nitrogen or oxygen electronegative atoms 
which made them sensitive to hydrogen bonding.  
 
Sorption studies were also performed with a NH2 SPE material with weak anion 
exchanger properties (Appendix E). The three pharmaceuticals were < 95% sorbed 
(apart for clofibric acid under condition 3 (% sorbed = 78.3%)) on this material under 
all eight different elution conditions. The comparison between the sludge phase and 
commercial SPE phases suggested that hydrophobicity was an important factor but 
not the only one in the mechanism of pharmaceutical-sludge sorption. More 
complex and combined interactions including ion-exchange, π-π and H-bonding as 
well as hydrophobic interactions should be considered in order to understand 
pharmaceutical-sludge sorption mechanisms. The 𝐾𝑂𝐶 theory, which only considers 
hydrophobic interactions, may not always accurately model pharmaceutical-sludge 
adsorption. This may be why it failed to give good predictions for pharmaceutical 
adsorption with sludge matrix. 
 
Figure 3.8 Bar charts comparing the sorbed percentage of the three test pharmaceuticals 
under eight experimental adsorption conditions (Table 3.7) using bare silica SPE material. 
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3.4 Summary 
SPE experiments were conducted to investigate the nature of the interaction 
between ionisable pharmaceuticals and sewage sludge. The physico-chemical 
nature of wet sludge precluded its direct use as an SPE sorbent. The mobile phase 
could not easily percolate through wet sludge. Mixing sludge with a selection of inert 
solid materials permitted pharmaceuticals in spiked mobile phase to percolate 
through SPE phases. Testing different candidate materials for their chemical 
inertness showed that the most appropriate material was PTFE. Using sludge in 
PTFE mixtures as the sorbent in SPE cartridges, it was possible to rapidly 
determine the amount of sorbed pharmaceutical. The results indicated that 
pharmaceutical-sludge interaction mechanisms involve hydrophobic interactions but 
also other interactions such as π-π, cation-exchange and hydrogen bonding 
interactions. The energy of these interactions can be of comparable or higher 
magnitude than the energy of van der Waals interactions (Sethi & Satake, 2010), 
which can explain why the existing 𝐾𝑂𝐶 theory-based models, which accounts for 
only hydrophobic binding, are poor for the sewage sludge matrix. These additional 
interactions must be taken into account in order to develop new models with 
improved predictive capability. This chapter has been published (Berthod, Roberts, 
& Mills, 2014b). 
 
Some optimisation of the appropriate packing material, sludge in PTFE ratio and 
solvent were required to develop a screening method for estimating the 𝐾𝑑 value 
and this is described in Chapter 4.  
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Chapter 4: Sorption Behaviour of Pharmaceuticals to 
Sewage Sludge 
 
4. 1 Introduction 
In this Chapter, a screening method for estimating the 𝐾𝑑 value was developed and 
fully validated based on the work described in Chapter 3. The first step of this work 
was to investigate the impact of different buffers on sorption in the OPPTS 835.1110 
test. Then, based on preliminary work on packing sewage sludge in cartridges 
(Berthod, Roberts, & Mills, 2014b), a new approach was developed based on SPE 
to measure 𝐾𝑑 values for a wide range of pharmaceuticals adsorbed to sewage 
sludge. The initial work (Chapter 3) investigated the performance of different inert 
packing materials (e.g. silica, silicon carbide, polyether-ether ketone and PTFE) that 
could be mixed with the sewage sludge in the SPE cartridges. PTFE was the best 
candidate material tested for this purpose because it was the most inert material 
tested and was easy to mix with the freeze dried sewage sludge and to pack in to 
SPE cartridges. The objective of the current work was to use this approach to 
develop and validate a robust, faster alternative to the OPPTS 835.1110 test for 
measuring sorption of compounds to sewage sludge, in order to be able to test a 
larger number of chemicals in a shorter period of time. 
 
4. 2 Materials and Methods 
4.2.1 Preparation of Test Solutions 
A stock of a mixture of clofibric acid, diclofenac and oxytetracycline with a nominal 
concentration of 1000 mg/L was prepared by dissolving 100 mg of the three 
substances in 5 mL of methanol and making up to 100 mL with reverse osmosis 
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(RO) water. The test concentration was nominally 10 mg/L and was achieved by 
200 µL additions of the clofibric acid, diclofenac and oxytetracycline nominal 1000 
mg/L stock solution, via displacement pipette, to 20 mL total volumes of mixed 
sludge in phosphate buffer solution (pH 7.4 ± 0.5) (Section 4.1.4.1). Duplicate 200 
µL samples of the stock solution were taken for high performance liquid 
chromatography (HPLC) analysis (Section 4.3). The mean of all replicates were 
used to calculate the test concentration. 
 
4.2.2 Activated Sludge 
Activated sludge was obtained from Totnes Sewage Treatment Works (Devon, UK).  
This works treats sewage of predominantly domestic origin (Appendix D). On return 
to the laboratory the sludge was maintained at room temperature and allowed to 
settle. The supernatant was then removed and a portion was put in the freezer. 
Settled sludge was centrifuged in batches at 2000 rpm (equivalent to RCF = 1,566) 
at 4°C for 15 min. The aqueous layer was decanted and discarded. The sludge 
pellets were washed three times with tap water. The sludge was centrifuged 
between washes and the supernatant was discarded between these washes. The 
final sludge pellet was freeze-dried using a ModulyoD freeze dryer (Thermo 
Electron Corp., Loughborough, UK). The freeze-dried sludge was disaggregated 
with a mortar and pestle before drying at 105°C for at least 3 h. The freeze-dried-
oven-dried sludge was sieved through a 500 µm sieve and stored in screw cap 
glass vials at room temperature. This is referred to as activated sludge throughout 
the thesis. The frozen sludge supernatant was left overnight to defrost at room 
temperature and then autoclaved before use. The pH of this solution was 9.03. RO 
water was directly taken from the source with no extra treatment and the pH of this 
solution was 8.04. 
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4.2.3 Preparation of Buffers and Salts 
To investigate the effects of buffers and salts tests were performed using a range of 
different buffers at different molarities and a 0.01 M calcium chloride salt solution, as 
used in the OECD 106 adsorption/desorption guideline (OECD, 2000) (Table 4.1). 
 
Table 4.1 List of buffers and salts tested to investigate potential effect on sorption to 
activated sludge. 
 
Experi
ment  
Buffer/Salt type Ion Molarity 
A OECD 301 low M  
Na
+
, K
+
, PO4
2-
 
3.7×10
-4 
M (Na
+
, PO4
2-
)  
3.1×10
-4 
M (K
+
) 
B OECD 301  3.7×10
-3 
M (Na
+
, PO4
2-
)  
3.1×10
-3 
M (K
+
) 
C OECD 301  high M 3.7×10
-2 
M (Na
+
, PO4
2-
)  
3.1×10
-2 
M
 
(K
+
) 
D OECD106  low M  
Ca
2+
, Cl
- 
 
1.0×10
-3 
M 
E OECD106  1.0×10
-2 
M 
F OECD106  high M 0.1 M 
G Sodium low M  
Na
+
, PO4
2-
 
 
3.7×10
-4 
M 
H Sodium  3.7×10
-3 
M 
I Sodium high M 3.7×10
-2 
M 
J Potassium low M  
K
+
, PO4
2-
 
 
3.1×10
-3 
M 
K Potassium  3.1×10
-2
 M 
L Potassium high M 3.1×10
-1
 M 
M Reverse osmosis water None None 
N Sludge supernatant Not characterised Not applicable 
O MOPS low M 3-morpholinopropane-
1-sulfonate  
2.0×10
-3 
M 
P MOPS 2.0×10
-2 
M 
Q MOPS high M 0.2 M 
R Tricine low M ion N-(2-Hydroxy-1,1-
bis(hydroxymethyl)eth
yl)glycine 
2.0×10
-3 
M 
S Tricine 2.0×10
-2 
M 
T Tricine high M 0.2 M 
 
The phosphate buffer used for this study was prepared according to OECD 301 
guideline (OECD, 1992) by dissolving 8.53 g of anhydrous potassium dihydrogen 
phosphate (KH2PO4), 21.75 g of anhydrous dipotassium hydrogen phosphate 
(K2HPO4) and 33.45 g of disodium hydrogen phosphate dihydrate (Na2HPO4.2H2O) 
in 1 L of RO water. The pH did not require adjustment and was 7.62 and remained 
within the range 7.4 ± 0.5. A 25 mL aliquot of this stock phosphate buffer was 
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diluted in 250 mL with RO water (Buffer C). A further 10 mL aliquot of the stock 
phosphate buffer was diluted to 1 L with RO water (Buffer B). Finally, a 25 mL 
aliquot of Buffer B was diluted in 250 mL with RO water (Buffer A). (Note: the buffer 
used for all other experiments was buffer B, diluted (1:100 v/v) solution of the stock 
buffer).  
 
The OECD 106 salt solution was prepared by adding 14.70 g of CaCl2.2H2O into 1 L 
of RO water (Buffer F). The pH of this solution was 7.77. A 25 mL aliquot of buffer F 
was diluted to 250 mL with RO water (Buffer E) (OECD, 2000). A 25 mL aliquot of 
buffer E was diluted to 250 mL with RO water (Buffer D). 
 
Sodium buffers were prepared by dissolving 3.34 g of disodium hydrogen 
phosphate dihydrate (Na2HPO4.2H2O) in 1 litre of RO water (Buffer I). The pH of this 
solution was 9.40.  A 50 mL aliquot of buffer I was diluted to 500 mL with RO water 
(Buffer H).  Finally, a 50 mL aliquot of buffer H was diluted to 500 mL with RO water 
(Buffer G).  
 
Potassium buffers were prepared by dissolving 3.85 g of anhydrous potassium 
dihydrogen phosphate (KH2PO4) and 2.18 g of anhydrous dipotassium hydrogen 
phosphate (K2HPO4) in 1 L of RO water (Buffer L). The pH of this solution was 6.65. 
A 50 mL aliquot of buffer L was diluted to 500 mL with RO water (Buffer K). Finally, 
a 50 mL aliquot of buffer K was diluted to 500 mL with RO water (Buffer J). 
 
MOPS organic buffer was prepared by dissolving 20.95 g of 3-morpholinopropane-
1-sulfonic acid (MOPS) in 500 mL of RO water (Buffer Q). The pH of this solution 
was 3.85. A 50 mL aliquot of buffer Q was diluted to 500 mL of RO water (Buffer P). 
Then a 50 mL aliquot of Buffer P was diluted to 500 mL with RO water (Buffer O). 
The tricine organic buffer was prepared by dissolving 17.92 g of tricine (N-(2-
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Hydroxy-1,1-bis(hydroxymethyl)ethyl)glycine) in 500 mL of RO water (Buffer T). The 
pH of this solution was 5.02. A 50 mL aliquot of buffer T was dilute to 500 mL with 
RO water (Buffer S). Then, 50 mL of Buffer S was dilute to 500 mL with RO water 
(Buffer R). 
 
4.2.4 The OPPTS 835.1110 Test Procedure 
The procedures used were based on those described in the OPPTS 835.1110 test 
guideline (EPA, 1998). The nominal room temperature under which the tests were 
carried out was 20  2ºC with red light conditions. The test was carried out using 
clofibric acid, diclofenac and oxytetracycline to determine the extent of sorption onto 
activated sludge at a nominal concentration of 10 mg/L. The sorption of clofibric 
acid, diclofenac and oxytetracycline was assessed by rolling glass tubes containing 
20 mL of a nominal 10 mg/L of clofibric acid, diclofenac and oxytetracycline in 
phosphate buffer (pH 7.4  0.5) without sludge, 2, 30 and 120 mg of activated 
sludge in duplicate, as well as duplicate Nalgene™ tubes with no sludge as a 
control, making up to a total of ten tubes. The tubes were rolled for 24 h on a rock 
roller at a speed setting equivalent to 60-120 rpm in the dark. The solutions were 
then centrifuged at 7,030 m/s2 at 4°C for 15 min before duplicate aliquots of 
supernatant were analysed by HPLC (Section 2.5). This test was then repeated for 
each buffer (twenty buffers in total). 
 
4.2.5 Transition from of the OPPTS 835.1110 Test to a SPE-based Approach 
Empty SPE cartridges were packed by hand with 500 mg of each of four 
sludge/PTFE mixtures (0.4, 6.0, 24.0 and 40.0% w/w sludge) in triplicate to test the 
sorption behaviour of each individual pharmaceutical. Only the ratio of sludge to 
PTFE changed, the final weight of material packed in the cartridge remained 
constant at 500 mg. The four different ratios were chosen to match those in the 
OPPTS 835.1110 test. Sludge packing ratios above 50% w/w were avoided as they 
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made elution through the bed difficult (Berthod, Roberts, & Mills,, 2014b). An 
additional test cartridge containing only PTFE (500 mg) was prepared. This was 
used to measure any sorption of the test compounds to the PTFE, plastic walls or 
frits of the SPE cartridge. PTFE was chosen as the bulk packing material as it is 
chemically inert, and was shown previously to exhibit minimal sorption for the test 
pharmaceuticals (Figure E1); hence, all of the observed sorption behaviour could be 
attributed to the sludge (Berthod, Roberts, & Mills, 2014b). Two control cartridges 
(one containing 500 mg of PTFE and the other packed with 500 mg of 40% w/w 
sludge in PTFE) were prepared to measure any background concentrations of the 
pharmaceuticals present in either the PTFE or the sludge. These cartridges were 
not dosed with the test compounds. 
 
All the packed SPE cartridges were first fully hydrated with phosphate buffer (2 mL) 
by letting the solution freely percolate through the bed by gravity over ~ 15 min. The 
thirteen test cartridges (whilst still moist from the previous step) were loaded with an 
aliquot (400 µL) of an aqueous solution (50 mg/L) of each individual pharmaceutical 
(or, in one experiment, a mixture of clofibric acid, diclofenac and oxytetracycline, all 
at 50 mg/L). The solution was allowed to percolate slowly into the bed (~ 15 min). 
The pharmaceuticals were then eluted using two sequential aliquots (2 mL) of 
phosphate buffer, being allowed to percolate freely for a time ranging from ~ 30 min 
for the lower sludge ratio to ~ 120 min for the higher ratio. This procedure ensured a 
high desorption efficiency for the analytes from the sorbent phase. The two 
sequential eluates were collected in separate vials (2 mL). The dissolved aqueous 
concentration of each test pharmaceutical contained in each vial was analysed by 
HPLC. The two control cartridges were not loaded with pharmaceuticals, but eluted 
only using two sequential aliquots (2 mL) of phosphate buffer and the eluates 
analysed as above. The total aqueous concentration of each pharmaceutical was 
estimated as the sum of the concentration found in each of the two eluates.  
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The SPE method was developed using three test pharmaceuticals: clofibric acid, 
diclofenac and oxytetracycline, representing low, medium and high 𝐾𝑑 values, 
respectively. These compounds were chosen for their acidic or zwitterionic 
character. Their physico-chemical properties are shown in Table 2.1. The 𝑝𝐾𝑎 
values suggest that clofibric acid and diclofenac were predominantly in the neutral 
form at low pH, (e.g. pH = 2) and in a negatively charged (carboxylate anion) form 
at intermediate and high pH values such as the pH of the phosphate buffer eluent 
(pH = 7.4). Oxytetracycline was always in its charged form. At low pH its tertiary 
amine group was positively charged. At pH = 4.5, the isoelectric point, it would be a 
zwitterion (positive amine plus negative phenol) and at higher pH values such as in 
this study (pH = 7.4), it would have a negative charge. Pharmaceuticals were tested 
individually following the OPPTS 835.1110 guideline and using the SPE method. A 
similar experiment was conducted with a solution of all three test compounds (all at 
50 mg/L) to assess if potential interferences between individual pharmaceuticals 
was likely to affect the results.  
 
In order to test the method more extensively, ten additional pharmaceuticals with a 
range of physico-chemical properties were individually tested using the SPE and 
OPPTS 835.1110 methods.  The ten pharmaceuticals listed in Table 2.2 covered a 
wide range of 𝑝𝐾𝑎, log 𝐾𝑂𝑊, molecular weights and therapeutic areas; they are 
widely used and hence likely to be found in WWTPs. Our laboratory had previously 
measured the 𝐾𝑑 values of these substances following the OPPTS 835.1110 
guideline.  
 
The overall reproducibility (ruggedness) of the method was evaluated by analysing 
the sorption behaviour of the three test compounds with two different samples of 
activated sewage sludge collected (separated by a three month interval) at the 
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Totnes wastewater treatment plant. Sets of cartridges were packed freshly and 
eluted using freshly prepared buffer. 
 
A stability study was conducted at the following time points: initial (T0), 1 week (T1), 
1 month (T2), 3 months (T3), 6 months (T4) and 1 year (T5) to assess whether SPE 
cartridges could be pre-packed in bulk and subsequently stored for future use, or if 
they had to be packed freshly for each experiment. 
 
Additional compounds were tested to generate new data or confirm literature data. 
These compounds, listed in Tables 2.3, 2.4 and 2.5, were screened on the SPE 
cartridges. The resulting data was used to evaluate existing models in Chapter 5 
and to evaluate a newly developed model based on molecular descriptors in 
Chapter 6. 
 
4.2.6 Calculations 
Each sample was injected in duplicate onto the HPLC system and the mean peak 
area (PA) of the two injections was used for calculation: 
 
𝐶𝑠𝑎𝑚𝑝𝑙𝑒 =   
𝑃𝐴𝑠𝑎𝑚𝑝𝑙𝑒 × 𝐶𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
𝑃𝐴𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
     Eq. 4.1 
 
The calculated 𝐶𝑠𝑎𝑚𝑝𝑙𝑒 was the concentration in the aqueous phase at the end of 
the test. 
 
𝐶𝑠𝑎𝑚𝑝𝑙𝑒  = 𝐶𝑎𝑞𝑢𝑒𝑜𝑢𝑠      Eq. 4.2 
 
 
To calculate the remaining fraction in the sludge: 
 
𝐶𝑠𝑙𝑢𝑑𝑔𝑒 = 𝑋/𝑚 =  
((𝐶𝑑𝑜𝑠𝑒𝑑− 𝐶𝑎𝑞𝑢𝑒𝑜𝑢𝑠)× 𝑉𝑏𝑢𝑓𝑓𝑒𝑟)
𝑚𝑠𝑙𝑢𝑑𝑔𝑒
     Eq. 4.3 
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Finally, 𝐾𝑑 is obtained from the following relation: 
 
𝐾𝑑 =
(
𝑋
𝑚
)
𝐶𝑎𝑞𝑢𝑒𝑜𝑢𝑠
     Eq. 4.4 
 
In these equations, 𝑋 is the mass of pharmaceutical adsorbed onto sludge (mg), 
calculated from the difference between the nominal aqueous concentration added to 
the test and 𝐶𝑎𝑞𝑢𝑒𝑜𝑢𝑠; 𝑚 is the dry mass of sludge used (kg); and 𝐶𝑎𝑞𝑢𝑒𝑜𝑢𝑠 is the 
concentration of pharmaceutical eluted from the SPE cartridge (mg/L). The overall 
𝐾𝑑 was calculated as the slope of the linear regression between 𝐶𝑎𝑞𝑢𝑒𝑜𝑢𝑠 and 𝑋 𝑚⁄  
over all four different sludge ratios for the three replicates (12 data points). 
Assuming the density of the aqueous phase was 1.0, the 𝐾𝑑 values have no units. 
 
4.3 Results and Discussion 
4.3.1 Effect of Buffers and Salts Concentration on Partitioning 
The results of 𝐾𝑑 measurements for the three pharmaceuticals under various 
buffers/salt conditions can be found in Table 4.2.  
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Table 4.2 𝑲𝒅 values for the three test compounds measured with different buffers and 
salts. 
Buffer 𝑲𝒅 clofibric acid 𝑲𝒅 diclofenac 𝑲𝒅 oxytetracycline 
A (OECD 301 low M) 0 85 3,749 
B (OECD 301) 51 392 5,455 
C (OECD 301 high M) 46 457 9,421 
D (OECD 106 low M) 0 572 3,629 
E (OECD 106) 15 835 3,197 
F (OECD106 high M) 7 846 1,210 
G (Sodium low M) 113 613 5,150 
H (Sodium) 125 223 5,402 
I (Sodium high M) 2 115 1,279 
J (Potassium low M) 70 245 5,068 
K (Potassium) 0 201 5,123 
L (Potassium high M) 0 293 9,400 
M (RO water) 0 22 7,499 
N (sludge supernatant) 791 633 3,825 
O (MOPS low M) 42 18 6,658 
P (MOPS) 88 0 5,523 
Q (MOPS high M) 84 358 4,908 
R (Tricine low M) 273 13 11,400 
S (Tricine) 47 19 4,921 
T (Tricine high M) 152 688 3,573 
 
In general, changing the molarity of the buffer had an effect on sorption, as 
observed in Figure 4.1.  For the sodium/potassium buffers (used in the OECD 301 
guideline), increasing the molarity increased the sorption of the pharmaceuticals to 
the sludge phase (Figure 4.1a). For the OECD 106 guideline related solutions, 
increasing the calcium chloride molarity decreased the sorption of oxytetracycline 
and clofibric acid but not the sorption of diclofenac, which remained constant 
(Figure 4.1b). The phenomenon could be due to the oxytetracycline complexing with 
Ca2+ cation in the aqueous phase and decreasing its availability for sorption 
equilibrium. For the buffer containing only sodium (Figure 4.1c), the higher the 
molarity, the lower the sorption. When increasing the molarity of the potassium only 
buffer (Figure 4.1d), the sorption of diclofenac and oxytetracycline was slightly 
increased, whereas the sorption for clofibric acid decreased compared with sorption 
at lower buffer molarity.  
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Figure 4.1 Effect of molarity on sorption for six different buffers. (a) buffer  from OECD 301, 
containing a mixture of Na
+
 and K
+
, (b) calcium chloride salt, (c) Na
+ 
only buffer, (d) K
+
 only 
buffer, (e) MOPS organic buffer, (f) tricine organic buffer (the missing bars in some 
experiment mean that the compound did not sorb at all and was fully recovered). 
 
These effects may be explained by partial ionisation of the compounds due to pH 
variation. The sodium only buffers had an observed pH of 9.40, at which both 
clofibric acid and diclofenac were effectively totally ionised and oxytetracycline was 
predominantly in anionic form. Therefore, oxytetracycline was more soluble in the 
aqueous phase, and less likely to sorb to the sludge phase. The potassium only 
buffers had an observed pH of 6.65, at which clofibric acid was practically totally 
ionised and may have resulted in a decrease in sorption. Diclofenac and 
oxytetracycline were present in both ionic and unionised form and when the molarity 
was increased, these species would partition preferably onto the sludge phase, 
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resulting in an increase in 𝐾𝑑. The 0.01 M calcium chloride salt solution had little or 
no buffering capacity. The increase of molarity decreased the sorption of 
oxytetracycline, increased the sorption of diclofenac, and had some inconsistent 
effect on the sorption of clofibric acid. The pH of the calcium chloride solution was 
7.77, which was relatively close to the Na/K buffer, but the effect of molarity was 
totally different. This may be explained by the nature of the ions in solution, Ca2+ 
being a stronger cation than Na+ and K+ and might compete or cluster with the 
oxytetracycline and clofibric acid. 
 
The organic buffers tested, MOPS and tricine, had observed pH values of 3.85 and 
5.02, respectively, which was not expected as they are part of the Good’s buffer 
family and should have a pKa around 6-8 (Good et al., 1966). MOPS buffer had a 
pH just at the clofibric acid pKa, so both ionic and neutral species would exist at the 
same time and reach equilibrium. The sorption of the three pharmaceuticals 
increased with the molarity of the buffer. Oxytetracyline did not seem to be affected 
by the molarity change. This might indicate that the cationic and the zwitterionic 
forms sorbed to the sludge phase by the same mechanism. Diclofenac was 
affected, but as both ionic and molecular forms were present, a trend could not be 
established, probably due to the constant inter-change between ionic and neutral 
form to reach equilibrium as the pH of the buffer was very close to the diclofenac 
pKa. Similarly, tricine had a pH close to the diclofenac pKa, so with increased 
molarity, diclofenac sorption increased too. The oxytetracycline presented a slight 
decrease in sorption with increased in molarity; this might be caused by competition 
with binding sites between the organic buffer and the zwitterion. Clofibric acid was 
slightly affected but with no definite trends, which may be explained by the 
compound being partially ionised and in constant exchange between the ionic and 
neutral forms. For these two organic buffers, it was hard to determine whether the 
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observed effects were due to the nature of the buffer itself or to the pH induced by 
the buffer. 
 
4.3.2 Effect of Buffer Composition on Partitioning 
The nature of the buffer appears to be critical for sorption. In Figure 4.2, the 𝐾𝑑 
values measured in this study were plotted against the 𝐾𝑑 values obtained using the 
OPPTS guideline method and the buffer from the OECD 301 guideline. The sodium 
and the potassium buffers had the same molarity as the OECD 301 buffer, which 
was a mixture of sodium and potassium phosphate buffers. The nature of buffer did 
not impact the measured 𝐾𝑑 for diclofenac nor oxytetracycline, but seemed to be 
critical for clofibric acid as the 𝐾𝑑 varied by 2 log units. 
  
 
 
Figure 4.2 Effect of sodium and potassium cations on sorption for clofibric acid (left), 
diclofenac (centre) and oxytetracycline (right). The solid red line represents the diagonal 
𝑦 =  𝑥. Solid line: sodium and potassium buffer, dashed line: sodium only buffer, dotted line: 
potassium only buffer. 
 
In Figure 4.3, activated sludge supernatant and RO water were compared with the 
OECD 301 phosphate buffer and the OECD 106 0.01 M calcium chloride salt 
solution. Both guideline-recommended solutions produced similar 𝐾𝑑 values and 
they were consistent with the 𝐾𝑑 values for sludge supernatant for diclofenac and 
oxytetracyline. However, they seemed to underestimate sorption of clofibric acid by 
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1 to 1.5 log units compared with the sludge supernatant. RO water did not seem to 
be a suitable solution to perform environmental sorption experiment as it 
underestimated low and medium sorptive compounds. 
 
 
 
 
Figure 4.3 Comparison of aqueous phase composition on observed partitioning for 
clofibric acid (left), diclofenac (centre) and oxytetracycline (right). The solid black line 
represents the diagonal 𝑦 =  𝑥 (Solid: sodium and potassium buffer, Dashed line: calcium 
chloride salt, Dotted: sludge supernatant, dashed and dotted: RO water). 
 
 
4.3.3 Comparison of 𝑲𝒅 values 
The results of the experiments comparing the testing of the three test 
pharmaceuticals either individually or as a mixture are shown in Figure 4.4. For the 
SPE method with the three test pharmaceuticals, the 𝐾𝑑 values and 95% confidence 
intervals (CI) were 𝐾𝑑  = 20, CI = 4-36 (individual) and 𝐾𝑑 = 15, CI = 2-33 (in mixture) 
for clofibric acid, 𝐾𝑑  = 92, CI = 25-210 (individual) and 𝐾𝑑 = 83, CI = 40-206 (in 
mixture) for diclofenac and 𝐾𝑑= 4,704, CI = 2,480-6,980 (individual) and 𝐾𝑑 = 4,788, 
CI = 2,516-7,060 (in mixture) for oxytetracycline. These values were comparable 
with those found with the OPPTS 835.1110 test and with values reported in the 
literature. In the case of clofibric acid, the CIs shown in Figure 4.4 for the SPE 
method are larger than those for the OPPTS test. This, however, is an artefact of 
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the logarithmic scale. For the OPPTS test, the 𝐾𝑑values and CIs for clofibric acid 
were 𝐾𝑑 = 29, CI = 24-82 (individual) and 𝐾𝑑 = 51, CI = 38-141 (in mixture). These 
CIs are wider than those found with the SPE method.   
 
A two-sided t-test on the 𝐾𝑑 values confirmed there was no evidence for a 
statistically significant difference (p = 0.518, CI for the differences = -155, 107) 
between the sorption behaviour when the three pharmaceuticals were applied to the 
sludge-packed SPE cartridge either individually or as a mixture. For the OPPTS 
835.1110 test, the 𝐾𝑑 values obtained by testing the pharmaceuticals individually 
and in a mixture were also comparable to each other (p = 0.481, and CI = -4,710, 
7,059), but the CIs were smaller for diclofenac, similar for clofibric acid and slightly 
wider for oxytetracycline when tested together in a mixture. These results indicate 
that the SPE method can potentially measure simultaneously the 𝐾𝑑 values of 
mixtures of compounds, thereby increasing laboratory throughput. None of the three 
pharmaceuticals tested were detected in the sludge or the PTFE used in the control 
cartridges. The recovery of the test pharmaceuticals from the cartridge containing 
only the PTFE support matrix was 100 ± 2 % (n = 3). This indicated that there was 
no sorption of the chemicals to the PTFE or SPE cartridges. All the observed 
sorption could therefore be attributed to the sludge. 
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Figure 4.4 Comparison between 𝐾𝑑 values (as logarithms) obtained with the SPE method 
and the OPPTS 835.1110 test. Values of 𝐾𝑑 are shown for the three pharmaceuticals tested 
individually and as a mixture, together with their respective literature values (Table 2.1). The 
error bars represent 95% confidence intervals. As only one literature value was available for 
oxytetracycline, no error bar is shown for this case. 
 
Although the experiment involved measuring the sorption of only three compounds, 
the correlation between log 𝐾𝑑  (OPPTS) and log 𝐾𝑑  (SPE) gave an 𝑟
2 = 0.99 with an 
equation of log 𝐾𝑑  (SPE) = 1.05 × log 𝐾𝑑  (OPPTS) – 0.35. This result indicated 
almost a 1:1 relationship between 𝐾𝑑 values obtained by the SPE and OPPTS tests. 
The method was, therefore, evaluated with a larger set of diverse pharmaceuticals. 
 
4.3.4 Method Validation 
To further validate the method, ten additional pharmaceuticals were tested. 𝐾𝑑 
values were obtained using the SPE method and compared with those obtained 
with the OPPTS 835.1110 method.  A log-log plot of these data (together with the 
results for the three test pharmaceuticals) gave a straight line relationship with a 
slope of 0.93 and 𝑟2 = 0.94 (Figure 4.5). No pharmaceuticals were detected in the 
sludge used in the control cartridges. Recovery of the ten pharmaceuticals from the 
cartridges containing only PTFE was 100 ± 2 % (n = 10).  
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Figure 4.5: Plot of log 𝐾𝑑 values obtained using the SPE and OPPTS 835.1110 methods for 
ten additional APIs to the three optimisation compounds (clofibric acid, diclofenac and 
oxytetracycline). The solid-line is the linear fit to the data: 𝑦 = 0.93𝑥 + 0.06   (𝑟2 = 0.94, 𝑛 =
13). The error bars show the 95% confidence intervals for log 𝐾𝑑 obtained with the SPE 
method. 
 
Table 4.3 shows that 𝐾𝑑 values obtained with the SPE method were comparable to 
values obtained with the OPPTS 835.1110 test using two samples of activated 
sewage sludge collected from the same wastewater treatment plant separated by a 
three-month period. The variability of the 𝐾𝑑 values is shown in Table 4.3. This 
range of variability is similar to that found with the OPPTS 835.1110 test due to the 
heterogeneous nature of the sewage sludge. For the OPPTS 835.1110 test a 
maximum variability of 𝐾𝑑 within a factor of 2 is considered acceptable, which 
corresponds to a range of 0.6 log units. Using the SPE method, the maximum 
variability was 0.16 log units, observed for diclofenac. 
 
Table 4.3: Variability, over a three-month period in the measurement
a
 of 𝐾𝑑  for three test 
pharmaceuticals using the SPE method. 
 Pharmaceuticals 
Day 1 Day 90 
𝑲𝒅 𝐥𝐨𝐠 𝑲𝒅 𝑲𝒅 𝐥𝐨𝐠 𝑲𝒅 
Clofibric acid 18.3 1.26 18.2 1.26 
Diclofenac  344.5 2.54 238.8 2.38 
Oxytetracycline 6,056.0 3.78 4,542.4 3.66 
a
measurements performed for four sludge/PTFE mixtures (0.4, 6.0, 24.0 and 
40.0% w/w sludge) in triplicate for each test pharmaceuticals. 
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4.3.5 Stability Study 
A twelve month stability study, at six defined time points was performed to establish 
the shelf-life of the prepared SPE cartridges. The SPE cartridges showed good 
stability over time (Figure 4.6). The variability in 𝐾𝑑 was less than 0.5 log units for 
clofibric acid and less than 0.3 log units for oxytetracycline. Diclofenac had the 
highest variability (0.62 log units) between 1 month and 6 months, which indicates 
that cartridges were best used within a month, but were potentially usable for up to 
a year. The sorption of diclofenac is known to be variable, and this is evidenced by 
the large range of 𝐾𝑑 values reported in the literature (𝐾𝑑  = 32-459). This variability 
was within a factor of two of the OPPTS 835.1110 test results (diclofenac 𝐾𝑑 = 146, 
CI = 15-277, variability of 1.27 log units). 
 
 
Figure 4.6: Plot of log 𝐾𝑑 values obtained using the SPE and OPPTS 835.1110 methods at 
six time points. The error bars represent the 95% confidence intervals associated with the 
log 𝐾𝑑 values. 
 
 
4.3.6 Comparison of Resource Requirements of the SPE and OPPTS 835.1110 
Methods 
The OPPTS 835.1110 guideline recommends a sample equilibration time of 16 h. In 
addition, samples require a centrifugation step to separate biosolids from the 
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aqueous phase prior to chemical analysis. With the SPE method, the set of 15 
cartridges could be eluted within 4 h. The cartridges preparation time is equivalent 
to the centrifuge tube preparation time in both methods. This shorter analysis time 
limits the possibility of biodegradability, with no need for sterilisation of the sludge or 
the equipment or special aseptic sampling handling procedures.  
 
4.3.7 Literature and Model Validation Compounds Screened with the SPE Approach 
The 𝐾𝑑 values resulting from the SPE method for the literature and the model 
validation compounds listed in Tables 2.3, 2.4 and 2.6 are shown in Tables 4.4 and 
6.8. For some compounds, more than one 𝐾𝑑 value was available and in this case 
an average of all the values obtained in primary and activated sludge was used. 
These compounds were tested on the SPE cartridges to compare the SPE value 
with the values reported in the literature. The results presented in Table 4.4 show 
that for most compounds, the difference was low, suggesting that the SPE method 
is comparable. 
 
Table 4.4 Comparison of 𝐾𝑑 values reported in the literature with those obtained with the 
SPE method. 
 
Literature SPE Difference 
 
𝑲𝒅 𝒍𝒐𝒈 𝑲𝒅 𝑲𝒅 𝒍𝒐𝒈 𝑲𝒅 𝑲𝒅 𝒍𝒐𝒈 𝑲𝒅 
Carbamazapine 84 1.92 78 1.89 6 0.03 
Clomipramine 17,000 4.23 1,288 3.11 15,712 1.12 
Clotrimazole 32,000 4.51 3,467 3.54 28,533 0.97 
Flutamide 1,500 3.18 513 2.71 987 0.47 
Hydroclorothiazide 23 1.36 20 1.31 3 0.05 
Mecillinam 55 1.74 33 1.52 22 0.22 
Paracetamol 307 2.49 331 2.52 -24 -0.03 
Roxithromycin 282 2.45 347 2.54 -65 -0.09 
TCEP 114 2.05 117 2.07 -3 -0.02 
 
 
Significant differences were observed for only three compounds: clomipramine, 
clotrimazole and flutamide. The literature values for these three compounds were 
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obtained from the same paper (Hörsing et al., 2011) on primary sludge with a 
different method. Those differences could be attributed to a difference in sensitivity 
of the method used. The SPE method was shown to give comparable results to the 
OPPTS835.1110 test, therefore, the 𝐾𝑑 obtained with the SPE method were 
considered more reliable. Very small differences were observed for the six 
remaining compounds, which showed that the use of the mean 𝐾𝑑 value of all the 
𝐾𝑑 values obtained in the literature was justified.  
 
4.4 Summary 
The choice of buffer in the sorption experiment is critical to adequately represent the 
sorption phenomenon that occurs in sewage treatment plants. Considerations of the 
observed pH of the solution, the nature of the cations present, and the molarity of 
the buffer need to be taken into account. This study highlighted that a mixture of 
cations such as that used in the buffer described in the OECD 301 guideline was 
suitable to represent the sorption phenomenon. The results in this chapter show that 
the new SPE method provides an alternative, simple, rapid and low-cost method for 
measuring 𝐾𝑑 values of APIs in sewage sludge. The method gave 𝐾𝑑 values that 
were comparable to those obtained using the OPPTS 835.1110 guideline. The new 
method is potentially applicable for use in environmental risk assessments, enabling 
more economic, wider-scale testing of a diverse range of compound classes. It is 
also suitable to test compounds needing a terrestrial risk assessment (log 𝐾𝑂𝑊 ≥ 4.0 
which is equivalent to log 𝐾𝑑 ≥ 3.6). The stability of the packed SPE cartridges was 
found to be satisfactory for up to a year. However, in order to reduce variability it is 
recommended the cartridges are used within a month of packing. The SPE method 
has been published in a peer-reviewed journal (Berthod, Roberts, Whitley, Sharpe & 
Mills, 2014a). 
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Chapter 5: Prediction of Sorption to Sewage Sludge 
from the Octanol-water Partition Coefficient 
 
5.1 Introduction 
The ability to model properties of interest offers the advantage of having an 
estimated value using a mathematical formula without the need of any experiment. 
This is extremely useful especially if the number of compounds is large as it can 
significantly reduce the time and cost of testing. Modelling can be used for the 
prediction of some property of interest, utilising the values of some other known 
properties in an established or hypothesised relationship. For example, 𝐾𝑂𝑊 
depends on chemical structure and may be predicted from variables that describe 
the relevant aspects of the structure. It is common to predict the partition coefficient 
(𝐾𝑑) in soil, sediment or sludge from another partition coefficient, often better 
understood, like the organic carbon-water (𝐾𝑂𝐶) or octanol-water (𝐾𝑂𝑊) partition 
coefficient. Most models used to estimate 𝐾𝑑 are linear models based on 𝐾𝑂𝐶 and 
𝐾𝑂𝑊. The theory behind this type of model is that for highly hydrophobic compounds 
the main mechanism of interaction is hydrophobicity, therefore 𝐾𝑂𝐶  and 𝐾𝑂𝑊 are the 
obvious properties to use. Such models have typically been developed for a specific 
class of compounds, using a specific matrix (i.e. soil or sediment). These models 
are extremely easy to use as they require only a single variable as input, and are 
widely studied, based on plenty of literature data. A number of software programs 
and databases are available to obtain 𝐾𝑂𝐶  and 𝐾𝑂𝑊 values for almost any 
pharmaceutical. From 𝐾𝑂𝐶 , the conversion to 𝐾𝑑 is done by multiplying 𝐾𝑂𝐶   by the 
fraction of organic carbon 𝑓𝑂𝐶, as shown in Equation 1.5. The wide array of models 
available is due to the diversity of chemicals being considered, which means that no 
single model has a domain of applicability broad enough to cover all compounds. 
For example, Sabljic et al. (1995) derived models for different types of compounds, 
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depending on their structures. Another example is Franco et al. (2013; 2008), who 
developed models depending on a compound’s ion class. Dobbs et al. (1989) and 
Matter-Muller (cited by Andersen et al., 2005) are the only authors to have 
developed a model directly for 𝐾𝑑, as opposed to the others who developed their 
models based on 𝐾𝑂𝐶. 
 
Most models for 𝐾𝑂𝐶 have been developed initially for soil, and validated on 
compounds such as pesticides. Pesticides became an environmental concern in the 
late 1950’s and the early 1960’s (Carson, 1962; US EPA, 2014) and an 
understanding of their fate in soil was needed. The point of entry of pesticides to the 
environment is generally through direct application to soil, whereas the first point of 
entry of pharmaceuticals in the environment is through WWTPs. This difference in 
the environmental matrix makes it inappropriate to apply soil-based models for the 
sorption of pesticides to pharmaceuticals in sludge. The major published models 
with their applicability domains are listed in Table 5.1. 
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Table 5.1 Published models for the prediction of 𝐾𝑑 and 𝐾𝑂𝐶  from 𝐷𝑂𝑊 and 𝐾𝑂𝑊 . 
Model Equation Matrix Compounds n 
Carballa
1
 log 𝐾𝑂𝐶  =  0.74 log 𝐷𝑂𝑊 + 0.15 Sludge Pharmaceuticals 12 
Sabljic1
2
 log 𝐾𝑂𝐶 =   0.81 log 𝐾𝑂𝑊 + 0.10 Soil 
Predominantly 
hydrophobic 
chemicals 
81 
Sabljic2
2
 log 𝐾𝑂𝐶 =   0.52 log 𝐾𝑂𝑊 + 1.02 Soil 
Non-
hydrophobic 
390 
Sabljic3
2
 log 𝐾𝑂𝐶 = 0.63 log 𝐾𝑂𝑊  +  0.90 Soil Phenols 54 
Sabljic4
2
 log 𝐾𝑂𝐶 =  0.47 log 𝐾𝑂𝑊 +  0.50 Soil 
Alcohols and 
organic acids 
36 
Dobbs
3
 log 𝐾𝑑  = 0.58 log 𝐾𝑂𝑊 + 1.14 Sludge Hydrophobic 10 
Matter-
Muller
4
 
𝐾𝑑  =  0.67 𝐾𝑂𝑊 + 0.39 Sludge Lipophilic N/A 
Karickhoff
4
 𝐾𝑑 =  𝑓𝑂𝐶 ×  0.41 𝐾𝑂𝑊 
Soil/ 
Sediment 
Polycyclic 
hydrocarbons 
5 
Huuskonen
5
 log 𝐾𝑂𝐶 =  0.6 log 𝐾𝑂𝑊 +  0.84 Soil 
Organic 
chemicals 
403 
Guo
6
 log 𝐾𝑂𝐶 =  0.49 log 𝐾𝑂𝑊 + 1.28 Soil 
Mixed organic 
compounds 
21 
Franco
7
 log 𝐾𝑂𝐶 =  0.60 log 𝐾𝑂𝑊 + 0.32 Soil 
REACH space 
neutrals 
31 
Franco
7
 
log 𝐾𝑂𝐶 = log(ф𝑛 × 10
0.54 log 𝐾𝑂𝑊+1.11 
             +ф𝑖𝑜𝑛 × 10
0.11 log 𝐾𝑂𝑊+1.54) 
Soil 
REACH space 
acid 
93 
Franco
8
 𝐾𝑂𝐶 = 10
0.31 log 𝐷𝑂𝑊+2.78 Soil 
REACH space 
bases 
65 
Franco
7
 
log 𝐾𝑂𝐶 = log(ф𝑛 × 10
0.50 log 𝐾𝑂𝑊+1.13 
            + ф−  × 10
0.11 log 𝐾𝑂𝑊+1.54 
             + ф+ ×  10
(𝑝𝐾𝑎 0.64)×(𝑓0.14)) 
Soil 
REACH space 
amphoteres 
6 
n is the number of compounds used in the model. 𝑓𝑂𝐶  is the fraction of organic carbon. ф is the 
fraction of neutral (n), ionic (ion) anionic (-) and cationic (+) species present in the system. 𝑓 
is the ration of 𝐾𝑂𝑊 by 𝐾𝑂𝑊 + 1. 
1
Carballa et al., 2008
 3
Dobbs et al., 1989 
5
Huuskonen, 2003 
7
Franco & Trapp, 2008 
2
Sabljic et al., 1995
  4
Karickhoff et al., 1981 
 6
Guo et al., 2004 
8
Franco et al., 2013  
 
Hydrophobic interactions with organic matter form the main contribution to sorption; 
therefore, to apply the soil-based models to sewage sludge a simple correction of 
the fraction of organic carbon could be made. In Chapter 3, it was demonstrated 
experimentally that hydrogen bonding, cation exchange and π-π interactions also 
play an important role in sorption mechanisms. Another weakness with some of the 
existing models is that they were derived using only a small number of compounds. 
An extreme example is the model of Cunningham (2008) which is based on only 
three compounds. Other models based on a larger number of compounds may 
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produce accurate predictions but their specific domain of applicability is restricted to 
the chemical space occupied by the compounds used to develop the model. 
 
In this chapter, the applicability of the existing models to the sorption of 
pharmaceuticals to sewage sludge was assessed using a set of experimental 𝐾𝑑 
values assembled from the literature. This dataset, which is larger than those used 
to derive the existing models for sorption to sewage sludge, was then used to 
develop new models for the prediction of 𝐾𝑑 from 𝐾𝑂𝑊. The performances of these 
new models were compared with those of the published models. 
 
5.2 Evaluation of Existing Models 
To evaluate the published models, the dataset of 𝐾𝑑 values compiled in Table 3.2 
was used. The analysis in Chapter 3 established that the 𝐾𝑑 values for activated 
and primary sludge were comparable and they were pooled together to generate the 
set of values for 119 pharmaceuticals listed in Table 5.2, along with their basic 
physico-chemical properties. 
 
Table 5.2 𝐾𝑑 values for 119 pharmaceuticals in activated and primary sludge from the 
literature, with calculated physico-chemical properties. 
Name 𝑲𝒅 
𝐥𝐨𝐠  
𝑲𝒅 ClogP ACDlogP 
ACDlogD 
pH7.4 
ACD 𝒑𝑲𝒂, 
Acid 
ACD 𝒑𝑲𝒂, 
Base n stdev 
Acetaminophen 307 2.49 0.49 0.34 0.34 9.86 1.72 4 568.99 
Albendazole 1,870 3.27 3.46 3.07 3.06 10.96 5.51 1 n/a 
Alfuzosin  1,800 3.26 2.55 -1.00 -2.38 n/a 8.06 1 n/a 
Amitriptyline 4,783 3.68 4.85 4.92 3.13 n/a 9.34 3 821.10 
Androstenedione 165 2.22 3.01 2.90 2.90 n/a n/a 2 12.73 
Androsterone 557 2.75 3.55 3.75 3.75 n/a n/a 2 31.82 
Atenolol 122 2.09 -0.11 0.10 -1.67 n/a 9.43 6 167.11 
Atorvastatin 207 2.32 4.46 4.00 0.89 13.57 0.39 2 12.73 
Atracurium  350 2.54 3.50 1.04 1.04 n/a n/a 1 n/a 
Atrazine 91 1.96 2.70 2.63 2.63 n/a 2.27 2 43.84 
Azelastine 6,400 3.81 6.14 n/a*
 
n/a* n/a 9.43 1 n/a 
Azithromycin 376 2.58 2.64 3.33 1.28 13.74 8.85 1 n/a 
Benzophenone 161 2.21 3.18 3.18 3.18 n/a n/a 1 n/a 
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Bicalutamide 140 2.15 2.71 4.94 4.94 11.18 n/a 2 65.41 
Biperiden  820 2.91 4.94 4.01 1.60 n/a 9.26 1 n/a 
Bisoprolol 40 1.60 1.83 2.14 0.38 n/a 9.42 1 n/a 
Bisphenol A 330 2.52 3.67 3.43 3.43 10.59 n/a 3 94.03 
Bupropion  85 1.93 3.21 3.47 3.27 n/a 7.16 1 n/a 
Caffeine 30 1.48 -0.04 -0.13 -0.13 n/a 0.52 2 0.00 
Candesartan 17 1.23 5.18 4.76 -1.85 3.65 4.23 2 2.47 
Carbamazapine 84 1.92 2.38 2.67 2.67 13.94 n/a 8 101.98 
Cediranib 7,760 3.89 5.28 3.89 1.25 n/a 10.05 1 n/a 
Celiprolol 85 1.93 1.86 1.92 0.20 n/a 9.50 1 n/a 
Chlorprothixene 38,000 4.58 5.48 6.05 4.39 n/a 9.19 1 n/a 
Ciprofloxacin 417 2.62 -0.72 0.65 -1.35 6.44 8.68 1 n/a 
Citalopram 540 2.73 3.13 2.51 0.34 n/a 9.79 1 n/a 
Clarithromycin 262 2.42 2.37 3.16 2.33 13.49 9.20 1 n/a 
Clofibric Acid 26 1.41 2.82 2.72 -1.49 3.70 n/a 3 8.44 
Clomipramine 17,000 4.23 5.92 5.40 3.37 n/a 9.67 1 n/a 
Clonazepam  570 2.76 2.38 2.34 2.34 11.21 1.55 1 n/a 
Clotrimazol 32,000 4.51 5.00 5.44 5.42 n/a 6.05 1 n/a 
Clozapine 1,686 3.23 3.71 2.36 2.23 n/a 7.33 2 62.23 
Codeine 14 1.15 0.98 1.20 0.30 13.72 8.30 1 n/a 
Cyclophosphamide 55 1.74 0.80 0.23 0.23 n/a 2.84 1 n/a 
Cyproheptadine  11,000 4.04 5.30 6.41 4.85 n/a 9.07 1 n/a 
Dapagliflozin 51 1.71 3.37 4.42 4.42 13.92 n/a 1 n/a 
DEET 71 1.85 2.16 1.96 1.96 n/a n/a 2 41.01 
Desloratadine 3,700 3.57 3.83 6.77 3.86 n/a 4.40 1 n/a 
Diazapam 106 2.03 2.96 2.91 2.91 n/a 3.40 7 110.80 
Diclofenac 207 2.32 4.73 4.06 0.83 4.18 n/a 7 196.37 
Dicycloverine 1,400 3.15 6.14 6.05 4.21 n/a 9.24 1 n/a 
Dihydrocodeine 12 1.08 1.26 1.39 0.32 n/a 8.53 1 n/a 
Dilantin 63 1.80 2.08 2.52 2.52 8.28 n/a 2 25.46 
Donepezil 3,600 3.56 4.60 4.71 3.29 n/a 8.84 1 n/a 
Doxepin 139 2.14 4.09 3.86 2.06 n/a 9.35 1 n/a 
Duloxetine 13,000 4.11 4.26 4.81 2.19 n/a 10.02 1 n/a 
Erythromycin 180 2.26 1.61 2.83 2.00 13.49 9.20 3 119.08 
Esomeprozole 48 1.68 2.56 2.17 2.17 8.50 5.08 2 17.47 
Estradiol (E2) 742 2.87 3.78 4.13 4.13 10.27 n/a 5 449.08 
Estriol 61 1.78 3.20 2.94 2.94 10.25 n/a 2 3.54 
Estrone (E1) 467 2.67 3.38 3.69 3.69 10.25 n/a 5 183.42 
Ethinylestradiol 
(EE2) 657 2.82 3.86 4.52 4.52 10.24 n/a 7 468.95 
Ezetimibe 2,300 3.36 3.96 3.26 3.25 9.72 n/a 1 n/a 
Felodipine 2,800 3.45 5.30 4.83 4.83 n/a 2.73 2 997.09 
Fenbendazole  4,100 3.61 4.18 3.75 3.74 10.80 5.38 1 n/a 
Fenoprofen 57 1.76 3.82 3.84 0.64 4.20 n/a 1 n/a 
Fexofenadine 2,700 3.43 1.96 4.80 2.30 13.61 9.41 1 n/a 
Fluoxetine 10,000 4.00 4.57 4.09 1.43 n/a 10.05 1 n/a 
Flutamide 1,500 3.18 3.34 3.72 3.72 13.12 n/a 1 n/a 
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Furosemide 158 2.20 1.90 3.10 -1.29 3.04 n/a 1 n/a 
Gefitinib 1,852 3.27 5.60 2.61 2.35 n/a 7.00 2 1737.22 
Gemfibrozil 46 1.67 3.94 4.39 1.74 4.76 n/a 5 32.24 
Glibenclamide 1,374 3.14 4.24 3.75 3.75 11.64 n/a 3 1928.18 
Glimepiride 2,100 3.32 3.96 2.94 2.94 11.65 n/a 1 n/a 
Haloperidol 10,000 4.00 3.85 3.01 2.11 n/a 8.04 1 n/a 
Hydroclorothiazide 23 1.36 -0.36 -0.07 -0.09 8.95 n/a 2 3.96 
Hydroxyzine 932 2.97 4.00 2.03 2.00 n/a 6.62 3 232.71 
Ibuprofen 74 1.87 3.68 3.72 0.73 4.41 n/a 5 30.94 
Ifosfamide 22 1.34 0.92 0.23 0.23 n/a 1.44 1 n/a 
Indomethacin 39 1.59 4.18 3.10 -0.33 5.74 n/a 1 n/a 
Iopromide 10 1.00 -1.73 -2.95 -2.95 10.62 n/a 1 n/a 
Irbesartan 700 2.85 6.04 4.25 1.14 4.16 2.64 1 n/a 
Ketoconazole 9,700 3.99 3.64 3.55 3.43 n/a 6.88 1 n/a 
Ketoprofen 90 1.96 2.76 2.81 -0.35 4.23 n/a 3 117.67 
Loperamide 14,000 4.15 4.66 4.26 3.53 n/a 7.76 1 n/a 
Loratidine 2,829 3.45 5.05 5.94 5.94 n/a 4.37 2 696.50 
Maprotiline 6,700 3.83 4.52 4.36 1.14 n/a 10.62 1 n/a 
Mecillinam 55 1.74 2.50 2.33 -0.19 2.46 9.04 1 n/a 
Mefenamic acid 364 2.56 5.29 5.33 1.93 3.73 n/a 2 98.99 
Meprobamate 36 1.56 0.92 0.70 0.70 13.39 n/a 2 8.49 
Methadone 76 1.88 4.17 4.20 2.54 n/a 9.18 1 n/a 
Metoprolol 65 1.81 1.49 1.79 0.01 n/a 9.43 1 n/a 
Mianserin 3,000 3.48 3.76 3.67 3.29 n/a 8.26 1 n/a 
Morphine 12 1.08 0.57 0.43 -0.36 13.71 8.31 1 n/a 
Naproxen 24 1.38 2.82 3.00 0.44 4.24 n/a 1 n/a 
Nefazodone 14,000 4.15 5.72 3.50 3.42 n/a 7.65 1 n/a 
Nordiazapam 65 1.81 3.02 3.15 3.15 11.73 3.22 1 n/a 
Olaparib 25 1.40 1.24 0.00 0.00 12.07 n/a 1 n/a 
Omeprazole 119 2.07 2.56 2.17 2.17 8.50 5.08 2 16.26 
Oxazepam 402 2.60 2.30 2.31 2.31 10.94 1.17 2 549.42 
Oxycodone 14 1.15 -0.04 1.67 1.27 13.36 7.62 1 n/a 
Oxytetracycline 4,354 3.64 -3.27 1.59 -1.17 13.20 4.74 3 2005.00 
Paroxetine 14,000 4.15 4.24 3.89 0.97 n/a 9.68 1 n/a 
Phenylphenol 500 2.70 3.06 2.94 2.94 10.00 n/a 2 215.67 
Pizotifen 4,700 3.67 4.70 6.12 4.48 n/a 9.18 1 n/a 
Primidone 27 1.44 0.88 0.40 0.40 12.56 n/a 3 19.14 
Progesterone 750 2.88 3.96 4.04 4.04 n/a n/a 1 n/a 
Propanolol 443 2.65 2.75 3.10 1.35 n/a 9.50 5 118.86 
Propyphenazon 15 1.18 1.35 1.74 1.74 n/a 1.46 1 n/a 
Quetiapine 340 2.53 2.99 1.56 1.55 n/a 6.74 2 205.08 
Raloxifene 2,521 3.40 5.90 4.74 3.32 8.78 8.61 1 n/a 
Repaglinide 170 2.23 5.30 4.69 1.52 4.20 5.77 1 n/a 
Risperidone 1242 3.09 2.71 2.88 2.29 n/a 8.07 3 572.45 
Roxithromycin 282 2.45 2.29 3.73 2.90 13.38 8.30 1 n/a 
Saxagliptin 31 1.50 -0.02 -0.14 -1.09 n/a 8.03 1 n/a 
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Sertraline 35,000 4.54 5.35 4.81 2.74 n/a 9.47 1 n/a 
Sotalol 18 1.26 0.23 0.32 -1.49 8.51 10.10 1 n/a 
Sulfamethoxazole 188 2.27 0.56 0.89 -0.25 5.81 1.39 6 151.62 
Sulfapyridine 295 2.47 0.84 0.03 -0.01 8.54 2.13 1 n/a 
TCEP 114 2.05 -1.96 0.24 -8.26 4.53 n/a 2 68.59 
Telmisartan 1,300 3.11 7.29 7.73 4.32 3.37 6.73 1 n/a 
Testosterone 168 2.22 3.41 3.48 3.48 n/a n/a 2 14.85 
Thiabendazole 103 2.01 2.36 2.47 2.47 10.53 3.40 1 n/a 
Tramadol 279 2.44 3.10 2.51 0.30 n/a 9.83 2 238.29 
Tricagrelor 1,571 3.20 2.55 0.40 0.40 n/a 3.05 2 160.51 
Trimethoprim 241 2.38 0.98 0.79 0.58 n/a 6.90 7 108.77 
Vandetanib 8,400 3.92 5.84 4.01 2.10 n/a 8.92 2 4082.48 
Verapamil 1,648 3.22 4.47 3.90 2.32 n/a 8.07 3 149.55 
Zibotentan 15 1.18 2.09 2.52 1.38 5.62 0.89 2 10.47 
Clog P and ACD descriptors calculated by C-Lab version 2.5.3, chemical predictive modelling 
software. Clog P and ACD log P are the log value of n-octanol/water partition coefficient of the neutral 
species, ACD log D pH 7.4 is the log value of the n-octanol/water partition coefficient at pH 7.4, ACD 
pKa, Acid/Base is the value of the dissociation constant for acid or base.  
*C-Lab failed to calculate values of ACD logP and ACD logD pH7.4 for azelastine. The values 
calculated by other programs were not consistent (ChemSpider reported ACD logP = 3.71 and ACD 
logD pH 7.4 = 1.81, while Chembl reported ACD logP = 3.47 and ACD logD pH 7.4 = 1.57) so these 
were left as missing values in the Table above. 
 
It is important to note that the average standard deviation for multiple values in this 
dataset was 0.28 log unit, with an extreme standard deviation of 1.33 log unit 
observed for zibotentan and 1.26 for oxazepam. 
 
To assess the performance of the published models, the root mean square error 
(RMSE) between the experimental 𝐾𝑑 values and the predicted ?̂?𝑑 values using 
ClogP as  log 𝐾𝑂𝑊,  was calculated for each model using the n = 119 compounds in 
Table 5.2, where:  
 
    𝑅𝑀𝑆𝐸 = √
∑(log 𝐾𝑑 – 𝑙𝑜𝑔 ?̂?𝑑)
2
𝑁
      Eq. 5.2 
 
The RMSE represents the average error of the whole dataset between predicted 
and observed values. It provides an estimate of the model error on the same scale 
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as the measured values. For better models, the measured and predicted values 
should be as close as possible, so the RMSE should be as small as possible. Figure 
5.1 shows the RMSE for each published model. 
 
 
Figure 5.1 Relative performances of the published models (Table 5.1) on a dataset of 119 
pharmaceuticals (Table 5.2) measured by root mean squared errors on log 𝐾𝑑 (RMSE).  
 
Figure 5.1 shows that the best models were Huuskonen, Dobbs, Sabljic2, Sabljic3, 
Guo and Franco, all with a RMSE less than 1.0. The Karickhoff and Carballa models 
performed worst on this dataset of pharmaceuticals, with RMSE of 2.18 and 1.94, 
respectively. The Carballa model was expected to perform better since it was 
developed using pharmaceuticals on sludge (Table 5.1) but this was not the case. A 
possible explanation for this is the low number of compounds (n = 12) on which this 
model was developed. 
 
In Chapter 1, the importance of ionisable compounds in the REACH chemical space 
was raised, therefore the performances of the models for each ion class was 
evaluated, with the results shown in Figure 5.2. In theory, the Franco model should 
have outperformed the others since it was developed specifically for different ion 
classes. This is confirmed in Figure 5.2, where noticeably smaller RMSE values 
(1.79 and 0.75) were observed for the zwitterionic and acidic classes. The Franco 
0.0
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(2013, 2008) model was the best with a RMSE less than 1.0 for three ion classes 
out of four, and it has the lowest RMSE for zwitterions (1.79). The Guo and Sabljic2  
models were relatively accurate for bases and neutral compounds with a RMSE ≤ 
0.7, but were slightly worse than the Franco model for acids (RMSE just above 1.0) 
and for zwitterions (RMSE = 1.94 and 2.13, respectively). The Huuskonen, Dobbs 
and Sabljic3 models which performed well on the whole dataset with a RMSE ≤ 1.0, 
showed poor predictive ability for zwitterions (RMSE ≥ 2.0) and acids (RMSE ≥ 1.3). 
 
 
Figure 5.2 Relative performances of the published models measured by root mean square 
error (RMSE) for 119 pharmaceuticals divided into four ion classes: acids, bases, neutrals 
and zwitterions. 
 
5.3 Regression-based Models 
In this section, new 𝐾𝑂𝑊-based models to predict 𝐾𝑑 for each ion class are derived 
from the dataset presented in Table 5.2. The regression analyses were performed 
using the Minitab© 16 Statistical Software (2010). The models are reported along 
with the coefficient of determination (𝑟2), the adjusted 𝑟2 value (𝑟𝑎𝑑𝑗
2 ), the RMSE, the 
p-value, the total variance (S), and the number of observations (n).  
5.3.1 Which Predictor to Use for 𝐥𝐨𝐠 𝑲𝑶𝑾? 
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Several methods are available to predict the logarithm of the octanol-water partition 
coefficient of the neutral form of a compound, log 𝐾𝑂𝑊 (also denoted by log 𝑃) and 
the octanol-water distribution coefficient at a given pH, log 𝐷𝑂𝑊, which varies with 
pH  for ionic compounds but remains constant for neutrals. Table 5.2 lists the values 
of some of these predictors, ClogP, ACDlogP, ACDlogD pH 7.4 and ACDlogD pH 
6.5, calculated by the AstraZeneca in-house C-Lab© software. All these predictors 
are highly correlated but the model can only have one input. Therefore, the 
predictors were evaluated to select the best one to use to build new 𝐾𝑂𝑊-based 
models. A normality test was performed and all the variables and response were 
normally distributed. 
 
ClogP 
To evaluate ClogP, a simple linear regression between the observed log 𝐾𝑑 values 
and ClogP was performed on the dataset, with the results shown in Figure 5.3. 
 
 
Figure 5.3 Plot of observed log 𝐾𝑑 values against ClogP. The solid line shows the 
regression equation 𝑙𝑜𝑔 𝐾𝑑  =  1.682 +  0.292 ×  ClogP (𝑟
2= 0.352, 𝑟𝑎𝑑𝑗
2  = 0.346, RMSE = 
0.741, p-value < 0.01, S = 0.748, n= 119).    
 
The residual plots in Figure 5.4 gave information on the quality of the model. Ideally, 
the normal probability plot should follow a straight line, and for this model this was 
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the case, apart from a slight deviation at the bottom and top. The plot of residuals 
versus fitted values should be scattered and random, which was the case for this 
model. The frequency histogram should have a normal distribution (i.e. approximate 
a Gaussian curve), which it did in this case.  
 
Figure 5.4 Residual plots for the linear regression between log 𝐾𝑑 and ClogP (log 𝐾𝑑  =
 1.68 +  0.29 ×  ClogP) for 119 pharmaceuticals.  
 
This model highlighted five high leverage compounds, which were detected by 
having a large standardised residual value or by their x-value giving a large 
leverage to the regression. The five compounds were identified as candesartan, 
iopromide, oxytetracycline, TCEP and telmisartan. All five compounds belonged to 
the acid or zwitterionic ionic classes, which were shown to be difficult classes for 
prediction based on log 𝐾𝑂𝑊 (section 5.2). After removal of these outliers, the 𝑟
2 of 
regression improved to 0.49. 
 
ACDlogP 
The same treatment (i.e. simple linear regression) was applied to the dataset using 
ACDlogP and the result is shown in Figure 5.5. 
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Figure 5.5 Plot of observed log 𝐾𝑑 values against ACDlogP. The solid line shows the 
regression equation 𝑙𝑜𝑔 𝐾𝑑  =  1.704 +  0.290 ACDlogP (𝑟
2 = 0.319, 𝑟𝑎𝑑𝑗
2 = 0.313, RMSE = 
0.831, p-value < 0.01, S = 0.764, n = 118).    
 
 
Figure 5.6 Residual plots for the linear regression between log 𝐾𝑑 and ACDlogP (𝑙𝑜𝑔 𝐾𝑑  =
 1.70 +  0.29 ACDlogP) for 118 pharmaceuticals.  
 
In this case, the histogram in Figure 5.6 did not follow a Gaussian distribution and 
the 𝑟2 value of 0.32 was slightly worse than the value of 𝑟2 = 0.35 obtained with 
ClogP. Another observation was the smaller number of compounds used for the 
model. Azelastine was a problematic compound for the ACD algorithm as it could 
not calculate a value for the predictor, and this compound was excluded. This model 
highlighted four unusual values, three of which were the same as in the previous 
model: candesartan, iopromide, and telmisartan. The fourth high leverage 
compound was identified as alfuzosin, a very weak base. All four compounds were 
ionisable, and the predictions based on log 𝐾𝑂𝑊 were unreliable. After removal of 
these outliers, the 𝑟2  value of the regression improved to 0.37. 
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ACDlogD pH 7.4 
ACDlogD pH 7.4 was selected as the pH 7.4 value was the same experimental 
value used for measuring 𝐾𝑑 in sludge.  
 
 
Figure 5.7 Plot of observed log 𝐾𝑑 values against ACDlogD pH 7.4. The solid line shows the 
regression equation 𝑙𝑜𝑔 𝐾𝑑  =  2.182 +  0.219 ACDlogD pH7.4 (𝑟
2 = 0.233, 𝑟𝑎𝑑𝑗
2 = 0.227, 
RMSE = 0.873, p-value < 0.01, S = 0.810, n = 118).  
 
The 𝑟2 associated with the regression was only 0.23, which was worse than both 
ClogP (𝑟2 = 0.35) and ACDlogP (𝑟2  = 0.32). The model also encountered the same 
issue as previously about the predictor calculation for azelastine. In Figure 5.8, a 
poor distribution on the normal probability plot (upper and lower region), and a 
failure to follow the expected Gaussian distribution on the frequency histogram, 
were observed.  
 
 
Figure 5.8 Residual plots for the linear regression between log 𝐾𝑑 and ACDlogD pH 7.4 
(log 𝐾𝑑 =  2.18 +  0.22 ACDlogD pH7.4) for 118 pharmaceuticals.  
120 
 
 
This model highlighted the highest number of unusual observations, six in total. 
Three of the compounds were the same as those in the ClogP model: iopromide, 
oxytetracycline and TCEP. Another high leverage compound was common to the 
ACDlogP model: alfuzosin. The last two were identified as paroxetine and sertaline, 
two bases with very high 𝐾𝑑 values. All six compounds were ionisable, making 
predictions based on log 𝐾𝑂𝑊 unreliable. After removal of these unusual 
observations, the 𝑟2 value improved to 0.34. 
 
Discussion 
The results of the linear regressions of log 𝐾𝑑 on the three predictors of log 𝐾𝑂𝑊 are 
summarised in Table 5.3. The model with ClogP was generally better with the 
highest 𝑟2 on the regression (0.35) and the use of the whole dataset. The C-Lab 
software was unable to generate values of ACDlogP and ACDlogD pH7.4 for the 
compound azelastine, which is a cationic pharmaceutical, so these regressions 
used only 118 pharmaceuticals out of the 119. Apart from this, the three models 
were broadly equivalent, and all are weak in terms of correlation, with 𝑟2 values from 
0.23 to 0.35. They had comparable numbers of unusual observations, all in the 
ionisable domain. After removal of the outliers for each model, ClogP still gave the 
best 𝑟2 for the regression withlog 𝐾𝑑. Therefore, the predictor chosen for further 
work was ClogP. 
 
Table 5.3 Coefficient of determination, RMSE and associated p-value for log 𝐾𝑑 and three 
log 𝐾𝑂𝑊 predictors. 
𝐥𝐨𝐠 𝑲𝑶𝑾 predictors 𝒓
𝟐 𝒓𝟐 (adj) RMSE p-value 
ClogP 0.352 0.346 0.741 < 0.01 
ACDlogP 0.319 0.313 0.831 < 0.01 
ACDlogD pH7.4 0.233 0.227 0.873 < 0.01 
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5.3.2 New ClogP-based Models 
Like the Franco approach (2013; 2008), the new ClogP-based model includes four 
regressions, one for each ionic class. The dataset was divided in four subsets, 
depending on the compound’s ion class. The neutral subset had 40 compounds, the 
basic 51, the acidic 21 and the zwitterionic 7. Due to the limited amount of data, this 
approach considered the whole set of data rather than splitting into two sets for 
model building and model validation.  
 
The regression equation obtained for the neutral compounds (eq. 5.1) gave an 𝑟2 of 
0.59, which is far better than the 𝑟2 of 0.35 obtained for the whole dataset. The 
model and diagnostic plots for the residuals are shown in Figure 5.9. 
log 𝐾𝑑 = 1.362 + 0.355 ClogP   Eq. 5.1 
𝑟2 = 0.592, 𝑟𝑎𝑑𝑗
2 = 0.581, 𝑅𝑀𝑆𝐸 = 0.445, 𝑝 < 0.01, 𝑆 = 0.457, 𝑛 = 40 
 
 
 
Figure 5.9 Plot of observed log  𝐾𝑑values against ClogP for neutral pharmaceuticals, with 
the regression model (eq. 5.1) shown as a solid line (left); diagnostic residual plots (normal 
probability, versus fits and frequency histogram)(right).   
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Similarly for the basic compounds, the regression equation obtained produced an 𝑟2 
of 0.69 confirmed the improvement on the subset compared to the whole dataset 
(𝑟2 = 0.35) (Figure 5.10). 
log 𝐾𝑑 = 1.244 +  0.490 ClogP   Eq. 5.2 
𝑟2 = 0.695, 𝑟𝑎𝑑𝑗
2 = 0.689, 𝑅𝑀𝑆𝐸 = 0.570, p <  0.01, 𝑆 = 0.581, 𝑛 = 51 
 
Figure 5.10 Plot of observed log 𝐾𝑑  values against ClogP for basic pharmaceuticals, with the 
regression model (eq. 5.2) shown as a solid line (left); diagnostic residual plots (normal 
probability, versus fits and frequency histogram) (right).     
  
For the acidic compounds, the regression gave a poor correlation with an 𝑟2 value 
of only 0.08 (𝑟𝑎𝑑𝑗
2  = 0.03) (Figure 5.11). The regression coefficient was 0.086, which 
indicated a very weak relationship between ClogP and log 𝐾𝑑. The p-value was 
0.214, above the 0.05 threshold, showing the model is not significant at the 5%  
level. 
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Figure 5.11 Plot of observed log 𝐾𝑑  values against ClogP for acidic pharmaceuticals, with 
the regression model log 𝐾𝑑 =  1.782 +  0.086 ClogP (𝑟
2= 0.080, 𝑟𝑎𝑑𝑗
2  = 0.031, RMSE = 
0.588, p-value = 0.214, S = 0.618, n = 21) shown as a solid line (left); diagnostic residual 
plots (right).     
 
In the zwitterionic group, the first concern was the number of observations; only 7 
pharmaceuticals were available, which made regression analysis difficult. In Figure 
5.12, the data are scattered with no clear trend. The regression analysis gave an 𝑟2 
of 0.02, indicating little or no relationship between the variables. This was confirmed 
by the regression coefficient of 0.03, showing that ClogP is not influencing 𝐾𝑑. The 
p-value was 0.761, above the 0.05 threshold, highlighting the lack of significance of 
this model. 
 
 
Figure 5.12 Plot of observed log 𝐾𝑑  values against ClogP for zwitterionic pharmaceuticals, 
with the regression model log 𝐾𝑑 =  3.117 −  0.027 ClogP (𝑟
2= 0.020, 𝑟𝑎𝑑𝑗
2  = -0.176, RMSE = 
0.550, p-value = 0.761, S = 0.651, n = 7) shown as a solid line (left); diagnostic residual 
plots (right).     
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The new ClogP models, summarised in Table 5.4, were improved for neutrals and 
bases (with 𝑟2 ≥ 0.6 and p-value < 0.05), but worsened for acids and zwitterions 
(with 𝑟2 < 0.1 and p-value > 0.05). The significantly lower amount of data for the 
latter class made it difficult to see any potential relationship. The leave-one-out 
cross-validation statistic 𝑞2 indicates that the models for neutrals and bases have 
reasonable predictive power.   
 
Table 5.4 Statistics of the new ClogP-based models for separate ion classes. 
Ion class 𝒓𝟐 𝒓𝒂𝒅𝒋
𝟐  𝒒𝟐 RMSE p-value n 
Neutral 0.592 0.581 0.577 0.445 < 0.001 40 
Base 0.695 0.689 0.668 0.570 < 0.001 51 
Acid 0.080 0.031 -0.059 0.588 0.214 21 
Zwitterion 0.020 -0.176 -0.385 0.550 0.761 7 
 
5.4 Comparison with Published Models 
It was interesting to compare the new ClogP based models to the published ones 
listed in Table 5.1. The three best existing models, Sabljic2, Guo and Franco, were 
compared with the newly developed ClogP-based models using the RMSE to 
measure their performance, with the results seen in Figure 5.13. 
 
 
Figure 5.13 Relative performance of the new ClogP-based models and the Sabljic2, Guo 
and Franco published models on the same dataset. Root mean square errors (RMSE) for 
each model for the 119 pharmaceuticals divided into four ion classes: acids, bases, neutrals 
and zwitterions. 
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The ClogP models outperformed all three existing models. This was most likely 
because the existing models were derived using different sets of different types of 
compounds, while the ClogP models have been assessed on the dataset from 
which they were built. External validation using an independent test set was not 
used in this instance due to the small number of values available in specific ion 
classes. Acids and zwitterions were included in Figure 5.13 for information purposes 
only as the ClogP models they generated were extremely poor (p-values > 0.05). It 
was interesting to note that even with the poor ClogP models obtained for the 
zwitterions and acids, they still outperformed more complex and ion class specific 
models such as Franco. Acids and zwitterions were generally the worst classes for 
accurate prediction based on 𝐾𝑂𝑊 which indicated that this descriptor alone was 
inadequate for the prediction of sorption for these ion classes.  
 
5.5 Summary 
The work described in this chapter showed that the use of the single model based 
on the 𝐾𝑂𝑊 descriptor is inadequate to predict sorption for the entire dataset of 
pharmaceuticals. Hence, separate models specific to each ion class were required, 
and these were shown to predict 𝐾𝑑 values more accurately than the existing soil-
based models. This was probably due to the fact that these models were derived 
from a dataset specifically focused on pharmaceuticals on sewage sludge, whereas 
the published models had a different domain of applicability, which were not 
exclusively dedicated to pharmaceuticals in sludge. This comparison of these 
models highlighted the limitation of the 𝐾𝑂𝐶/𝐾𝑂𝑊 theory, in which hydrophobicity is 
assumed to be the main mechanism of interaction for pharmaceuticals in sludge, 
especially in the case of acids and zwitterions. Other descriptors besides 𝐾𝑂𝑊 are 
needed to understand and model adequately these ion classes. The results found in 
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this chapter were consistent with those found in Chapter 3, describing the 
mechanisms of sorption of pharmaceuticals to sewage sludge. Hydrophobicity was 
not sufficient to wholly explain the sorption of pharmaceuticals to sewage sludge, 
especially for acids and zwitterions, which might sorb via other types of interaction 
such as ion-exchange or hydrogen bonding. Other descriptors required for 
predictive purposes need to be selected to be able to describe these other types of 
interactions. 
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Chapter 6: Prediction of Sorption to Sewage Sludge 
from Structure-based Molecular Descriptors 
6.1 Introduction 
The limitations of using a single descriptor, the octanol-water partition coefficient 
𝐾𝑂𝑊, to predict the value of the partition coefficient 𝐾𝑑 have been highlighted in the 
previous chapter. Additional descriptors, relevant to sorption mechanisms, must be 
considered if more accurate predictions are to be obtained. A molecular descriptor 
is simply a numerical value encoding chemical information, calculated from a 
symbolic representation of a molecule. A general assumption is that similar 
structures have similar properties. Therefore, descriptors derived from structure 
(e.g. 𝐾𝑂𝑊) can be used to predict a given property (e.g. 𝐾𝑑).  Molecular descriptors 
may consist of continuous variables (e.g. 𝑝𝐾𝑎, 𝐾𝑂𝑊) or discrete variables (e.g. 
number of rotatable bonds, ring count). The number of molecular descriptors used is 
dependent upon the level of accuracy required with the model. The molecular 
formula is considered as one-dimensional and molecular descriptors such as the 
number of atoms, or the molecular weight can be calculated from this information. 
Descriptors such as the bond and ring counts require the two-dimensional chemical 
structure. The full three-dimensional conformation allows the calculation of 
descriptors such as polar and non-polar surface areas, dipole moment and van der 
Waals surface area. In some cases, several alternative molecular descriptors have 
been developed using different algorithms to predict a particular physico-chemical 
property. For example, in the previous chapter, ClogP and ACDlogP were two 
descriptors used to predict log log 𝐾𝑂𝑊, and these variables were calculated by 
different methods. Several thousand molecular descriptors are available (Todeschini 
& Consonni, 2008) but they often occur as groups of related descriptors (such as 
the Abraham and WHIM descriptors mentioned in Chapter 1). Normally, the 
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grouping aims to provide self-contained, general-purpose descriptor sets, able to 
predict a range of physico-chemical properties.  
 
Some molecular descriptors, such as molecular weight or molecular volume, are 
easier to interpret than others. In this Chapter, a selection of molecular descriptors, 
potentially relevant to describe the sorption phenomenon, were used to build 
predictive models. Two methods were used for this: partial least squares (PLS), a 
linear method commonly used in quantitative structure-activity relationships 
(QSARs) and artificial neural networks (ANNs), a machine-learning method which 
allows derivation of non-linear models.  
 
6.2 Selection of Molecular Descriptors 
For this research, a range of potentially relevant sets of descriptors was chosen. 
These sets could be particularly useful to understand why the partitioning behaviour 
of acids and zwitterions to sewage sludge were poorly predicted by the existing 
𝐾𝑂𝑊-based models. The Abraham descriptors were not used as some discrepancies 
arise with these descriptors; the reported Abraham descriptors were not consistent, 
as they have been refined over several years (Stovall et al., 2005; Zhao et al., 2001; 
Zissimos, Abraham, Du, et al., 2002) and it was not clear which version to use. 
Furthermore, the most recent tabulated version of those descriptors did not include 
values for several compounds of interest (Abraham & Acree, 2010; Abraham et al., 
2004; Clarke, 2009; Zissimos et al., 2002a, 2002b). 
 
The first set of descriptors selected, the AstraZeneca descriptors, was calculated 
using the AstraZeneca in-house C-Lab© software. This set was chosen as it 
contained only fourteen descriptors, listed in Table 6.1, making the overall set a 
manageable size. All fourteen descriptors were simple and easily interpretable. The 
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categorical ion class variable was encoded into four numerical descriptors, in order 
to have only one model for all four ion classes. 
 
Table 6.1 AstraZeneca molecular descriptors. 
Lipophilicity Size/shape H-bonding Drugability 
ClogP Molecular weight (MW) Ion class Lipinski score 
ACDlogP Volume (VOL) 
Hydrogen Bond Acceptors 
(HBA) 
 
ACDlogD7.4 
Number of rotatable bonds 
(RotBond) 
Hydrogen Bond Donors 
(HBD) 
 
ACDlogD6.5 Number of rings (RingCount) Polar Surface Area (PSA)  
 
Non-polar surface area 
(NPSA)  
 
 
 
The second descriptor set, was calculated by the Molecular Operating Environment© 
(MOE) software (Chemical Computing Group Inc., 2014). The MOE descriptors are 
more numerous, running into the hundreds; a full list is available on the Chemical 
Computing Group Inc.’s website (Chemical Computing Group Inc., 2014). A subset 
of the MOE descriptors, the VSurf descriptors, is particularly interesting as it is the 
MOE implementation of the VolSurf descriptors, which are easier to interpret 
(Cruciani, Crivori, Carrupt, & Testa, 2000). The VSurf subset has 76 variables, 
hence is more manageable in size. They cover a wide range of properties from size 
and shape to hydrophobic and hydrophilic properties (Cruciani et al., 2000) as 
shown in Table 6.2. 
 
Table 6.2 The MOE VSurf descriptors. 
Vsurf code Property Vsurf code Property 
vsurf_V  Interaction field volume  vsurf_S  Interaction field surface area  
vsurf_S  Surface rugosity  vsurf_S  Surface globularity  
vsurf_W  
Hydrophilic volume (8 
descriptors)  
vsurf_IW  
Hydrophilic integy moment (8 
descriptors)  
vsurf_A  Amphiphilic moment  vsurf_CW  Capacity factor (8 descriptors)  
vsurf_D  Hydrophobic volume (8 
descriptors)  
vsurf_DW  Contact distances of vsurf_EWmin (3 
descriptors)  
vsurf_ID  
Hydrophobic integy moment (8 
descriptors)  
vsurf_EDmin  
Lowest hydrophobic energy (3 
descriptors)  
vsurf_CA  Critical packing parameter  vsurf_Wp  Polar volume (8 descriptors)  
vsurf_HL  
Hydrophilic-Lipophilic (2 
descriptors)  
vsurf_EWmin  
Lowest hydrophilic energy (3 
descriptors)  
vsurf_DD  
Contact distances of 
vsurf_DDmin (3 descriptors)  
vsurf_HB1  H-bond donor capacity (8 descriptors)  
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Two further sets of descriptors were selected from the 4,885 Dragon descriptors 
(Maur et al., 2006) calculated by C-Lab© using Dragon version 6.0.26. The WHIM 
descriptors are a set of 99 topological descriptors, depending on the geometry, 
shape and orientation of the molecule (Todeschini & Gramatica, 2002). The 
GETAWAY (GEometry, Topology and Atom-Weights AssemblY) descriptors 
(Consonni & Todeschini, 2002) are a set of 197 descriptors derived from a 
molecular influence matrix defined by the atomic coordinates. The final set of 
descriptors studied, the ParaSurf descriptors, are derived from four major properties 
on the iso-density surface of the molecule: the molecular electrostatic potential, the 
local ionisation energy, the local electron affinity and the local polarisability (Clark, 
2010).   
 
In each case, the descriptors were calculated from the SMILES representation of 
the molecules (Weininger, 1988; Weininger et al., 1989). Three-dimensional 
structures generated with MOE were used to calculate the three-dimensional MOE 
descriptors and the ParaSurf descriptors. 
 
 
6.3 Data Preparation  
6.3.1 Variable Pre-treatment 
The different sets of molecular descriptors chosen differed in the number of 
descriptors they contained. In order to remove variables that were unlikely to 
contribute to the model and to have a manageable number, some preliminary 
“cleaning” work was required (Tropsha et al., 2003). For each set, a pre-treatment 
was applied to the variables to allow the selection of the most relevant ones.  
 
First, the variables with a non-significant p-value associated with their Pearson 
correlation coefficient with log 𝐾𝑑 were removed. Although this treatment limited the 
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nature of relationship with 𝐾𝑑 to linear types rather than other non-monotonic 
relationships such as parabolic or periodic, it resulted in some sets of descriptors 
giving a more manageable size by removing a certain number of variables. It was 
also impossible to investigate all the possible types of relationships between all the 
variables in all the descriptor sets chosen with 𝐾𝑑 . The coefficient of variation 
(standard deviation/mean) was another criterion for variable selection. Any variable 
with a coefficient of variation below 0.1 was removed as it implied that the variable 
had a very low dynamic range and therefore, not likely to be contributing to the 
model for 𝐾𝑑 enough to be considered as an important mechanism of sorption 
(Tropsha, 2010). Finally, all the remaining variables were standardised by 
subtracting the mean and dividing by the standard deviation. 
 
 
6.3.2 Training and Validation Set Selection 
The dataset used for model building was the same set of 119 pharmaceuticals, 
including 21 acids, 40 neutrals, 51 bases and 7 zwitterions or cationics (atracurium 
and azelastine), used in the previous chapter (Table 5.2). To enable comparisons of 
the performance of models built from different sets of descriptors, the dataset was 
divided into a training set and an external validation set. The training set was used 
to build the models, while the validation set was excluded from the training 
procedures and used only to provide an independent assessment of the models’ 
performance, following standard practice (Gramatica, 2007). At least 15-20% of the 
dataset is recommended for the external validation set (Tropsha, 2010). Several 
methods for splitting the dataset so that the external validation set is representative 
of the whole dataset have been proposed, but no general consensus has emerged 
on the best procedure to follow (Martin et al., 2012). Due to the relatively small size 
of the dataset in this case, 19 pharmaceuticals, comprising 16% of the dataset, 
were selected for the external validation set. These were chosen randomly, to 
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reflect the distribution of the ion classes within the dataset, then adjusted manually 
to ensure the range of 𝐾𝑑 values was also representative of the whole dataset. This 
resulted in the external validation set containing 3 acids, 6 neutrals, 8 bases, 1 
zwitterion and 1 cationic shown in Table 6.2. 
 
Table 6.3 The 19 compounds selected as the external validation set. 
Compound 
𝐥𝐨𝐠 𝑲𝒅 
experimental 
Ion 
Class Compound 
𝐥𝐨𝐠 𝑲𝒅 
experimental 
Ion 
Class 
Azelastine 3.81 Cationic Loratidine  3.45 Neutral 
Caffeine  1.48 Neutral Meprobamate  1.56 Neutral 
Cediranib  3.89 Base Oxazepam  2.60 Neutral 
Clozapine  3.23 Base Progesterone 2.88 Neutral 
DEET 1.85 Neutral Roxithromycin  2.53 Base 
Dihydrocodeine  1.08 Base Sotalol  1.26 Base 
Duloxetine  4.11 Base Sulfamethoxazole  2.35 Acid 
Fexofenadine  3.18 Zwitterion Tramadol  2.44 Base 
Gemfibrozil  1.65 Acid Verapamil  3.21 Base 
Glibenclamide  3.04 Acid 
    
 
 
 
 
6.4 Partial Least Squares 
PLS is a multivariate approach which reduces data dimensionality with respect to 
both dependent and independent variables by combining them into components, 
where each component is a linear combination of the different variables depending 
on their relevance for the component. A relevant variable has a high coefficient, or 
loading, in the linear combination. The different components may then be 
interpreted according to the different loadings of the variables. PLS is particularly 
useful when the number of descriptors exceeds the number of compounds 
(Eriksson et al., 2003). As well as model building, it has a cross-validation option, 
calculating the leave-one-out cross-validation statistic 𝑄2, which is an internal model 
validation tool used to choose the appropriate number of components to include in a 
PLS model. To calculate 𝑄2, each compound is successively removed from the 
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dataset and a predicted value 𝑦𝑝𝑟𝑒𝑑 for this compound is obtained from a model 
derived from the remaining compounds. The value of 𝑄2 is then given by: 
𝑄2 = 1 −
∑(𝑦𝑝𝑟𝑒𝑑−𝑦)
2
∑(𝑦−?̅?)2
    Eq. 6.1 
 
where ?̅? is the mean of the observed values 𝑦 and the summation is over the 
compounds in the dataset. 
 
A quantitative measure for the goodness of fit is given by the parameter 𝑅2 (the 
explained variation), while, on the other hand, the predictive ability is given by the 
goodness of prediction parameter 𝑄2 (the predicted variation). Usually 𝑅2 and 𝑄2 
parameters vary differently with increasing model complexity; 𝑅2 is inflationary and 
rapidly approaches unity as model complexity increases (the number of 
component), while 𝑄2 will not automatically approach 1. After a certain degree of 
model complexity, the predictive ability will not improve any further. The value of 𝑄2 
value will reach a plateau, and then decrease as the predictive ability is degraded. 
Hence, the number of components determined will be a trade-off between fit and 
predictive ability where both 𝑅2 and 𝑄2 need to be as high as possible at the same 
time. Without a high 𝑅2 it is impossible to obtain a high 𝑄2. Generally, a 𝑄2 > 0.5 is 
considered good and a 𝑄2 > 0.9, excellent (Eriksson, Johansson, Kettaneh-Wold, & 
Wold, 2001). Differences between 𝑅2 and 𝑄2 larger than 0.3 indicated the presence 
of irrelevant model terms or outlying data points. 
 
6.4.1 Procedure 
After the data pre-treatment and removal of uncorrelated or constant variables, each 
set of descriptors was processed by the PLS routine in Minitab©. For each of the five 
sets of descriptors chosen, 𝑅2, 𝑄2 and 𝑅𝑝𝑟𝑒𝑑
2 were calculated by Minitab©. The 
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𝑅𝑝𝑟𝑒𝑑
2 represented the goodness of fit of the 19 validation compounds between 
values predicted by the model and the experimental values. The component 
loadings and weights were also recorded to obtain a final model equation in terms of 
the original variables rather than the components. The best model was selected with 
the highest 𝑄2 value, as shown in the example in Table 6.4, where the model with 
only one component was selected for the AstraZeneca set whereas the model with 
5 components was better for the MOE set. 
Table 6.4 Example of model selection for the AstraZeneca and MOE descriptors. 
Number of 
components 
AstraZeneca MOE 
𝑹𝟐 𝑸𝟐 𝑹𝟐 𝑸𝟐 
1 0.420 0.356 0.315 0.233 
2 0.450 0.336 0.469 0.234 
3 0.472 0.295 0.583 0.236 
4 0.488 0.266 0.639 0.310 
5 0.497 0.251 0.705 0.334 
6 0.500 0.245 0.746 0.279 
 
6.4.2 Results  
The results of the PLS analysis are shown in Table 6.5. The 𝑄2 values remained 
low (lower than the ‘good’ 0.5 threshold) but 𝑅𝑝𝑟𝑒𝑑
2  was around 0.6 for both the MOE 
and AstraZeneca sets. A difference of 0.37 was observed between the 𝑅2 and 𝑄2 
values for the MOE descriptors, which indicated either too many outliers or more 
likely the presence of irrelevant model terms. The MOE set included 100 variables 
after pre-treatment compared to 12 for the AstraZeneca set. 
 
Table 6.5 Performance of PLS models with the different sets of descriptors. 
Descriptors sets Training set  
𝑹𝟐 
Training set 𝑸𝟐 Validation set  
𝑹𝟐-pred 
MOE 0.705 0.334 0.627 
Vsurf 0.271 0.193 0.444 
AstraZeneca 0.420 0.356 0.654 
Parasurf 0.272 0.219 0.184 
Getaway 0.159 0.107 0.387 
WHIM 0.195 0.115 0.031 
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The ParaSurf, Getaway and WHIM descriptor sets were not investigated further as 
their statistical performance was extremely poor (𝑅2, 𝑄 and 𝑅𝑝𝑟𝑒𝑑
2  ≤ 0.4), suggesting 
that they did not contain variables sufficiently relevant to the sorption of 
pharmaceuticals to sewage sludge to produce effective models. The analysis of the 
PLS components for the whole MOE set was difficult due to the large number of 
variables involved. The VSurf subset, however, was easier to interpret, with the 
results revealing that the first component was related to hydrophobicity, with 
variables such as hydrophobic volume having high positive loadings while 
hydrophilic descriptors having high negative loading (Table 6.6). The second 
component was related to size with the two highest loadings corresponding to 
VSurf_V (interaction volume) and VSurf_S (surface area). The third component 
corresponded to hydrophilicity, with descriptors such as hydrophilic energies and 
hydrophilic integy (interaction energy) moments having the highest loading. 
 
The AstraZeneca set was also relatively easier to interpret due to its small number 
of variables.  The first component consisted of properties mainly associated with 
hydrophobicity, as all the variables ClogP, ACDlogP, ACDlogDpH7.4 loaded highly 
on this component (Table 6.6). The second component was associated more with 
the ion classes as bases had the highest loading, followed by the Lipinski score and 
the NPSA. 
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Table 6.6 Variable loadings on the first two PLS components (C1 and C2) for AstraZeneca 
and VSurf descriptor sets. 
AstraZeneca VSurf 
Variable C1 C2 Variable C1 C2 
ClogP  0.446 -0.152 vsurf_CP  0.172 -0.096 
ACDlogP  0.446 -0.163 vsurf_CW3 -0.187 0.083 
ACDlogD pH7.4 0.430 -0.351 vsurf_CW4 -0.220 0.103 
ACDlogD pH6.5 0.375 -0.522 vsurf_CW5 -0.223 0.122 
RingCount 0.245 -0.038 vsurf_D1 0.158 0.258 
NPSA 0.228 0.282 vsurf_D2  0.164 0.256 
PSA   -0.253 0.149 vsurf_D3   0.166 0.255 
Neutral  -0.125 -0.547 vsurf_D4    0.175 0.239 
Bases  0.265 0.631 vsurf_D5     0.188 0.217 
Acid   -0.169 -0.192 vsurf_D6      0.207 0.180 
Lipinski score  0.115 0.304 vsurf_D7 0.198 0.165 
 vsurf_D8  0.173 0.179 
vsurf_EDmin1 -0.078 -0.218 
vsurf_EDmin2 -0.094 -0.204 
vsurf_EDmin3 -0.092 -0.198 
vsurf_EWmin1 0.150 -0.153 
vsurf_EWmin2 0.151 -0.155 
vsurf_EWmin3 0.150 -0.163 
vsurf_HB4 -0.160 0.238 
vsurf_HB5 -0.168 0.236 
vsurf_HB6 -0.170 0.234 
vsurf_HB7 -0.173 0.199 
vsurf_HB8 -0.147 0.155 
vsurf_HL1 -0.214 0.129 
vsurf_ID1 -0.133 0.062 
vsurf_ID2 -0.146 0.068 
vsurf_ID3 -0.150 0.071 
vsurf_ID4 -0.149 0.069 
vsurf_ID5 -0.150 0.071 
vsurf_ID7   -0.133 0.074 
vsurf_IW4  0.1001 -0.040 
vsurf_IW5 0.109 -0.036 
vsurf_IW6    0.109 -0.056 
vsurf_IW8   -0.100 0.055 
vsurf_S    0.041 0.315 
vsurf_V   0.049 0.305 
vsurf_W4  -0.178 0.229 
vsurf_W5  -0.183 0.229 
vsurf_W6  -0.180 0.231 
vsurf_W7  -0.171 0.205 
vsurf_W8 -0.145 0.166 
vsurf_Wp4 -0.168 0.080 
vsurf_Wp5 -0.158 0.078 
 
The PLS work demonstrated an improvement in prediction for this dataset 
compared to the ClogP-based models developed in Chapter 5, but still had weak 
model building capabilities with both 𝑅2 and 𝑄2 remaining below 0.5 (Table 6.5). 
This may reflect the limitations of linear modelling techniques. A non-linear 
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modelling technique, ANN, was therefore used in an attempt to improve prediction 
of 𝐾𝑑.  
 
 
6.5 Artificial Neural Networks 
ANNs are computational models that perform multi-factorial analyses. Inspired by 
networks of biological neurons, ANN models contain layers of ‘artificial neurons’, 
which are simple computing nodes that operate as non-linear summing devices 
(Dayhoff & DeLeo, 2001). The connections between the nodes are assigned 
weights and the input to each node is a weighted combination of the values of 
incoming connections. 
The higher a weight, the stronger the influence of the input which it multiplies.  
Weights can also be negative, meaning that the signal is inhibited by the negative 
weight. Depending on the weights, the computation of the neuron will be different. In 
the case of an ANN of hundreds or thousands of neurons, it would be quite 
complicated to find by hand all the necessary weights. Therefore, algorithms are 
used to adjust the weights of the ANN in order to obtain the desired output from the 
network. This process of adjusting the weights is called learning or training 
(Gershenson, 2014). Successful training can result in ANNs that perform tasks such 
as predicting an output value, classifying an object, approximating a function, 
recognizing a pattern in multi-factorial data, and completing a known pattern. Many 
applications of ANNs have been reported in the literature, and applications for 
example in medicine are growing (Dayhoff & DeLeo, 2001). 
Multi-layered perceptrons (MLPs) containing several layers of computational nodes 
are trained by a method known as “back-error propagation” (Dayhoff & DeLeo, 
2001). These networks are also known as ‘feed-forward’ networks as the data flows 
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from the input nodes through successive layers of computational nodes to the 
output node(s). The computational capabilities of three-layered neural networks 
were studied by Hornik et al. (1989), who showed in their general function 
approximation theorem that, with appropriate internal parameters (weights), a neural 
network could approximate an arbitrary nonlinear function. Because classification 
tasks, prediction, and decision support problems can be restated as function 
approximation problems, this finding showed that neural networks have the potential 
for solving major problems in a wide range of application domains (Dayhoff & 
DeLeo, 2001). An example of a three-layered neural network is shown in Figure 6.1. 
 
Figure 6.1 A three-layered artificial neural network. 
  
 
To avoid over-training or over-fitting the networks, a Bayesian interpretation can be 
added to the network (Burden et al., 2000). The Bayesian approach is suitable for 
this type of network training as the trained network is represented by a distribution 
of weights, rather than a single set of weights. The weight distribution depends on a 
hyperparameter representing the network errors, with a second hyperparameter 
correcting any over-fitting of the data. These hyperparameters may be determined 
simultaneously with the optimal network weights by Mackay’s evidence procedure 
(MacKay, 1996). The hyperparameters are used to calculate the ‘evidence’, a 
numerical assessment of the importance of each network. The soft network pruning 
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method called Automatic Relevance Determination (ARD) allows the network to 
estimate the importance of each input  by separating the weights into different 
classes; effectively turning the irrelevant variables off. This allows all variables, 
including those that contribute only a little to the output, to be included in the 
analysis without skewing the results, as irrelevant variables will have their weights 
reduced automatically. ARD has two main advantages over other pruning methods: 
it is firmly based on probability theory, and it is carried out automatically (Burden et 
al., 2000). 
 
 
6.5.1 Variables Pre-processing 
For the ANN work, variables went through an extra pre-processing step in addition 
to the pre-treatment mention in Section 6.2. The aim of the extra treatment was to 
remove highly correlated variables. For this purpose, two alternative procedures 
were applied: Corchop (standing for correlation chop) and unsupervised forward 
selection (UFS). The Corchop treatment starts with all the variables and proceeds 
by eliminating one variable from each pair of highly correlated ones (Livingstone & 
Rahr, 1989). The UFS method starts with no variable and builds a set of variables 
with the least multiple correlations (Whitley, Ford, & Livingstone, 2000). Corchop 
was applied with a Matlab© script, while UFS was performed by a Windows 
command-line program. The extra treatment was applied to the AstraZeneca and 
VSurf descriptor sets, as the PLS results suggested that these had the most 
potential to improve prediction of 𝐾𝑑. 
 
6.5.2 Neural Network Protocol and Methodology 
Once the extra variable selection was completed, the reduced set of variables was 
used to train ANNs in Matlab©, using the ARD procedure available in the Matlab© 
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compatible Netlab software package (Nabney, 2002). The division of compounds 
remained the same as for the PLS analysis, with 100 pharmaceuticals used to train 
the networks and 19 used for external validation. For each descriptor set, a total of 
100 networks were built using two hidden units with 20 training cycles per network. 
The results for each network included a list of the variables with a binary code for 
relevance (0 = irrelevant variable, 1 = relevant variable), as well as statistics such as 
the sum of squares error (SSE), the mean squared error (MSE), the 𝑅2 values for 
both training and validation sets and the log of the evidence (log 𝑒𝑣, based on the 
hyperparameters 𝛼 and 𝛽). The Matlab© code used to train the networks is listed in 
Appendix F.  
 
Once the best network for each descriptor set was identified (with the highest 
log 𝑒𝑣), it was used to explore the influence of each relevant variable in the model. 
An amended training matrix was created with 𝐾𝑑 values ranging from -2 to 2 with a 
0.1 increment for the variable of interest, while the remaining variables were set to 0 
(the mean of the standardised variables). The amended matrix was then loaded into 
Matlab©, and the response was acquired using the multi-layered perceptron forward 
feed (mlpfwd) Netlab function. A plot for each variable was drawn to observe the 
influence of the variable on the model.  
 
The best networks were also applied to predict the log 𝐾𝑑  values of the eighteen 
compounds described in Section 2.5 (which had not been tested with the OPPTS 
835.111 test), and these were compared to the log 𝐾𝑑 values measured with the 
SPE method developed in Section 4.3.3. This was done to provide an additional 
validation test using measured 𝐾𝑑 values that were not available when the networks 
were trained. 
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6.5.3 Results 
The overall summary of results obtained using the ANN for both AstraZeneca and 
Vsurf is shown in Table 6.7. 
 
Table 6.7 Summary of the results for the optimal networks trained using the AstraZeneca 
and VSurf descriptors with different variable selection treatments: no treatment (None), 
unsupervised forward selection (UFS) and correlation chop (Corchop). 
Descriptor set 𝑹𝟐 training set 𝑹𝟐 validation test set Treatment 
AstraZeneca 0.680 0.684 None/UFS 
AstraZeneca 0.638 0.784 Corchop 
Vsurf 0.575 0.685 None 
Vsurf 0.584 0.685 Corchop 
Vsurf 0.543 0.705 UFS 
 
AstraZeneca Set 
For the AstraZeneca set, UFS did not remove any of the 12 variables, whereas 
Corchop removed the ACDlogD pH7.4 variable, which was found to be highly 
correlated with ACDlogP and ACDlogD pH6.5. The difference in performance of the 
optimal ANNs caused by removing this single variable was an increase of 0.1 in the 
𝑅2 value of the validation set, with a smaller decrease of 0.04 in the 𝑅2 value of the 
training set, so the predictions were improved with only a small compromise in fitting 
the training set data (Table 6.7). The best network for the AstraZeneca set was a 
network generated with the Corchop treatment, using 11 variables. A value of 0.78 
for the 𝑅2 for the validation set is between the 0.5 considered as ‘good’ and the 0.9 
considered as ‘excellent’. In this network (net090), only 6 variables were influential: 
ClogP, ACDlogP, polar surface area (PSA), Neutral, Base and Acid. The influence 
of the first three variables on the network output is shown in Figure 6.2. The other 
three variables are indicator variables, with only two input values (representing yes 
or no), and their influence on the network cannot be studied in the same way. 
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Figure 6.2 Effect of the most influential continuous inputs on the output of the optimal 
network (net090) for the AstraZeneca descriptors after Corchop treatment. (a) ClogP, (b) 
ACDlogP, (c) PSA. 
 
It was interesting to see that ClogP had a greater influence on the network output 
than ACD log P, and that this influence was not linear but sigmoidal. The network 
has a relatively small, but almost oscillatory dependence on PSA. This network was 
mainly based on ClogP and the ion class. 
 
VSurf Set 
For the VSurf set, the Corchop procedure removed 26 of the 43 variables and UFS 
removed 21, leaving 17 and 22 variables, respectively. Comparing the optimal 
ANNs in Table 6.4, removing 26 variables with Corchop led to a slight increase of 
0.01 in the 𝑅2 value of the training set, while keeping the 𝑅2 of the validation set 
almost unchanged. Removing 21 variables with UFS led to a slight decrease of 0.03 
in the 𝑅2 value of the training set, while slightly increasing the 𝑅2 of the validation 
set by 0.02. These results show that the full set of 43 VSurf descriptors has many 
inter-correlated variables that may be removed with little effect on the performance 
of the trained ANNs. The 𝑅2 values of 0.68 and 0.70 for the validation set found with 
the Corchop and UFS reduced datasets, respectively, are between the 0.5 
considered as ‘good’ and the 0.9 considered as ‘excellent’. The best network for the 
VSurf set was generated with the Corchop treatment; it was chosen because a 
smaller number of variables was used (17 compared with 22 for UFS), making the 
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interpretation easier. This network (net068) had only nine influential variables: 
Vsurf_CW3, Vsurf_D1, Vsurf_EWmin1, Vsurf_HB4, Vsurf_HB8, Vsurf_ID1, 
Vsurf_IW8, Vsurf_V and Vsurf_Wp5. These variables were then studied in the 
network to understand how they impact on the model (Figure 6.3). 
 
 
  
 
 
Figure 6.3 Effect of the most influential continuous inputs on the output of the optimal 
network (net068) for the VSurf set after Corchop treatment. (a) Vsurf_CW3, (b) Vsurf_D1, (c) 
Vsurf_EWmin1, (d) Vsurf_HB4, (e) Vsurf_HB8, (f) Vsurf_ID1, (g) Vsurf_IW8, (h) Vsurf_V and 
(i) Vsurf_Wp5. 
 
The descriptor representing hydrophilic regions was Vsurf_CW3 (capacity factor, 
ratio of hydrophilic surface on the overall molecule surface), and Vsurf_D1 
(hydrophobic volume) was the descriptor representing the hydrophobic region. It is 
interesting to note that the Vsurf_D1 had a sigmoidal influence, similar to ClogP for 
the AstraZeneca network. The variable with the smallest amplitude was 
Vsurf_EWmin1, which encodes for the distances between the best three local 
energy minima (interaction energies) when a water probe interacts with a target 
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molecule (Cruciani et al., 2000). Hydrogen bonding was represented by three 
descriptors: Vsurf_HB4, Vsurf_HB8 and Vsurf_Wp5 (polar volume). Two interaction 
energy (integy) moments were measured: Vsurf_ID1 for the imbalance of the 
hydrophobic regions across the molecule and Vsurf_IW8 for the hydrophilic regions. 
Vsurf_V, a size descriptor, represents the water-excluded volume (in Å3). This 
network was mainly based on hydrophobicity (Vsurf_D1 second highest amplitude) 
and hydrophilicity (Vsurf_CW3, Vsurf_HB4 (highest amplitude), Vsurf_HB8 and 
Vsurf_Wp5) of the molecule. 
 
The VSurf descriptors depend on the atomic charges, whereas other descriptors 
such as the AstraZeneca do not, so including the charges that are appropriate to the 
sludge environment. The former set of variables may therefore provide a better 
basis for constructing predictive models of the binding of pharmaceuticals to sludge.  
Due to the limitation of the SMILES notation, the 3-D protonation procedure in 
MOE® was used to obtain the structures of the charged species. MOE® then used 
the charged structures to calculate the VSurf descriptors of the charged species. 
The PLS results gave a 𝑅2 of 0.316 and a 𝑄2 of 0.238 on the training set and a  
𝑅𝑝𝑟𝑒𝑑
2  of 0.370 on the external validation set, which was not noticeably different to 
the results for the uncharged forms. The ANN results gave the best results for the 
training set without any treatment with a 𝑅2-training of 0.896 but a 𝑅2-test of 0.311. 
The best results for the test set was obtained with the UFS treatment and gave a  
𝑅2-training of 0.803 but a 𝑅2-test of 0.454. These results showed an improvement 
on model building capability (𝑅2-training) of 0.3 but a decrease in prediction ability of 
0.3(𝑅2-test). The difference between training and test sets were wider for the 
charged forms than for the uncharged forms, which meant using the charged 
compounds had only a small effect on the predictive ability of the models and, 
therefore, the charged form networks were not selected. 
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Prediction for Additional Validation Compounds 
 
The 18 compounds described in Section 2.5 were screened using both networks 
(AstraZeneca and VSurf) to assess the quality of the prediction of the neural 
networks. The results are shown in Table 6.8 for the experimental values and table 
6.9 for the modelled values. 
Table 6.8 𝐾𝑑 values for the model validation compounds obtained with the SPE approach. 
Compound 𝑲𝒅 𝒍𝒐𝒈 𝑲𝒅 
Allopurinol 500.2 2.70 
Ceftazidime 611.3 2.79 
Fulvestrant ND ND 
Lesinurad 38.8 1.59 
Selumetinib 125.8 2.10 
Zibotentan 15.0 1.18 
Amlodipine 2,271.1 3.36 
Amoxicillin 1,831.6 3.26 
Aspirin 40.1 1.60 
Bendroflumethiazide 757.9 2.88 
Ergocalciferol 18,935.0 4.28 
Lansoprazole 144.2 2.16 
Levothyroxine sodium 7,283.7 3.86 
Lisinopril 4,357.7 3.64 
Metformin hydrochloride 29.3 1.47 
Ramipril 36.6 1.56 
Salbutamol 156.6 2.19 
Simvastatin 5,182.6 3.71 
ND: Not determined. This compound was highly sorptive to cartridges, plastic, frit and PTFE 
therefore the determination of 𝐾𝑑 was not possible but it is believed to be high (log 𝐾𝑑  > 4.0). 
 
Table 6.9 Values of log 𝐾𝑑 predicted by the AstraZeneca and VSurf neural networks 
compared to the log 𝐾𝑑 values measured using the SPE method. 
Compound  AstraZeneca ANN VSurf ANN  𝐥𝐨𝐠 𝑲𝒅 SPE 
Allopurinol 1.59 1.65 2.70 
Ceftazidime 1.65 2.83 2.79 
Fulvestrant 3.85 3.14 > 4.0 
Lesinurad 1.58 1.55 1.59 
Selumetinib 3.47 1.74 2.10 
Zibotentan 1.57 2.05 1.18 
Amlodipine 3.69 1.67 3.36 
Amoxicillin 1.80 1.18 3.26 
Aspirin 1.57 1.77 1.60 
Bendroflumethiazide 2.55 1.07 2.88 
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Ergocalciferol 3.86 3.98 4.28 
Lansoprazole 2.70 1.66 2.16 
Levothyroxine 
Sodium 
3.53 1.64 3.86 
Lisinopril 2.21 1.21 3.64 
Metformin HCl 1.62 1.46 1.47 
Ramipril 2.71 2.61 1.56 
Salbutamol 1.94 1.11 2.19 
Simvastatin 3.62 2.84 3.71 
 
The AstraZeneca ANNs appeared to be more efficient at predicting the sorption of 
the 18 compounds with a RMSE of 0.78 compared to the Vsurf network with a 
RMSE of 1.23. In addition to the RMSE, the performance of the two networks was 
assessed by the difference between the measured log 𝐾𝑑 values and the ANN 
predicted log 𝐾𝑑 values (Figure 6.4). The AstraZeneca network achieved a better 𝑅
2 
of 0.4 compared to the 𝑅2 of 0.1 obtained with the VSurf network, but both show 
only weak correlations. 
 
Allopurinol, amoxicillin, lisinopril and ramipril were hard to predict using both 
networks (RMSE(AZ ANN) = 1.30, RMSE(VSurf ANN) = 1.76). Both networks 
performed better without these four compounds with a RMSE of 0.55 for the AZ 
network and a RMSE of 1.03 for the Vsurf network. The overall best network was 
the one built using the AstraZeneca descriptors as it provided accurate prediction 
for more compounds (12 compounds within 0.3 log unit for the AZ network versus 7 
for the VSurf network) and the fewer descriptors made it easier to interpret. The 0.3 
log unit standard error observed on the predicted values matched the average 
standard deviation observed for the experimental values. 
 
147 
 
 
Figure 6.4 Plots of 𝐥𝐨𝐠 𝑲𝒅 values predicted by the ANN models against the values obtained 
with the SPE method. (a) AstraZeneca ANN, (b) VSurf ANN. The regression equation for (a) 
is 𝐥𝐨𝐠 𝑲𝒅 (𝑨𝑵𝑵)  =  𝟎. 𝟔𝟏 𝐥𝐨𝐠 𝑲𝒅 (𝑺𝑷𝑬)  +  𝟎. 𝟖𝟗 with 𝑹
𝟐 = 0.44 (n = 18 compounds) and for 
(b) 𝐥𝐨𝐠 𝑲𝒅 (𝑨𝑵𝑵)  =  𝟎. 𝟑𝟎 𝐥𝐨𝐠 𝑲𝒅 (𝑺𝑷𝑬)  +  𝟏. 𝟏𝟓 with 𝑹
𝟐 = 0.13 (n = 18 compounds). The 
dashed line is the diagonal (𝒚 = 𝒙). 
 
6.6 Discussion 
 
The comparison between the AstraZeneca ANN and PLS models and previous 
linear models was evaluated. The whole dataset consisted of 100 compounds used 
to build/train the model and 19 compounds used to externally validate the model, 
giving a total of 119 compounds. The performances of the VSurf ANN and 
AstraZeneca ANN and PLS models appear similar to that of the new ClogP-based 
model described in Chapter 5. The results of this comparison are shown in Figure 
6.5. 
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Figure 6.5 Relative performance of the Sabljic 2, Guo and Franco models with the new 
ClogP-based model, the AstraZeneca (AZ) PLS model and the AZ and VSurf ANN models 
measured by root mean square errors for the 119 pharmaceuticals divided into four ion 
classes: acids, bases, neutrals and zwitterions. 
 
Figure 6.5 shows a significant improvement for the acidic and zwitterionic classes 
with a RMSE below 1.0 for the PLS and the AZ ANN models. Qualitatively, the new 
ClogP regressions seemed better but the models for acids and zwitterions were not 
statistically significant, with a p-value largely above the 0.05 threshold. One of the 
main advantages of these PLS and ANN models is the use of only one equation for 
all ion classes, so in the case of an unknown compound, knowledge of the ion class 
would not be required prior to submitting the compound to the model.  
 
The zwitterionic compounds were all better predicted with the AZ network, with the 
highest standard error of 1.26 log unit observed for oxytetracycline compared with 
2.06 with the PLS model and 4.37 with the log 𝐾𝑂𝑊 -based model, and the lowest 
standard error of 0.18 log unit observed for fenbendazole compared with 0.78 with 
the PLS model and 2.36 with the log 𝐾𝑂𝑊 -based model. 
 
𝐾𝑑 values for the acidic compounds were also better predicted with PLS and ANN 
models compared with log 𝐾𝑂𝑊 -based model. For example, the best improvement in 
prediction was observed for TCEP, the initial standard error of 2.39 log unit was 
improved to 1.58 log unit with the PLS model and to a further 0.49 log unit with the 
AZ network. Both sulfamethoxazole and sulfapyridine had their standard error 
reduced from 2.03 and 2.08 respectively, to 0.78 and 0.90 respectively with the AZ 
network. 
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6.7 Summary 
The developed ANN models produced a noticeable improvement in the prediction of 
𝐾𝑑 compared to the initial log 𝐾𝑂𝑊-based models, and also to the linear regression 
models (simple regression fits and based on PLS). Although some compounds 
remain difficult to predict well, the majority of compounds are accurately predicted 
with 82% of the 137 compounds within 1.0 log unit, of which 59% within 0.5 log units 
of experimental measurements. The ANNs also provided evidence of nonlinear 
dependencies between 𝐾𝑑 and both the lipohilicity parameter ClogP and the 
hydrophobic volume VSurf_D1. Both Vsurf_D1 and ClogP descriptors represent 
hydrophobicity and they both had sigmoidal relationship, exhibiting saturation. They 
placed the emphasis on the importance of the ion class as a categorical descriptor, 
rather than the 𝑝𝐾𝑎 value and the pH of the media. The PSA was also shown to 
influence the binding mechanisms of molecules to sewage sludge. A great 
improvement was observed for the problematic acidic and zwitterionic ion classes, 
with the use of only one model. Overall, ANN models improved the understanding of 
sorption mechanisms in sewage sludge by drawing attention to key variables 
required for accurate prediction. They out-performed all the existing single variable 
𝐾𝑂𝑊-based models, illustrating the benefit of using multiple descriptors for the 
prediction of 𝐾𝑑  values. These models can be useful tools to facilitate the 
prioritisation of compounds potentially needing a terrestrial risk assessment 
(log 𝐾𝑑 ≥ 3.6).   
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Chapter 7: Extension of the SPE Method to Soil 
Matrices 
 
7.1 Introduction 
After the encouraging experimental results (Chapter 4) of the SPE approach with 
sewage sludge packed into cartridges to assess the sorption of pharmaceuticals, it 
was logical to explore other matrices such as soils. Soil was the natural extension to 
sewage sludge as, sometimes, sewage sludge can be used as fertiliser and is, in 
this case, directly applied to soil. From the soil, pharmaceuticals have the potential 
to be taken up by plants (Cater et al., 2014) or washed away in run-off (Halling-
Sørensen et al., 1998) to end up in rivers and sediments. Therefore, the study and 
understanding of the fate of pharmaceuticals in the soil is important. Pesticides can 
also reach soils via irrigation with reclaimed water (Kinney et al., 2006), and through 
leakage from sewer drain or via flooding (Oppel et al., 2004). Veterinary 
pharmaceuticals, however, are excreted by animals directly onto the soil (ter Laak, 
Gebbink, & Tolls, 2006). Since the focus of this thesis was on human 
pharmaceuticals, veterinary pharmaceuticals were not considered. 
 
Soils have functions, such as provisioning food supplies, habitat for biodiversity and 
water storage, regulating erosion, gas and climate, supporting soil formation and 
nutrient cycling and a cultural function (heritage, recreation and cognitive) for 
humans (Haygarth & Ritz, 2009). Soils are very different to sewage sludge and are 
typically characterised by their composition of different percentages of sand, clay 
and silt. The classification of the soil type is normally determined with the aid of a 
diagram called the soil texture triangle (Figure 7.1).  
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Figure 7.1 Soil texture triangle ((USDA,1951). 
 
 
 
They are also classified depending on their organic matter content. The main 
difference between sewage sludge and soil is the organic carbon content: typically 
30-50% in sewage sludge but rarely over 15% in European soil (Jones et al., 2005). 
The presence of clay and other minerals in soil allows the pH to vary from ~ 4 to ~ 
8, as opposed to the narrower pH range (6-8 units) observed in sewage sludge. 
Because of all these variables in the soil, a myriad of different soils can exist, unlike 
sewage sludge, where only four types are present. For environmental testing 
purposes, the OECD 106 guideline (OECD, 2000) provides guidance on what types 
of soil should be tested (Table 7.1). 
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Table 7.1 Guidance for selection of soil samples for adsorption-desorption (OECD, 2000). 
Soil 
type 
pH range 
(in 0.01 M CaCl2) 
Organic 
carbon content 
(%) 
Clay content 
(%) 
Soil texture 
1 4.5-5.5 1.0-2.0 65-80 Clay 
2 >7.5 3.5-5.0 20-40 Clay loam 
3 5.5-7.0 1.5-3.0 15-25 Silt loam 
4 4.0-5.5 3.0-4.0 15-30 Loam 
5 < 4.0-6.0
a 
< 0.5-1.5
a,b 
< 10-15
a
 Loamy sand 
6 > 7.0 < 0.5-1.0
 a,b
 40-65 Clay loam/clay 
7 < 4.5 > 10 < 10 Sand/loamy sand 
a
The respective variables should preferably show values within the range given. If, however, difficulties 
in finding appropriate soil material occur, values below the indicated minimum are accepted. 
b
Soils with less than 0.3% organic carbon may disturb correlation between organic content and 
adsorption. Thus, it is recommended the use of soils with a minimum organic carbon content of 0.3%. 
 
 
The OECD 106 guideline also recommends the use of 0.01 M calcium chloride as 
the aqueous phase for the adsorption/desorption batch equilibrium experiment, as 
opposed to the phosphate buffer used in the sewage sludge experiment. The 
guideline claims that the use of calcium chloride improves centrifugation and 
minimises the cation exchange interactions.  
 
The adaptation of the previously developed SPE method (Chapter 4) from sewage 
sludge to soil is not as straightforward as simply replacing one matrix with another. 
Consideration of the pH, organic and clay content of the soil, the nature of the 
aqueous phase, the ion class and 𝑝𝐾𝑎 of the test compounds need to be made to 
fully cover all the existing differences between sewage sludge and soil. In this 
chapter preliminary investigations were made to assess the practicality of 
developing a soil-based SPE cartridge screening method for estimating the 𝐾𝑑 
values of pharmaceuticals in soil. 
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7.2 Material and Methods 
 
7.2.1 Soil Properties 
For this study, three soils were selected to span the typical range of soil physico-
chemical properties used in agricultural practice (OECD, 2000). The three soils 
were types 2, 5 and 7 mentioned in Table 7.1 and were supplied by Lufa Speyer 
(Speyer, Germany). Table 7.2 summarises the properties of the three selected soils. 
The range of pH covered by the three soils was 3.4-6.1, the organic content (OC) 
ranged from 0.7 to 12.8 % and the cation exchange capacity (CEC) range was 6.2-
29.1 meq/100 g. 
 
Table 7.2 Physico-chemical properties of three soils for adsorption studies. 
Soil number 
pH in 
CaCl2 
OM 
(%) 
OC 
(%) 
CEC 
(meq/100 g) 
PSD 
Sand  
% 
PSD 
Silt 
% 
PSD 
Clay 
% Texture 
SOIL/2010/02 6.1 10.2 5.9 26.7 52 16 32 
sandy 
clay 
loam 
SOIL/2010/04 3.4 22.1 12.8 29.1 82 7 11 
loamy 
sand 
SOIL/2010/05 4.8 1.2 0.7 6.2 76 11 13 
sandy 
loam 
OM: Organic matter, OC: organic carbon, CEC: cation exchange capacity, PSD: particle size 
distribution (Sand: 2.00-0.05 mm, Silt 0.05-0.002 mm, Clay < 0.002 mm). 
 
 
7.2.2 Effect of Aqueous Phases on Sorption Experiments 
Tests were performed by using three aqueous phases: a 0.01 M calcium chloride 
salt solution, as used in the OECD 106 adsorption/desorption guideline (OECD, 
2000), a phosphate buffer and filtered rain water. A 0.1 M calcium chloride salt stock 
solution was prepared by adding 14.70 g of CaCl2.2H2O into 1 L of RO water. The 
pH of this solution was 7.77.  A 25 mL aliquot of this solution was diluted to 250 mL 
with RO water to make the 0.01 M calcium chloride solution. The phosphate buffer 
used for this study was prepared according to OECD 301 guideline (OECD, 1992) 
by dissolving 8.53 g of anhydrous potassium di-hydrogen phosphate (KH2PO4), 
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21.75 g of anhydrous di-potassium hydrogen phosphate (K2HPO4) and 33.45 g of 
di-sodium hydrogen phosphate dehydrate (Na2HPO4.2H2O) in 1 L of RO water. The 
pH did not require adjustment as it was 7.62 (within the method’s stated range 7.4 ± 
0.5). A 10 mL aliquot of the stock phosphate buffer was diluted to 1 L with RO water 
to make the phosphate buffer solution. The rain water was collected in Brixham, 
Devon between 13th and 16th of December 2013 for the SPE experiments and 
between 15th and 20th January 2014 for the OECD 106 experiments. All the rain 
water collected was filtered through 1.6 µm glass microfiber filter paper (grade 
GF/A, Whatman, GE Healthcare, UK) to remove any solid material that could 
interfere with sorption. A portion of the rain water collected in January was sent off 
to a third party laboratory (CEMAS Ltd, Wokingham, UK) for analysis of calcium 
content, hardness and dissolved organic carbon (Appendix G). 
 
7.2.3 Experimental Setup 
SPE Experiments 
A 500 mg aliquot of PTFE packing material was weighed and packed into empty 
SPE cartridges to act as sorption control. For all three soils, the soil/PTFE 
experiments were performed working with four different ratios: 20%, 50%, 80% and 
100% soil in PTFE (packing material) w/w. After careful mixing of the soil and 
packing materials, 500 mg of the mixture was packed into each SPE cartridge for 
sorption experiments. All adsorption measurements were performed in duplicate. 
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OECD 106 Experiments 
Glass centrifuge tubes were prepared as detailed in Table 7.3.  
 
Table 7.3 Experimental design to determine 𝐾𝑑 values in soil with calcium chloride, 
phosphate buffer and rain water. 
Solid phase 
Aqueous 
phase 
Dry weight of soil 
phase (mg) 
Volume of aqueous 
phase (mL) 
Dosing 
Sandy clay 
loam 
calcium 
chloride  
or 
phosphate 
buffer 
or 
rain water 
100 10 Y 
100 10 Y 
250 10 Y 
250 10 Y 
400 10 Y 
400 10 Y 
500 10 Y 
500 10 Y 
500 10 N 
Loamy sand 
100 10 Y 
100 10 Y 
250 10 Y 
250 10 Y 
400 10 Y 
400 10 Y 
500 10 Y 
500 10 Y 
500 10 N 
Sandy loam 
100 10 Y 
100 10 Y 
250 10 Y 
250 10 Y 
400 10 Y 
400 10 Y 
500 10 Y 
500 10 Y 
500 10 N 
No solid 
0 10 Y 
0 10 N 
 
 
Prior to dosing, each tube was left to equilibrate with the soil specified in Table 7.3 
and 10 mL of 0.01 M calcium chloride solution, phosphate buffer or rain water for at 
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least 16 h at 20 ± 2 °C under red light conditions. At the end of the equilibration 
period, tubes were dosed with pharmaceuticals dissolved in RO water. Tubes were 
maintained at 20 ± 2 °C.  All tubes were then stoppered and rolled for approximately 
24 h at 60–120 rpm under red light conditions followed by centrifugation at 2,000 
rpm (equivalent to RCF = 1,566), at 4°C, for 15 min to separate the aqueous layer in 
the tubes containing soil. The aqueous layer was collected and analysed by HPLC 
with UV detection as described in Section 2.5. 
 
7.2.4. Preparation of Test Solutions 
Paracetamol was added to the initial three method development compounds as a 
neutral reference substance. A stock of paracetamol, clofibric acid, diclofenac and 
oxytetracycline with a nominal concentration of 1000 mg/L was prepared by 
dissolving 100 mg of the four substances in 5 mL of methanol and making up to 100 
mL with reverse osmosis (RO) water.  A 1 mL aliquot of this stock solution was then 
diluted in 20 mL of 0.01 M calcium chloride, phosphate buffer and filtered rain water 
to achieve a dosing concentration of 50 mg/L. A 400 µL aliquot of each was then 
dosed onto the SPE cartridges and eluted with 2 × 2 mL of aqueous phase, 
resulting with a concentration of 5 mg/L. For the OECD 106 experiment, the test 
concentration was nominally 10 mg/L. This concentration was achieved by 100 µL 
additions of the clofibric acid, paracetamol, diclofenac and oxytetracycline nominal 
1000 mg/L stock solution, via displacement pipette, to 10 mL total volumes of mixed 
soil in the relevant 0.01 M calcium chloride, phosphate buffer or filtered rain water.  
All calculations were performed as described in Section 4.2.6, replacing 𝐶𝑠𝑙𝑢𝑑𝑔𝑒 by 
𝐶𝑠𝑜𝑖𝑙. 
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7.3 Results and Discussion 
7.3.1 Influence of Aqueous Phase 
The influence of the aqueous phase on the sorption behaviour is shown in Figure 
7.2. Different trends were observed for the three different aqueous phases. Figure 
7.2 suggested that the sorption behaviour of the pharmaceuticals in the tubes was 
different to the sorption behaviour in the SPE cartridges. In Table 7.4, the 
corresponding correlation between log 𝐾𝑑  values obtained with the SPE method and 
the log 𝐾𝑑  values obtained with the OECD 106 method are summarised. 
 
  
  
Figure 7.2 Plots of log 𝐾𝑑 values obtained using the SPE method (vertical axis) and the 
OECD 106 method (horizontal axis) for four pharmaceuticals (a) paracetamol, (b) clofibric 
acid , (c) diclofenac and (d) oxytetracycline) with three different aqueous phases ( ) calcium 
chloride solution, ( ) phosphate buffer, ( ) rain water on three different soils (S1, S2 & S3). 
Note: the 𝐾𝑑 values were obtained by calculating the slope of 9 data points at different soil 
ratios for both SPE and OECD methods. 
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In Table 7.4, the only statistically meaningful correlation was obtained for 
paracetamol, a neutral compound, in rain water, with an 𝑟2 of 0.95 and a correlation 
coefficient close to 1. These results highlighted that the aqueous phase was 
important, and the synthetic buffer or 0.01 M calcium chloride salt was not suitable 
to reproduce rain water, which would mimic typical environmental conditions but 
would still be different to pore water. The rain water sample analysis (Appendix G) 
revealed that the concentration of calcium was 0.5 mg/L (equivalent to 1.25 × 10-5 
mol/L) which was about a thousand times less than in the 0.01 M calcium chloride 
solution. Another point to note was that the 0.01 M calcium chloride solution did not 
seem to out-perform the phosphate buffer as no statistically significant relationship 
was found for any of the two aqueous phases. This implied that cation exchange 
interactions might not have to be minimised. Sorption seemed to be generally higher 
with 0.01 M calcium chloride solution (apart for clofibric acid). 
 
Table 7.4 Summary of correlations between log 𝐾𝑑values obtained using the SPE method 
and the OECD 106 method (n = 3). 
Aqueous 
phase 
Paracetamol Clofibric acid Diclofenac Oxytetracycline 
Calcium 
chloride  
𝑦 =  0.15𝑥 + 1.80 
𝑟2 = 0.842 p=0.26 
𝑦 =  0.13𝑥 + 0.89 
𝑟2 = 0.784 p=0.31 
𝑦 =  −0.04𝑥 + 1.42 
𝑟2 = 0.002 p=0.97 
𝑦 =  −0.17𝑥 + 2.50 
𝑟2 = 0.036 p=0.55 
Phosphate 
buffer 
𝑦 =  0.78𝑥 + 0.64 
𝑟2 = 0.743 p=0.34 
𝑦 =  0.26𝑥 + 1.25 
𝑟2 = 0.810 p=0.29 
𝑦 =  −0.25𝑥 + 1.66 
𝑟2 = 0.293 p=0.64 
𝑦 =  −0.52𝑥 + 3.16 
𝑟2 = 0.605 p=0.43 
Rain water 𝑦 =  0.91𝑥 + 0.04 
𝑟2 = 0.946 p=0.15 
𝑦 =  −0.06𝑥 + 1.13 
𝑟2 = 0.839 p=0.26 
𝑦 =  −0.19𝑥 + 2.23 
𝑟2 = 0.049 p=0.86 
𝑦 =  −0.28𝑥 + 3.01 
𝑟2 = 0.424 p=0.88 
 
 
7.3.2 Influence of Soil Types 
The three soils tested had different properties, such as organic carbon content, 
cation exchange capacity and pH. Figure 7.3 shows the influence of the different 
soil properties on two compounds: paracetamol and oxytetracycline. Paracetamol 
was chosen because it is a neutral compound; hence it remained in the same 
neutral form across the pH range, unlike ionisable compounds, which can form 
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charged and uncharged species depending on their 𝑝𝐾𝑎 and the pH, and should 
help the interpretation of the sorption behaviour by removing any potential ion 
exchange or other pH-related mechanisms of interaction. Oxytetracycline was 
chosen due to its zwitterionic character and one of its 𝑝𝐾𝑎’s being close to the pH of 
the soil. Also, there was a contrast in 𝐾𝑑 values, paracetamol has a relatively low 𝐾𝑑 
value compared to the high 𝐾𝑑  value of oxytetracycline. For simplification purposes, 
only one aqueous phase was represented in Figure 7.3. Rain water was selected as 
this was the closest aqueous phase to environmental conditions. 
 
 
 
 
 
Figure 7.3 Plots of log 𝐾𝑑 values (x-axis) obtained using the SPE method ( ) and the 
OECD 106 method ( ) for paracetamol (a) and oxytetracycline (b) with rain water 
depending on three different physico-chemical properties of three different soils (% organic 
carbon (top), cation exchange capacity (middle) and pH (bottom)). The 𝐾𝑑 values were 
obtained from the slope of 8 data points at different soil ratios. All the log 𝐾𝑑 values were 
within ± 0.5 log unit range. 
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The first general observation in Figure 7.3 was that there was a very small variation 
in log 𝐾𝑑 with each of the soil properties. For paracetamol there was less than 0.5 
log unit variation and less than 1.0 log unit variation for oxytetracycline. The small 
variation in log 𝐾𝑑 made the interpretation difficult. It was hard to determine whether  
the soil properties had anl effect on partitioning or if the number of soils tested was 
too low and more extreme soil properties should have been used. Bigger 
differences were also expected between the two compounds as, in theory, the 
neutral paracetamol should not have been affected by pH or cation-exchange 
capacity whereas the zwitterionic character of the oxytetracycline should have 
resulted in different 𝐾𝑑 values at different pH and cation exchange capacities. In the 
soils selected for the test, the soil with the highest CEC also had the highest organic 
carbon content. The only trend observed with the organic carbon content was with 
oxytetracycline for the SPE method. This trend did not seem to be present for the 
OECD 106 method for low organic carbon content soil. However, the OECD 106 
guideline stipulates that for extremely low carbon content, it might be difficult to 
obtain accurate results. Another trend with the cation exchange capacity was 
observed for oxytetracycline with the SPE method, but again, not confirmed in the 
OECD 106 test.  
 
Trends with the pH were observed for paracetamol with both the SPE and OECD 
106 methods. Sorption seemed to increase with pH. This trend was not confirmed 
for oxytetracycline but this was due to the soils having a pH very close to 
oxytetracycline 𝑝𝐾𝑎’s (3.3 and 7.3) and it could have disrupted the sorption. The 
method seemed to have an impact on sorption as the SPE and OECD methods 
gave different results. 
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7.4 Summary 
The extension of the SPE method for sludge to soil was not straightforward, as 
anticipated. Many more parameters apply to soil, such as the organic carbon 
content, the cation exchange capacity, the pH and the method of sorption. More 
soils need to be tested to assess if the lack of correlation between the SPE 
cartridges and the OECD 106 method were due to poor precision at lower organic 
carbon content or if the method itself led to a genuine difference in the sorption 
behaviour. This work showed the importance of the nature of the  aqueous phase in 
sorption experiments and that 0.01 M calcium chloride solution might not be the 
most environmentally relevant phase for such experiments. The data also 
highlighted that organic carbon was not the only driver for partitioning but pH and 
cation exchange capacity played an important role, especially for ionisable 
compounds such as oxytetracycline and confirmed the overall hypothesis of the 
thesis that the organic carbon content alone was not sufficient to describe 
partitioning in natural matrices. 
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Chapter 8: Conclusions and Recommendations 
Concerns over the presence of pharmaceuticals in the aquatic environment at 
relatively low concentration have grown recently. Some pharmaceuticals are 
biodegraded effectively in WWTPs but others sorb onto sludges that may 
subsequently be applied to land. It is important to know how pharmaceuticals 
partition between the sludge and aqueous phases to determine their fate in the 
environment. As the number of pharmaceuticals grows, experimental 
measurements of sludge-water partition coefficients are not always possible and 
predictive models are often used in environmental risk assessments. 
 
The overall aim of this thesis was to investigate mechanistic approaches to 
predicting the sorption characteristics of pharmaceuticals. The general assumption 
has been that hydrophobicity, and its predictor 𝐾𝑂𝐶/𝐾𝑂𝑊, determined the sorption 
behaviour of pharmaceuticals. There was little published research on the 
environmental matrix in which the sorption of pharmaceuticals occurred. This 
research thesis mainly focused on sewage sludge, usually the first medium of entry 
of pharmaceuticals to the environment, and extended a little to soil. On both 
experimental and modelling aspects, this research thesis unfolded a much more 
complex set of mechanisms of sorption of pharmaceutical to sewage sludge. 
Hydrophobicity did play a role but so did hydrophilicity and ion-exchange. 
 
This research covered: 
• An improved understanding of sorption and partitioning mechanisms occurring 
between the sewage sludge matrix and pharmaceutical compounds as well as the 
characterisation of physico-chemical properties of the sewage sludge environmental 
matrix (Chapter 3). 
163 
 
• The validation of a new SPE-based method for faster measurements of 𝐾𝑑 as 
an alternative to the OPPTS test (Chapter 4). 
• The refinement of existing models based on 𝐾𝑂𝑊 and 𝑓𝑂𝐶 for 𝐾𝑑 prediction; 
specifically to address the gap regarding partitioning of ionisable compounds 
(Chapter 5).  
• The validation of new PLS and ANN types of model based on molecular 
descriptors unique to each molecule to improve current predictions (Chapter 6). 
• An attempt to expand the knowledge gathered for the sewage sludge matrix to 
the soil matrix by extending the newly developed method to soils (Chapter 7). 
 
8.1 Importance of Mechanistic Approaches 
This thesis highlighted the importance of taking a mechanistic approach in the 
prediction of 𝐾𝑑. It showed that the assumption of hydrophobicity as the main 
sorption mechanism was not sufficient to describe and predict the sorption 
behaviour of pharmaceuticals to environmental matrices. The thesis employed both 
laboratory and computer-based experimentation to unfold the mechanisms of 
interaction between pharmaceuticals and sewage sludge. Both approaches 
confirmed that hydrophobicity was part of the mechanisms of interaction but could 
not account on its own for all the interactions. The laboratory experimentation 
revealed that π-π, cation-exchange and hydrogen bonding interactions were also 
important in sorption of pharmaceutical to sewage sludge. The computed-based 
experimentation via modelling uncovered other interactions such as hydrophilicity, 
size and ion class, but also confirmed experimental findings with hydrogen bonding 
and hydrophobicity.  
 
It is also important to note that the choice of buffer in sorption experiment will 
probably have an effect on the sorption behaviour of the tested compounds and 
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needs to be carefully selected in order to represent the environmental conditions as 
realistically as possible. 
 
8.2 Outcomes and Applications 
The findings of this study could be incorporated into recommendations that would 
allow pharmaceutical companies to have a better awareness of the fate of their 
products in the environment. The new SPE method could be used instead of the 
OPPTS test to reduce testing time per pharmaceutical. It could allow more 
pharmaceuticals to be tested and have a fully comprehensive account of their fate in 
a WWTP. The ANN-based model could be used early in the drug development 
process to help assess the potential impact of newly developed pharmaceuticals on 
the environment. 
 
From a regulatory point of view, this research could help further develop current 
environmental risk assessment guidelines. The new SPE method could be included 
in the phase II Tier A section, or even replace the OPPTS 835.1110 
adsorption/desorption test. The ANN-based model could also be included in the 
ERA of pharmaceutical at an earlier, screening, stage in order to help prioritising the 
compounds that will probably need a terrestrial risk assessment.  
 
8.3 Future Work 
This research clearly showed the limitation of hydrophobicity as a sorption 
mechanism. The main focus of this research was the sewage sludge environmental 
matrix. As a result of time and cost restraints, soils were briefly explored and 
sediments were not tested at all. To build on this research, more types of soil 
environmental matrix could be tested to identify mechanisms of interaction and 
more method development would be needed to adapt the SPE method to soils. In 
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parallel, a literature search on available soil 𝐾𝑑 data as well as available models to 
predict 𝐾𝑑 in soil could be launched in order to evaluate and develop more 
appropriate models for pharmaceuticals in soil. Sediments could be investigated as 
another environmental matrix as they are a receiving matrix for pharmaceuticals that 
have not been completely removed by WWTPs and which are emitted in a treated 
waste water. As well as testing other environmental matrices, attempts to apply the 
new SPE method to other types of chemicals rather than pharmaceuticals could be 
explored. 
 
8.4 Conclusions 
 Sewage sludge, as an environmental matrix, should be selected carefully as 
differences exist between different types of sludge. They are not all 
equivalent. 
 A new SPE method for the measurement of 𝐾𝑑 in sewage sludge was 
developed and fully validated. This method is a faster alternative to the 
OPPTS 835.1110 test needed in pharmaceutical ERA phase II Tier A. 
 𝐾𝑂𝑊 was not an appropriate descriptor to account for the sorption 
mechanisms of acidic and zwitterionic pharmaceuticals to sewage sludge but 
was acceptable for neutral and basic pharmaceuticals. 
 A new molecular descriptor ANN-based model for the prediction of 𝐾𝑑 in 
sewage sludge was developed and validated. The model out-performed 
existing models available in the literature even though 𝐾𝑑 for a few 
compounds remained difficult to predict. 
 Hydrophobicity alone was not sufficient to describe mechanisms of sorption in 
sewage sludge. Both laboratory and modelling work revealed that 
hydrophobicity should be considered alongside hydrophilicity (hydrogen 
166 
 
bonding, PSA) and ion class (cation exchange) to provide more accurate 𝐾𝑑 
values. 
 Soils as environmental matrices are different to sewage sludge and cross-over 
of data between the two should be avoided, unless appropriate leaching 
experiments are performed. 
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Appendix A: Therapeutic Use of the Study Compounds 
 
A.1 Clofibric acid 
Clofibric is a metabolite of the cholesterol-lowering pharmaceutical drug clofibrate. 
 
A.2 Diclofenac 
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) used to reduce 
inflammation and as a mild analgesic in certain condition. Diclofenac was introduced 
to the UK in 1979 (Breen, McNicholl, Cosgrove, McCabe, & Stevens, 1986). 
Diclofenac accumulated in livestock animals and then poisoned the vulture feeding 
on the carcasses, causing renal failure. Renal failure is a known side effect of 
diclofenac (Brater, 2002) and vultures do not have the enzyme to break down the 
chemical. The loss of about ten million vultures had major ecological consequences 
across the Indian subcontinent that can potentially threaten human health. Indeed, 
with the disappearance of vultures, a rise in population of feral dogs has been 
observed, which caused concern of an increased risk of rabies (Swan et al., 2006). 
As well as harming vultures, a number of studies (Schwaiger, Ferling, Mallow, 
Wintermayr, & Negele, 2004; Triebskorn et al., 2004) showed that diclofenac is also 
harmful to freshwater fish species such as rainbow trout. Diclofenac has recently 
been added to the WFD watch list (Water UK, 2013).  
 
A.3 Oxytetracycline 
Oxytetracycline was discovered in the late 1940s and it is part of the broad-
spectrum tetracycline group of antibiotics. Broad-spectrum refers to the ability of the 
molecule to act against a wide range of bacteria (gram-positive and gram-negative) 
(Taber, 2001) as opposed to narrow spectrum, which targets specific bacteria only 
(Todar, 2001). In humans, oxytetracycline is used to treat infections such as chest 
infection, eye infection, urinary tract infection and pneumonia. It can also be used 
for the treatment of acne. With animals, oxytetracycline can be used to control 
outbreaks of American and European foulbrood in honeybees, to prevent disease 
and infections and to correct breathing disorders in livestock such as cattle and 
poultry.  
 
A.4 Bicalutamide 
Bicalutamide is a non-steroidal anti-androgen used in the treatment of prostate 
cancer (See & Tyrrell, 2006) and hirsutism (Müderris, Bayram, Özçelik, & Güven, 
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2002). The mechanism of interaction consists in binding to the androgen receptor 
and preventing its activation and subsequent up-regulation of androgen responsive 
genes by androgenic hormones (Furr & Tucker, 1996). In addition, bicalutamide 
accelerates the degradation of the androgen receptor (Waller, Sharrard, Berthon, & 
Maitland, 2000). 
 
A.5 Candesartan 
Candesartan is an angiotensin II receptor antagonist used in the treatment of 
hypertension. A study revealed that candesartan therapy reduced morbidity and 
mortality in congestive heart failure (Pfeffer et al., 2003). 
 
A.6 Esomeprazole 
Esomeprazole is a proton pump inhibitor used to reduce acid secretion in the 
stomach. It is used in the treatment of gastroesophageal reflux disease 
(GORD/GERD) (heartburn) and duodenal ulcers (Li et al., 2006). 
 
Esomeprazole is the active (S)-enantiomer of omeprazole, the racemic mixture. It 
was found that the (S)-enantiomer is better metabolised than the (R)-enantiomer 
(AstraZeneca, 2014).  
 
A.7 Felodipine 
Felodipine is a calcium antagonist. This type of medication disrupts the movement 
of calcium (in the Ca2+ form) through calcium channel (Elliott & Ram, 2011). It is 
mainly used to control hypertension by decreasing blood pressure, but also to alter 
heart rate, to prevent cerebral vasospasm (clots in the brain) and to reduce chest 
pain caused by angina. 
 
A.8 Gefitinib 
Gefitinib is part of the oncology therapeutic area. It is used for certain breast, lung 
and other cancers. It is an epidermal growth factor receptor inhibitor in target cells. 
Gefitinib acts to block signals for cancer cell growth and survival in advanced non-
small cell lung cancer (Lynch et al., 2004). 
 
A.9 Ibuprofen 
Ibuprofen is a non-steroidal anti-inflammatory drug used for pain relief, fever 
reduction and against swelling. Ibuprofen is a ‘core’ medicine in the World Health 
Organisation (WHO)’s model list of essentials medicines (WHO, 2013). Ibuprofen 
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was developed in the 1960s and introduced in the UK in 1966 (Rainsford, 2003). It 
is widely used and available over the counter since 1983 which makes it a good 
candidate to be tested in this study. 
 
A.10 Propranolol 
Propranolol is a non-selective beta blocker used in the treatment of hypertension. It 
belongs to the cardiovascular therapeutic area. It was the first successful beta 
blocker developed in the 1960s by British scientist James W Black (Black, Crowther, 
Shanks, Smith, & Dornhorst, 1964). Propranolol is on the WHO’s list of essential 
medicines (WHO, 2013). Beta blockers interfere with the binding to the receptor of 
epinephrine and other stress hormones, and weaken the effects of stress. They are 
particularly used for the management of cardiac arrhythmias, protecting the heart 
from a second heart attack (secondary prevention), and hypertension (Cruickshank, 
2010). Propranolol is a good candidate for this study as it has been used for a long 
time and is more likely to be present in the environment. 
 
A.11 Quetiapine fumarate 
Quetiapine fumarate is part of the neuroscience, neurobiology and central nervous 
system family. It is an atypical anti-psychotic used in the treatment of schizophrenia, 
bipolar disorder and along with anti-depressant to treat major depressive disorders 
(Kahn et al., 2007).  
 
A.12 Ticagrelor 
Ticagrelor is part of the cardiovascular family. It is a platelet aggregation inhibitor 
indicated in the prevention of thrombotic events such as stroke or heart attack. It is 
designed for patients with acute coronary syndrome or myocardial infarction. This 
drug is relatively new to Europe, being approved for use by the European 
Commission in December 2010 (EMEA, 2011). 
 
A.13 Vandetanib 
Vandetanib is part of the oncology therapeutic area. It is an anti-cancer drug used 
for the treatment of tumours of the thyroid gland. It works as a kinase inhibitor of a 
number of cell receptors, mainly the vascular endothelial growth factor receptor and 
the epidermal growth factor receptor (AstraZeneca, 2011). It also can be used for 
the treatment of late-stage metastatic medullary thyroid cancer in adult patients who 
are not eligible for surgery (Jefferson, 2011). 
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A.14 Allopurinol 
Allopurinol is used to treat hyperuricemia, an excess of uric acid in the blood 
plasma, and its complications (e.g. chronic gout) (Dalbeth & Stamp, 2007). It is a 
xanthine oxidase inhibitor (Pacher, Nivorozhkin, & Szabó, 2006). By inhibiting the 
enzyme responsible for the production of uric acid, it decreases uric acid formation.  
 
A.15 Ceftazidime 
Ceftazidime is an antibiotic. It is part of the β-lactam family and more specifically is 
in the cephem subgroup under the cephalosporins. It has a broad spectrum activity 
against gram-positive and gram-negative bacteria. Ceftazidime is usually reserved 
for the treatment of infections caused by a particular bacterium, Pseudomonas 
aeruginosa. It is also the first line of treatment for the rare tropical infection 
melioidosis (Sagent, 2012). Ceftazidime is on the WHO’s list of essential medicines 
(WHO, 2013). 
 
A.16 Fulvestrant 
Fulvestrant belongs to the oncology family. It is a selective estrogen receptor down-
regulator indicated for the treatment of hormone positive metastatic breast cancer in 
post-menopausal women with disease progression following anti-estrogen therapy 
(Howell et al., 2002). 
 
A.17 Lesinurad 
Lesinurad is a phase III clinical trials candidate for the treatment of gout and 
cytotoxic-induced hyperuricaemia (Fleischmann et al., 2014). Gout is the most 
common form of inflammatory arthritis. 
 
A.18 Selumetinib 
Selumetinib is a drug currently being investigated for the treatment of various types 
of cancer, e.g. non-small cell lung cancer (Jänne et al., 2013). 
 
A.19 Zibotentan 
Zibotentan is an anti-cancer candidate. It works by blocking growth receptors on 
cancer cells called endothelin receptors. It can be called an endothelin blocker or 
endothelin receptor antagonist. It failed a phase III clinical trial for prostate cancer 
(Nelson et al., 2012) but other trials are planned.  
 
A.20 Carbamazepine 
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Carmabazepine is an anticonvulsant and mood-stabilizing drug recommended in the 
treatment of epilepsy and bipolar disorder (Brodie, Richens, Yuen, & Group, 1995). 
It can also be used for the attention-deficit hyperactivity disorder, schizophrenia, 
phantom limb syndrome, borderline personality disorder and post-traumatic stress 
disorder. Carbamazepine is typically used for the treatment of seizure disorders and 
neuropathic pain.  
 
A.21 Clomipramine 
Clomipramine is a tricyclic antidepressant. It is used in the treatment of obsessive 
compulsive disorder (Deveaugh-Geiss et al., 1992; Katz, DeVeaugh-Geiss, & 
Landau, 1990), major depressive disorder, panic disorder and body dysmorphic 
disorder. 
 
A.22 Clotrimazole 
Clotrimazole is and anti-fungal medication used in the treatment of fungal infection. 
It is used for vaginal yeast infections, oral thrush and ringworm and can also treat 
athlete’s foot (Clayton & Connor, 1973). It is commonly available over the counter in 
many dosage forms. 
 
A.23 Flutamide 
Flutamide is a non-steroidal anti-androgen drug used for the treatment of prostate 
cancer. It prevents cancer cell growth stimulation by competing with testosterone 
and dihydrotestosterone for binding to androgen receptor in the prostate gland 
(Sogani, Vagaiwala, & Whitmore, 1984). Flutamide has been largely replaced by a 
newer member of this class, bicalutamide (A.4), due to a better side-effect profile 
(Kolvenbag & Blackledge, 1996). 
 
A.24 Hydrochlorothiazide 
Hydrochlorothiazide is a diuretic drug. It is used for the treatment of hypertension, 
congestive heart failure, oedema, diabetes insipidus and the prevention of kidney 
stones (Frishman, Bryzinski, Coulson, & et al., 1994). It works by inhibiting the 
kidney’s ability to retain water. This reduces the volume of the blood, decreasing 
blood return to the heart, lowering the vascular resistance.  
 
A.25 Mecillinam 
Mecillinam is an extended spectrum antibiotic from the penicillin family (β-lactam). It 
is used for treatment of urinary tract infections, typhoid and parathyphoid fevers. It is 
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considered to be active only against gram-negative bacteria except Pseudomonas 
aeruginosa (Noguchi, Matsuhashi, & Mitsuhashi, 1979). 
 
A.26 Paracetamol 
Paracetamol is also called acetaminophen in the United States, Canada and Japan. 
It is a widely used analgesic and antipyretic, available over the counter (OTC). It is 
used for as a pain reliever and a fever lowerer as cold and flu remedy (Anderson, 
2008). It is listed in the WHO’s essential medicine (WHO, 2013). 
 
A.27 Roxithromycin 
Roxithromycin is an antibiotic from the macrolide family. It is used for the treatment 
of respiratory tract, urinary and soft tissue infections. Roxithromycin prevents 
bacteria from growing, by interfering with their protein synthesis. It targets mainly 
gram-positive bacteria, but can be effective against certain gram-negative ones as 
well (Chantot, Bryskier, & Gasc, 1986). 
 
A.28 TCEP 
TCEP (tris(2-carboxyethyl)phosphine) is not an API, it is a reducing agent frequently 
used in biochemistry and molecular biology applications (Rüegg, Rudinger, & 
Timasheff, 1977). It is soluble in water and available as a stabilized solution at 
neutral pH and immobilized onto an agarose support to facilitate removal of the 
reducing agent. TCEP is also used in the preparation process for gel 
electrophoresis and in the tissue homogenization process for RNA isolation. It was 
included in this study because of its strong links to the biomedical field. 
 
A.29 Amlodipine 
Amlodipine is a calcium channel blocker used for the treatment of hypertension 
(Frick, McGibney, & Tyler, 1988), angina chest pain and coronary artery disease. It 
acts to lower blood pressure by relaxing arterial smooth muscles.  
 
A.30 Amoxicillin 
Amoxicillin is a moderate spectrum antibiotic belonging to the β-lactam family. It is 
used to treat bacterial infections such as otitis, pharyngitis, pneumonia, sinusitis 
(Wald et al., 1984), skin, urinary tract, Salmonella and Chlamydia infections 
(Turrentine & Newton, 1995). It became available in 1972 (Bodey & Nance, 1972) 
and it is the most common antibiotic prescribed to children due to its better 
absorption following oral administration. 
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A.31 Aspirin 
Aspirin, also known as acetylsalicylic acid, is an analgesic, antipyretic and anti-
inflammatory drug from the NSAID family. The active metabolite of aspirin, salicylic 
acid, was discovered in 1763 by Edward Stone (Vlachojannis, Magora, & Chrubasik, 
2011). Aspirin was first synthesized by Felix Hoffmann in 1853 (Rinsema, 1999). 
Aspirin also has an anti-platelet effect and at low dose can help prevent heart 
attacks, strokes and blood clots (Awtry & Loscalzo, 2000). It is in the WHO’s list of 
essential medicine (WHO, 2013). 
 
A.32 Bendroflumethiazide 
Benzodroflumethiazide is a thiazide diuretic used in the treatment of hypertension 
(Hallin, Andrén, & Hansson, 1983). It inhibits sodium readsorption in the kidneys. In 
some cases, it can be recommend in the treatment of recurring kidney stone 
(Backman, Danielson, Johansson, Ljunghall, & Wikstrom, 1979). 
 
A.33 Ergocalciferol 
Ergocalciferol is a pro-vitamin form of vitamin D. It is used as a vitamin D 
supplement (Holick et al., 2011; Prince et al., 2008). Strictly speaking it is more a 
food complement than a pharmaceutical but due to its common usage, it is included 
in this study. 
 
A.34 Lansoprazole 
Lansoprazole is a proton-pump inhibitor used to lower the gastric acids production 
in the stomach. It is indicated for the treatment of ulcers and gastroesophageal 
reflux disease (GERD) (Lai et al., 2002). 
 
A.35 Levothyroxine 
Levothyroxine is a synthetic form of the thyroid hormone thyroxine. It is used in the 
treatment of thyroid hormone deficiency in hypothyroidism (Fish et al., 1987).  
 
A.36 Lisinopril 
Lisinopril is an angiotensin-converting enzyme inhibitor prescribed for hypertension, 
congestive heart failure and heart attacks (Packer et al., 1999). It can also be used 
to prevent renal and retinal complications of diabetes (Chaturvedi et al., 1998).  
 
A.37 Metformin 
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Metformin is an anti-diabetic drug acting by suppressing glucose production by the 
liver. It is the preferred treatment for type 2 diabetes (Knowler et al., 2002). It is on 
the WHO’s list of essential medicines (WHO, 2013). 
 
A.38 Ramipril 
Ramipril is an angiotensin-converting enzyme inhibitor, used in the treatment of high 
blood pressure and congestive heart failure (Yusuf et al., 2000).  
 
 
 
A.39  Salbutamol 
Salbutamol is a β2-adrenergic receptor agonist used to treat asthma and chronic 
obstructive pulmonary disease (Ullman & Svedmyr, 1988). It is in the WHO’s 
essential medicine list (WHO, 2013). 
 
A.40 Simvastatin 
Simvastatin is a hypolipidemic drug used in the treatment of hypercholesterolemia 
(Scandinavian Simvastatin Survival Study, 1994). It is recommended to be used 
only after other measures such as diet, exercise, and weight reduction have not 
improved cholesterol levels sufficiently. It is in the WHO’s essential medicine list 
(WHO, 2013). 
 
 
References to Appendix A 
Anderson, B. J. (2008). Paracetamol (Acetaminophen): mechanisms of action. Pediatric 
Anesthesia, 18(10), 915-921.  
AstraZeneca. (2011). full prescribing information Caprelsa. from http://www1.astrazeneca-
us.com/pi/vandetanib.pdf  
AstraZeneca. (2014). Full prescribing information Nexium. In AstraZeneca (Ed.). 
Awtry, E. H., & Loscalzo, J. (2000). Aspirin. Circulation, 101(10), 1206-1218.  
Backman, U., Danielson, B. G., Johansson, G., Ljunghall, S., & Wikstrom, B. (1979). Effects 
of Therapy with Bendroflumethiazide in Patients with Recurrent Renal Calcium 
Stones. British Journal of Urology, 51(3), 175-180.  
Black, J. W., Crowther, A. F., Shanks, R. G., Smith, L. H., & Dornhorst, A. C. (1964). A new 
andrenergic: beta-receptor antagonist. The Lancet, 283(7342), 1080-1081.  
Bodey, G. P., & Nance, J. (1972). Amoxicillin: in vitro and pharmacological studies. 
Antimicrobial Agents and Chemotherapy, 1(4), 358-362.  
Brater, D. C. (2002). Renal Effects of Cyclooxygyenase-2-Selective Inhibitors. Journal of 
Pain and Symptom Management, 23(4), S15-S20. 
Breen, E. G., McNicholl, J., Cosgrove, E., McCabe, J., & Stevens, F. M. (1986). Fatal 
hepatitis associated with diclofenac. Gut., 27, 1390-1393.  
194 
 
Brodie, M. J., Richens, A., Yuen, A. W. C., & UK Lamotrigine/Carbamazepine Monotherapy 
Trial Group. (1995). Double-blind comparison of lamotrigine and carbamazepine in 
newly diagnosed epilepsy. The Lancet, 345(8948), 476-479. 
Chantot, J.-F., Bryskier, A., & Gasc, J.-C. (1986). Antibacterial activity of roxithromycin: a 
laboratory evaluation. The Journal of Antibiotics, 39(5), 660-668.  
Chaturvedi, N., Sjolie, A.-K., Stephenson, J. M., Abrahamian, H., Keipes, M., Castellarin, A., 
Fuller, J. H. (1998). Effect of lisinopril on progression of retinopathy in normotensive 
people with type 1 diabetes. The Lancet, 351(9095), 28-31.  
Clayton, Y. M., & Connor, B. L. (1973). Comparison of clotrimazole cream, Whitfield's 
ointment and Nystatin ointment for the topical treatment of ringworm infections, 
pityriasis versicolor, erythrasma and candidiasis. British Journal of Dermatology, 
89(3), 297-303.  
Cruickshank, J. M. (2010). beta blockers in hypertension. The Lancet, 376(9739), 415-416.  
Dalbeth, N., & Stamp, L. (2007). Allopurinol Dosing in Renal Impairment: Walking the 
Tightrope Between Adequate Urate Lowering and Adverse Events. In Seminars in 
dialysis (Vol. 20, No. 5, pp. 391-395). Blackwell Publishing Ltd, Oxford, UK.  
Deveaugh-Geiss, J., Moroz, G., Biederman, J., Cantwell, D., Fontaine, R., Greist, J. H., & 
Landau, P. (1992). Clomipramine Hydrochloride in Childhood and Adolescent 
Obsessive-Compulsive Disorder—a Multicenter Trial. 31(1), 45-49.  
Elliott, W. J., & Ram, C. V. S. (2011). Calcium Channel Blockers. The Journal of Clinical 
Hypertension, 13(9), 687-689.  
EMEA. (2011). Assessment report for Brilique. London. 
Fish, L. H., Schwartz, H. L., Cavanaugh, J., Steffes, M. W., Bantle, J. P., & Oppenheimer, J. 
H. (1987). Replacement Dose, Metabolism, and Bioavailability of Levothyroxine in 
the Treatment of Hypothyroidism. New England Journal of Medicine, 316(13), 764-
770.  
Fleischmann, R., Kerr, B., Yeh, L.-T., Suster, M., Shen, Z., Polvent, E., & Miner, J. N. 
(2014). Pharmacodynamic, pharmacokinetic and tolerability evaluation of 
concomitant administration of lesinurad and febuxostat in gout patients with 
hyperuricaemia. Rheumatology, ket487.  
Frick, M. H., McGibney, D., & Tyler, H. M. (1988). Amlodipine: A Double-Blind Evaluation of 
the Dose-Response Relationship in Mild to Moderate Hypertension. Journal of 
Cardiovascular Pharmacology, 12, S76-S78.  
Frishman, W. H., Bryzinski, B. S., Coulson, L. R., & et al. (1994). A multifactorial trial design 
to assess combination therapy in hypertension: Treatment with bisoprolol and 
hydrochlorothiazide. Archives of Internal Medicine, 154(13), 1461-1468.  
Furr, B. J. A., & Tucker, H. (1996). The preclinical development of bicalutamide: 
pharmacodynamics and mechanism of action. Urology, 47(1, Supplement 1), 13-25.  
Hallin, L., Andrén, L., & Hansson, L. (1983). Controlled Trial of Nifedipine and 
Bendroflumethiazide in Hypertension. Journal of Cardiovascular Pharmacology, 
5(6), 1083-1085.  
Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A., Heaney, 
R. P., Weaver, C. M. (2011). Evaluation, treatment, and prevention of vitamin D 
deficiency: an Endocrine Society clinical practice guideline. The Journal of Clinical 
Endocrinology & Metabolism, 96(7), 1911-1930.  
Howell, A., Robertson, J. F., Albano, J. Q., Aschermannova, A., Mauriac, L., Kleeberg, U. R., 
Morris, C. (2002). Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in 
postmenopausal women with advanced breast cancer progressing after prior 
endocrine treatment. Journal of Clinical Oncology, 20(16), 3396-3403.  
Jefferson, E. (2011). FDA approves new treatment for rare form of thyroid cancer. FDA news 
release 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm250168.htm  
195 
 
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., & 
Smith, P. (2013). Selumetinib plus docetaxel for KRAS-mutant advanced non-small-
cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. The 
Lancet Oncology, 14(1), 38-47.  
Kahn, R. S., Schulz, S. C., Palazov, V. D., Reyes, E. B., Brecher, M., Svensson, O., & 
Meulien, D. (2007). Efficacy and tolerability of once-daily extended release 
quetiapine fumarate in acute schizophrenia : A randomized, double-blind, placebo-
controlled study. The Journal of Clinical Psychiatry, 68(6), 832-842.  
Katz, R. J., DeVeaugh-Geiss, J., & Landau, P. (1990). Clomipramine in obsessive-
compulsive disorder. Biological Psychiatry, 28(5), 401-414.  
Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. 
A., & Nathan, D. M. (2002). Reduction in the incidence of type 2 diabetes with 
lifestyle intervention or metformin. The New England Journal of Medicine, 346(6), 
393-403.  
Kolvenbag, G. J. C. M., & Blackledge, G. R. P. (1996). Worldwide activity and safety of 
bicalutamide: a summary review. Urology, 47(1, Supplement 1), 70-79.  
Lai, K. C., Lam, S. K., Chu, K. M., Wong, B. C. Y., Hui, W. M., Hu, W. H. C., & Wong, J. 
(2002). Lansoprazole for the Prevention of Recurrences of Ulcer Complications from 
Long-Term Low-Dose Aspirin Use. New England Journal of Medicine, 346(26), 
2033-2038.  
Li, J., Zhao, J., Hamer-Maansson, J. E., Andersson, T., Fulmer, R., Illueca, M., & Lundborg, 
P. (2006). Pharmacokinetic properties of esomeprazole in adolescent patients aged 
12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, 
open-label study. Clinical Therapeutics, 28(3), 419-427.  
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. 
W.,Haber, D. A. (2004). Activating Mutations in the Epidermal Growth Factor 
Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. 
New England Journal of Medicine, 350(21), 2129-2139. 
Müderris, İ. İ., Bayram, F., Özçelik, B., & Güven, M. (2002). New alternative treatment in 
hirsutism: bicalutamide 25 mg/day. Gynecological Endocrinology, 16(1), 63-66.  
Nelson, J. B., Fizazi, K., Miller, K., Higano, C., Moul, J. W., Akaza, H., Gleave, M. (2012). 
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients 
with castration-resistant prostate cancer metastatic to bone. Cancer, 118(22), 5709-
5718.  
Noguchi, H., Matsuhashi, M., & Mitsuhashi, S. (1979). Comparative Studies of Penicillin-
Binding Proteins in Pseudomonas aeruginosa and Escherichia coli. European 
Journal of Biochemistry, 100(1), 41-49.  
Pacher, P., Nivorozhkin, A., & Szabó, C. (2006). Therapeutic effects of xanthine oxidase 
inhibitors: renaissance half a century after the discovery of allopurinol. 
Pharmacological Reviews, 58(1), 87-114.  
Packer, M., Poole-Wilson, P. A., Armstrong, P. W., Cleland, J. G., Horowitz, J. D., Massie, 
B. M., & Uretsky, B. F. (1999). Comparative effects of low and high doses of the 
angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in 
chronic heart failure. Circulation, 100(23), 2312-2318.  
Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., & 
Yusuf, S. (2003). Effects of candesartan on mortality and morbidity in patients with 
chronic heart failure: the CHARM-Overall programme. The Lancet, 362(9386), 759-
766.  
Prince, R. L., Austin, N., Devine, A., Dick, I. M., Bruce, D., & Zhu, K. (2008). Effects of 
ergocalciferol added to calcium on the risk of falls in elderly high-risk women. 
Archives of Internal Medicine 168(1), 103-108.  
196 
 
Rainsford, K. (2003). Discovery, mechanisms of action and safety of ibuprofen. International 
journal of clinical practice. Supplement(135), 3-8.  
Rinsema, T. J. (1999). One hundred years of aspirin. Medical History, 43(4), 502-507.  
Rüegg, U. T., Rudinger, J., & Timasheff, C. H. W. H. a. S. N. (1977). Reductive cleavage of 
cystine disulfides with tributylphosphine. Enzyme Structure Part E, 47,  111-116 
Sagent. (2012). Ceftazidime leaflet from  
http://www.sagentpharma.com/Products/Ceftazidime/Catalog/Ceftazidime_PI1.pdf  
Scandinavian Simvastatin Survival Study Group. (1994). Randomised trial of cholesterol 
lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin 
Survival Study (4S). The Lancet, 344(8934), 1383-1389.  
Schwaiger, J., Ferling, H., Mallow, U., Wintermayr, H., & Negele, R. (2004). Toxic effects of 
the non-steroidal anti-inflammatory drug diclofenac: Part I: histopathological 
alterations and bioaccumulation in rainbow trout. Aquatic Toxicology, 68(2), 141-150.  
See, W. A., & Tyrrell, C. J. (2006). The addition of bicalutamide 150 mg to radiotherapy 
significantly improves overall survival in men with locally advanced prostate cancer. 
Journal of Cancer Research and Clinical Oncology, 132(1), 7-16.  
Sogani, P. C., Vagaiwala, M. R., & Whitmore, W. F. (1984). Experience with flutamide in 
patients with advanced prostatic cancer without prior endocrine therapy. Cancer, 
54(4), 744-750.  
Taber, C. W. (2001). Taber's Cyclopedic Medical Dictionary: Indexed (19th ed.): F a Davis 
Company, Philadelphia, Pennsylvania, USA. 
Todar, K. (2001). Antimicrobial Agents in the Treatment of Infectious Disease.   Retrieved 
30th May, 2014, from 
http://textbookofbacteriology.net/antimicrobial.html  
Turrentine, M. A., & Newton, E. R. (1995). Amoxicillin or erythromycin for the treatment of 
antenatal Chlamydia infection: a meta-analysis. Obstetrics & Gynecology, 86(6), 
1021-1025.  
Ullman, A., & Svedmyr, N. (1988). Salmeterol, a new long acting inhaled beta 2 
adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. 
Thorax, 43(9), 674-678.  
Vlachojannis, J., Magora, F., & Chrubasik, S. (2011). Willow Species and Aspirin: Different 
Mechanism of Actions. Phytotherapy Research, 25(7), 1102-1104.  
Wald, E. R., Reilly, J. S., Casselbrant, M., Ledesma-Medina, J., Milmoe, G. J., Bluestone, C. 
D., & Chiponis, D. (1984). Treatment of acute maxillary sinusitis in childhood: A 
comparative study of amoxicillin and cefaclor. The Journal of Paediatrics 104(2), 
297-302.  
Waller, A., Sharrard, R., Berthon, P., & Maitland, N. (2000). Androgen receptor localisation 
and turnover in human prostate epithelium treated with the antiandrogen, casodex. 
Journal of Molecular Endocrinology, 24(3), 339-351.  
WHO. (2013). WHO Model List of Essential Medicines (18th ed.) WHO Medicines web: 
http://www.who.int/medicines/publications/EML. 
Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., & Dagenais, G. (2000). Effects of an 
angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-
risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. The 
New England Journal of Medicine, 342(3), 145-153.  
  
197 
 
Appendix B: Results of Statistical Tests Comparing Partition 
Coefficients of Pharmaceuticals in Different Types of Sewage 
Sludge 
 
 
 
 
 
Figure B1 Matrix plot of reported 𝐾𝑑 values of pharmaceuticals with different types of 
sewage sludge. 
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Figure B2 Probability plots of reported log 𝐾𝑑 values of pharmaceuticals with four different 
types of sewage sludge. 
 
 
 
 
Figure B3 normality plot for ClopP (left), ACDlogP (centre) and ACDlogD pH7.4 (right) 
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Figure B4 Plot for 𝑲𝒅 values reported for primary sludge (𝑲𝒅 primary) against the 𝑲𝒅 values 
of the same compound obtained with activated sludge (𝑲𝒅 activated). The regression 
equation is 𝑲𝒅 𝒑𝒓𝒊𝒎𝒂𝒓𝒚 =  𝟎. 𝟗𝟐 𝑲𝒅 𝒂𝒄𝒕𝒊𝒗𝒂𝒕𝒆𝒅 +  𝟏𝟐𝟑 (solid line) with 𝒓
𝟐 = 0.83 (n = 43 
compounds).  The dashed line is the diagonal (𝒚 = 𝒙  ). 
 
 
 
 
 
Figure B5 Plot for 𝐾𝑑 values reported for secondary sludge (𝐾𝑑 secondary) against the 𝐾𝑑 
values of the same compound obtained with activated sludge (𝐾𝑑 activated). The regression 
line is 𝐾𝑑  𝑠𝑒𝑐𝑜𝑛𝑑𝑎𝑟𝑦 =  0.91 𝐾𝑑  𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑒𝑑 +  245 (solid line) with an 𝑟
2 of 0.61 (n = 21 
compounds).  The dashed line is the diagonal (𝑦 = 𝑥).  
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Figure B6 Plot for 𝐾𝑑 values reported in digested sludge (𝐾𝑑 digested) against the 𝐾𝑑 values 
of the same compound obtained with activated sludge (𝐾𝑑  activated). The regression line is 
𝐾𝑑  𝑑𝑖𝑔𝑒𝑠𝑡𝑒𝑑 =  0.23 𝐾𝑑   𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑒𝑑 +  77 (full line) with an r
2
 of 0.84 (n = 19 compounds). 
The dashed line is the diagonal (x = y). After removal of the top right outlier, the regression 
equation is 𝐾𝑑  𝑑𝑖𝑔𝑒𝑠𝑡𝑒𝑑 =  0.51 𝐾𝑑  𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑒𝑑 +  25 (dotted line) with an 𝑟
2of 0.72 (n = 18).  
 
 
 
 
 
 
 
Figure B7 Plot for log𝐾𝑑 values reported in digested sludge (log𝐾𝑑 digested) against the log 
𝐾𝑑 values of the same compound obtained with primary (left) and secondary (right) sludge 
(log𝐾𝑑  primary and secondary). The regression line is 
𝑙𝑜𝑔𝐾𝑑  𝑑𝑖𝑔𝑒𝑠𝑡𝑒𝑑 =  0.77 𝑙𝑜𝑔𝐾𝑑  𝑝𝑟𝑖𝑚𝑎𝑟𝑦 +  0.08 (left full line) with an r
2
 of 0.78 (n = 19 
compounds) and 𝑙𝑜𝑔𝐾𝑑  𝑑𝑖𝑔𝑒𝑠𝑡𝑒𝑑 =  0.64 𝑙𝑜𝑔𝐾𝑑  𝑠𝑒𝑐𝑜𝑛𝑑𝑎𝑟𝑦 +  0.30 (right full line) with an r
2
 
of 0.64 (n = 16 compounds). The dashed line is the diagonal (𝑥 =  𝑦) 
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Table B1 Results for the coefficients of the linear regression analysis for the different sludge 
types on the measured Kd values. 
Coefficients 
Models n Coefficients t p Adjusted r
2
 
B Std. Error 
1 
(Constant)  0.83 0.24 3.48 0.001  
Activated vs. Primary 43 0.69 0.10 6.62 0.001 0.52 
 2 
(Constant) 
Activated vs. Secondary 
21 1.30 
0.50 
0.46 
0.21 
2.81 
2.39 
0.011 
0.027 0.23 
 3 
(Constant) 
Activated vs. Digested 
19 0.14 
0.81 
0.30 
0.14 
0.45 
5.85 
0.656 
0.001 0.67 
 4 
(Constant) 
Primary vs. Secondary 
51 0.17 
0.89 
0.26 
0.04 
0.66 
11.15 
0.509 
0.001 0.72 
 5 
(Constant) 
Primary vs. Digested 
19 0.082 
0.77 
0.27 
0.10 
0.30 
7.80 
0.769 
0.001 0.78 
 6 
(Constant) 
Secondary vs. Digested 
16 0.30 
0.64 
0.37 
0.13 
0.82 
4.99 
0.424 
0.001 0.64 
 
Table B3 Results of paired sample t-tests for reported 𝐾𝑑  values of pharmaceuticals for different types of sewage sludge. 
 
 
 
  
     n 
Paired Differences t df p 
 
Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
   
Lower Upper 
Pair 1 Kd Activated–Kd Primary 43 -0.15 0.488 0.101 -0.30 0.01 -2.01 42 0.051 
Pair 2 Kd Activated–Kd Secondary 21 -0.248 0.771 0.168 -0.60 0.10 -1.47 20 0.157 
Pair 3 Kd Activated–Kd Digested 19 0.252 0.403 0.092 0.06 0.45 2.73 18 0.014 
Pair 4 Kd Primary–Kd Secondary 51 0.183 0.505 0.071 0.041 0.32 2.58 50 0.013 
Pair 5 Kd Primary–Kd Digested 19 0.511 0.429 0.099 0.304 0.72 5.19 18 <0.000 
Pair 6 Kd Secondary–Kd Digested 16 0.661 0.681 0.170 0.298 1.02 3.88 15 0.001 
t = Student’s t-statistic 
df = degrees of freedom 
p = p-value associated with the t-test. 
N: Number of pharmaceuticals included in the test. 
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Appendix C: Powder Characterisation Report 
C1.Thermogravimetry Analysis 
Principle 
Thermogravimetry (TGA) is a technique that measures the change in weight of a sample when it is 
heated, cooled or held at constant temperature. Its main use is to characterise materials with regard 
to their composition. 
 
Apparatus 
The apparatus was a TGA 92 -12 from Setaram as shown in Figure C1. 
 
 
Figure C1 
The sample was weight in a small crucible and placed in the TGA apparatus. A gradient of 
temperature from ambient to 600°C was applied at rate of 5°C/min, controlled by the TG standalone 
software as per Figure C2: 
 
Figure C2 
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Results 
Silica: Silicon Carbide 
 
Silica was stable across the temperature range. The initial loss of around 5% up to 100°C was due to 
water loss. Silicon carbide was very stable across the temperature range. 
 
PTFE PEEK 
 
PTFE was stable up to 500°C. Above 500°C, it fully vaporised. 
PEEK was stable up to over 500°C. It melted around 550°C and above. 
 
FDS 
 
The initial weight loss up to 100°C was due to water loss. The further weight loss was attributed to 
volatile organic matter loss. 
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C2. Scanning Electron Microscopy 
Principle 
The Scanning Electron Microscopy (SEM) uses a focused beam of high-energy electrons to generate 
a variety of signals at the surface of solid specimens. The signals that derive from electron-sample 
interaction reveal information about the sample including external morphology (texture), topography, 
chemical composition, and crystalline structure and orientation of materials making up the sample. 
 
Apparatus 
The apparatus used was a NeoScope JCM 5000 from JEOL supplier as per Figure C3.
 
Figure C3 
The sample was spread on a special disc (Figure C4) and any excess sample was removed by 
compressed air. 
 
Figure C4 
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The Scanning Electron Microscopy pictures have been acquired via the JCM5000 NeoScope software 
under vacuum with an acceleration voltage of 10 kV as shown in Figure C5. 
 
Figure C5 
 
The freeze dried sludge sample has been metallised with a thin layer of gold due to his lack of 
conductivity. The polymer samples PTFE and PEEK have been sprayed with EMI 35 Kontakt Chemie 
conductive coating aerosol and let to dry before putting them onto the NeoScope 5000. The rest of 
the samples (Silica and silicon Carbide) was tested without further treatment as they were conductive 
enough. 
 
 
Results 
 
The results are shown in the photos below. Three photos per sample have been selected to represent 
20, 50 and 100 µm zoom.
207 
 
 
Silica 
 
 
Silicon Carbide 
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PTFE 
 
 
PEEK 
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Freeze dried sludge 
 
C3. Specific Surface Area (BET) 
Principle 
The specific surface area of a powder is estimated from the amount of nitrogen adsorbed in 
relationship with its pressure, at the boiling temperature of liquid nitrogen under normal atmospheric 
pressure. The observations are interpreted following the model of Brunauer, Emmett and Teller (BET 
method). 
 
Apparatus 
The apparatus used to measure the specific surface area was a Sorptomatic 1990 series shown in 
Figure C6. 
 
Figure C6 
Figure C7 focuses on the cell compartment maintained at constant temperature of 77°K by liquid 
nitrogen stored in a Dewar: 
 
Figure C7 
The cell itself after a measurement is shown in Figure C8. The sample is accurately weighted in the 
cell and immersed in liquid nitrogen until equilibration of pressure. The blank is done on the sample 
with helium, known for its little or no sorptive properties. 
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Figure C8 
The sorptomatic 1990 software controls the acquisition parameter and measures the ratio P/P0 
(pressure at equilibrium/pressure at saturation) (Figure C9). 
 
Figure C9 
 
 
Results 
The summary of the results: 
 
 best estimate (10% rsd) 
Sample 
Specific surface 
area 
Porous volume Pores diameter 
Micro porous 
volume 
m
2
/g 
cm
3
/g nm cm
3
/g 
Silica 420 0.81 7.5 0.16 
SiC 2.9 non-porous non-porous non-porous 
PEEK 80 0.19 9.5 0.03 
PTFE 2.6 non-porous non-porous non-porous 
Sludge 2.5 0.03 54 0 
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Micro porous volume range is across 2-50 nm pore size. 
 
The results are presented in individual mini reports for each sample: 
Silica: 
Specific Surface Area  (BET)  =  420  m
2
.g
-1 
Pores Volume  BJH (ads)  borne 0,9  =   0,81 cm
3
.g
-1
       
 
Mean Dia  ads  =  7,2 nm        
Max Dia ads = 7,4 nm        
 Pores Volume BJH (des)  borne 0,96  =   0,88 cm
3
.g
-1
        
Mean Dia  des  =  5,4 nm       
Max Dia des =   5,5 nm          
Estimation of microporous volume:  0,16 cm
3
.g
-1        
 
 
 
 
       
 
 
 
Silicon Carbide 
Specific Surface Area (BET)  =  2,9 m
2
.g
-1 
Pores Volume  BJH (ads)  borne 0,96  =   0,01 cm
3
.g
-1
      Non significant 
 
Mean Dia ads       Non significant 
Max Dia ads           Non significant 
 Pores Volume BJH (des)  borne 0,96  =   0,01 cm
3
.g
-1
   Non significant    
Mean Dia des    Non significant 
Max Dia des        Non significant 
Estimation of microporous volume Non significant     
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PEEK 
Specific Surface Area (BET)  =  80  m
2
.g
-1 
Pores Volume  BJH (ads)  borne 0,9  =   0,19 cm
3
.g
-1
       
 
Mean Dia ads  =  12,3 nm        
Max Dia ads = 9,4 nm        
 Pores Volume BJH (des)  borne 0,96  =   0,24 cm
3
.g
-1
        
Mean Dia des  =  6,9 nm       
Max Dia des =   3,4 nm          
Estimation of microporous volume 0,03 cm
3
.g
-1
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                                                 Isotherm 
This isotherm is a type II with a hysteresis loop H3 which is a characteristic of pores formed by 
aggregates. 
BJH desorption 
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PTFE                            
Specific Surface Area (BET droite)  =  2,6 m
2
.g
-1     
Pores Volume  BJH (ads)  borne 0,96  =   0,03 cm
3
.g
-1
   Non significant 
 
Mean Dia ads  =  Non significant 
Max Dia ads     Non significant 
 Pores Volume BJH (des)  borne 0,96  =   0,03 cm
3
.g
-1
       Non significant 
Mean Dia des  Non significant 
Max Dia des  Non significant 
Estimation of microporous volume   0,001 cm
3
.g
-1
       Non significant 
 
 
 
Freeze dried sludge 
Specific Surface Area (BET droite)  =  2,5  m
2
.g
-1 
Pores Volume  BJH (ads)  borne 0,96  =   0,03 cm
3
.g
-1
   Non significant 
 
Mean Dia ads  =  54 nm       Non significant 
Max Dia ads = 62 nm       Non significant 
Pores Volume BJH (des)  borne 0,96  =   0,02 cm
3
.g
-1
       Non significant 
Mean Dia des  =  52 nm      Non significatif 
Max Dia des  =   60 nm       Non significatif 
Estimation of microporous volume   0,00 cm
3
.g
-1
       Non significant 
              FDS/2012/02  E 
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                                                  Isotherm 
This isotherm could be a type III, but weak precision.  
                                                  Isotherm 
Very weak porosity, probably non-porous (adsorption very weak with net breakage at liquefaction (of 
liquid nitrogen condensation); different desorption, probably due to condensed nitrogen evaporation). 
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C4. Particle Size Distribution 
Principle 
Particle size distribution was measured by laser diffraction. The technique of laser diffraction is based 
on the principle that particles passing through a laser beam will scatter light at an angle that is directly 
related to their size: large particles scatter at low angles, whereas small particles scatter at high 
angles. The laser diffraction is accurately described by the Fraunhofer Approximation and the Mie 
theory, with the assumption of spherical particle morphology. The measurable size ranges from 50 
[nm] to 1000 [μm].  It is possible to carry out the measurement on dry powders by adapting specific 
equipment. The limitations of this method appear for small sizes (< 1 [μm], Mie theory), for non-
spherical particles, and for materials with a low refractive index with respect to the dispersive medium. 
 
Apparatus 
A Malver mastersizer 2000 was used as shown in Figure C10. 
 
Figure C10 
The Malvern was adequately equipped to measure powders as shown in Figure C11. 
 
Figure C11 
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A tip of spatula full of sample was dropped onto the aperture and instantly wetted through stirring 
(1,300 rpm) in the water flowing in the system (Figure C12). More sample was added to reach a laser 
obscuration between 5-15% for accurate measurement. 
 
Figure C12 
 
Results 
Silica 
 
 
Silicon carbide 
 
PTFE 
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For the PTFE the measurement is only approximate because of the nature of the PTFE being 
extremely hydrophobic, it was hard to solubilise it and laser obscuration was only 0.28% (instead of 
5% minimum). 
 
PEEK 
 
 
Freeze dried sludge 
 
 
 
 
 
C5. Conclusion 
The physico-chemical analysis gave us information of the nature of the material tested. 
A summary of measurement can be found in the Table C1 below: 
 
Table C1 
 TGA SEM BET PSD 
Silica Stable 
Spherical 
homogeneous 
420.0 m
2
.g
-1 
(pores 0.81 cm
3
.g
-1
) 
20-30 µm 
Silicon carbide Stable 
Non spherical 
homogeneous 
2.9 m
2
.g
-1
 
(non porous) 
40-60 µm 
PTFE 
500°C 
(vaporise) 
Small aggregates 
polymer 
2.6 m
2
.g
-1 
(non porous) 
200-300 µm 
PEEK 
550°C 
(melt) 
Large aggregates 
polymer 
80 m
2
.g
-1 
(pores 0.19 cm
3
.g
-1
) 
300-500 µm 
Freeze dried sludge 
200°C 
(VOM) 
Non spherical 
heterogeneous 
2.5 m
2
.g
-1 
(pores 0.03 cm
3
.g
-1
) 
400-600 µm 
 
All the materials tested are more stable, have a similar or larger surface area and are smaller in 
particle size than the freeze-dried sludge sample. Therefore all are suitable packing material. 
 
The PTFE was chose in favour of his lack of interaction with the sludge, and the three compounds 
used for the Solid phase extraction experiments.  
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Appendix D: Schematic and Aerial Views of Totnes Wastewater 
Treatment Plant. 
 
D1. Schematic view of Totnes wastewater treatment plant.. 
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D2. Aerial view of Totnes wastewater treatment plant. 
The red arrow indicated the activation tanks from where the activated sludge for this 
research was collected. 
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Appendix E: Additional SPE Results for Chapter 3 and 4 
 
The results from Chapter 3 are presented in Figures E1 to E3. Figure E1 is used in Chapters 
3 and 4 
 
 
 
 
Figure E1: diagram of the solid phase extraction procedure. 1. 2 mL conditioning/cartridge 
wetting, 2.Dosing, 3. 2 mL elution 1, 4. 2 mL elution 2 
 
 
 
Figure E2 Plot comparing the adsorbed percentage of the three test pharmaceuticals under eight 
experimental adsorption conditions on four packing materials: Silica, Silicon carbide, PTFE and 
PEEK.  
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Figure E3 Bar charts comparing the adsorbed percentage of the three test pharmaceuticals under the 
Table 4 eight experimental adsorption conditions on 100% sludge in PTFE mixture. Values of log Kd of 
1.34, 2.11 and 3.85 correspond to clofibric acid, diclofenac and oxytetrcycline, respectively 
 
 
 
 
 
Figure E4: Bar charts comparing the adsorbed percentage of the three test pharmaceuticals under 
the Table 4 eight experimental adsorption conditions on NH2 commercial phase SPE cartridge. Values 
of log Kd of 1.34, 2.11 and 3.85 correspond to clofibric acid, diclofenac and oxytetrcycline, respectively 
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Appendix F: Matlab Code for Generating ANNs 
 
function train_nets(nnets, labels, xtrain, ytrain, xtest, ytest) 
%TRAIN_NETS Train a set of networks using Automatic Relevance Determination 
(ARD) 
% 
%   TRAIN_NETS(NNETS, LABELS, XTRAIN, YTRAIN, XTEST, YTEST) trains NNETS 
%   networks using the specified training data. 
% 
%   LABELS is a (1 x NDESCRIPTOR) row vector of variable names 
%   XTRAIN is a (NTRAINCOMPOUNDS by NDESCRIPTORS) matrix of training set 
descriptors 
%   YTRAIN is a (NTRAINCOMPOUNDS x 1) column vector of training set 
responses 
%   XTEST  is a (NTESTCOMPOUNDS by NDESCRIPTORS) matrix of test set 
descriptors 
%   YTEST  is a (NTESTCOMPOUNDS x 1) column vector of test set responses 
% 
%   A table of outputs is written to the CSV file results.txt 
  
%  28/05/2014 
  
% seed the random number generator 
% uncomment one of the next two lines 
rng('shuffle');  % for production runs 
%rng('default');  % for repeatability 
  
% predefined matrix to store results 
output = zeros(nnets, length(labels)+10); 
  
% for each network 
for n=1:nnets 
    % train the network using ARD 
    % train_ard_net is a slightly modified version of the Netlab demev1.m 
    [net, gamma, logev] = train_ard_net(labels, xtrain, ytrain); 
  
    % extract a logical vector showing the descriptors with low 
    % hyperparameters. The cutoff of 100 is arbitrary. 
    hyper = (net.alpha(1:net.nin) < 100); 
  
    % calculate stats for the network performance on the training set 
    [ssetrain, msetrain, rsqtrain] = netstats(net, xtrain, ytrain); 
  
    % calculate stats for the network performance on the test set 
    [ssetest, msetest, rsqtest] = netstats(net, xtest, ytest); 
  
    % insert the results into the output matrix 
    output(n,:) = [n, hyper', ssetrain, ssetest, msetrain, msetest, 
rsqtrain, rsqtest, net.beta, gamma, logev]; 
  
    % save the network in a .mat file 
    netname = sprintf('net%03d.mat', n); 
    save(netname, 'net'); 
end 
  
% add the network number and errors to the labels 
labels = ['network'; labels; 'ssetrain'; 'ssetest'; 'msetrain'; 'msetest'; 
'rsqtrain'; 'rsqtest'; 'beta'; 'gamma'; 'logev']; 
  
  
223 
 
% save the results to a CSV file results.txt 
  
fid = fopen('results.txt','w'); 
ncols = length(labels); 
nrows = size(output,1); 
ndesc = size(xtrain,2); 
  
for i=1:ncols-1 
    fprintf(fid, '%s,', char(labels(i))); 
end 
  
fprintf(fid, '%s\n', char(labels(ncols))); 
  
for i=1:nrows 
    fprintf(fid,'%d,', output(i,1)); 
    for j=1:ndesc 
        fprintf(fid,'%d,', output(i,j+1)); 
    end 
    for j=1:ncols-ndesc-2 
        fprintf(fid,'%f,', output(i,ndesc+j+1)); 
    end 
    fprintf(fid,'%f\n', output(i,ncols)); 
end 
  
fclose(fid); 
 
 
  
Appendix G: Rain Water Analysis by CEMAS Ltd, Wokingham, UK. 
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